

Author Index

- Abdel-Haq B, *see* Salvetti, 963
 Abiko Y, *see* Matsumura, 719
 Abraham PA, *see* Opsahl, 221
 Adamantidis M, *see* Libersa, 808
 Aladjem M, *see* Aviv, 335
 Alberti A, *see* Bracchetti, 261
 Alcazar JM, *see* Ruilope, 979
 Alcocer L, *see* Cobo, 73
 Ale JJ, *see* Milei, 1519
 Alicandri C, *see* Boni, 265
 Aliot E, *see* Simon, 1467
 Amende I, Herrmann G, Simon R, Hood WP Jr., Wenzlaff P, Lichtlen PR. Protective effects of pretreatment with intracoronary nifedipine on myocardial ischemia and dysfunction, 887
 Amery A, *see* Staessen, 1237
 Amici E, *see* Gambelli, 951
 Amstein R, *see* Fetkovska, 105
 Ansani L, *see* Longhini, 751
 Antona C, *see* Monopoli, 59
 Aoki T, *see* Hayashi, 969
 Arakawa K, *see* Sasaki, 1033
 Arcaro G, *see* Sheiban, 957
 Arosio E, *see* Sheiban, 957
 Arrigo F, Consolo F. Long-term therapy with slow-release nifedipine in essential hypertension, 941
 Ash KO, *see* Hunt, 357
 Ashino K, *see* Minamisawa, 1417
 Assogna G, *see* Lavezzaro, 119
 Assogna G, *see* Malatino, 123
 Audouin P, *see* Sellier, 820
 Aviv A, Aladjem M. Essential hypertension in blacks: Epidemiology, characteristics and possible roles of racial difference in sodium, potassium, and calcium regulation, 335
 Bachmann KF, *see* Gansser, 475
 Baracca E, *see* Longhini, 751
 Baranowska B. The effect of clonidine on hormone release mediated through activation of opiate receptors, 1113
 Barat JL, *see* Bricaud, 861
 Barilla F, Pelliccia F, Valente A, Cianfrocca C, Romeo F, Reale A. Acute effects of nifedipine versus isosorbide dinitrate on exercise tolerance in patients with isolated coronary artery occlusion and collaterals, 905
 Barlow CW, Friedman BM, Myburgh DP, Soicher ER, Steenkamp WFF, Smith DHG. Effects of therapy with diet and simvastatin on atherosclerosis in hypercholesterolemic patients, 1389
 Bartels GL, Remme WJ, Wiesfeld ACP, Kok FJ, Look MP, Krauss XH, Kruyssen HACM. Duration and reproducibility of initial hemodynamic effects of flosequinan in patients with congestive heart failure, 705
 Baudet M, *see* Lardoux, 1337
 Bauer JH, *see* Reams, 207
 Bauer JH, *see* Reams, 1331
 Bauer U, *see* Haerer, 515
 Bayés de Luna A, Guindo J, Borja J, Roman M, Madoery C. Recasting the approach to the treatment of potentially malignant ventricular arrhythmias after the CAST study, 651
 Bayés de Luna A, Opie LH. Introduction to symposium on arrhythmias, 649
 Bel KJ, *see* Tio, 695
 Benckroun N, *see* Catroux, 816
 Bentivoglio M, *see* Corea, 1501
 Berckmans T, *see* Detry, 841
 Bergamin M, *see* Dorigo, 1477
 Berioli S, *see* Corea, 1501
 Bernard A, *see* de Marneffe, 523
 Bernier M, *see* Curtis, 1169
 Bhigjee AI, *see* Hoosen, 363
 Bianchini C, *see* Corea, 1501
 Bigger JT Jr. Clinical aspects of trial design: What can we expect from the cardiac arrhythmia suppression trial?, 657
 Biglioli P, *see* Monopoli, 59
 Blauw GJ, *see* Van Zweiten, 1443
 Boni E, Alicandri C, Fariello R, et al. Effect of enalapril on parasympathetic activity, 261
 Bonnet J, *see* Bricaud, 861
 Borggreffe M, Breithardt G. Holter monitoring vs. programmed ventricular stimulation, 555
 Boriani G, *see* Capucci, 281
 Borja J, *see* Bayés de Luna, 651
 Borsatti A, *see* Calo, 983
 Bottero G, Morosetti P, Morosetti M, Meloni C, Meschini L, Taccone Gallucci M, Casciani CU. Acute effects of sublingual nifedipine on left ventricular function in hemodialysis hypertensive patients, 991
 Boujelben F, *see* de Marneffe, 523
 Boussens B, *see* Bricaud, 861
 Bracchetti D, Gradnik R, Alberti A, et al. Comparison of bisoprolol and captopril for the treatment of essential hypertension in the elderly, 261
 Breithardt G, *see* Borggreffe, 555
 Bricaud H, Brottier L, Barat JL, Combe C, Boussens B, Bonnet J. Cardioprotective effect of trimetazidine in severe ischemic cardiomyopathy, 861
 Brigden G, *see* Broadhurst, 435
 Broadhurst PA, Brigden G, Heber M, Lahiri A, Raftery EB. Twenty-four hour ambulatory blood pressure profile of a new, sustained-release preparation of nifedipine, 435
 Brochier M, *see* Monpere, 824
 Brottier L, *see* Bricaud, 861
 Brugada J, *see* Brugada P, 619
 Brugada P, Smeets JLRM, Brugada J, Farré J. Mechanism of action of sotalol in supraventricular arrhythmias, 619
 Brune S, Schmidt T, Tebbe U, Kreuzer H. Influence of long-term treatment with ketanserin on blood pressure, pulmonary artery pressure and cardiac output in patients with heart failure, 85
 Brunelli C, Spallarossa P, Ghigliotti G, Caudullo M, Iannetti M, Caponnetto S. Intravenous nifedipine prevents ergonovine-induced myocardial ischemia in patients with stable effort angina, 909
 Bühler FR, *see* Fetkovska, 105
 Bühler FR, *see* Kiowski, 935
 Burke TJ, Singh H, Schrier RW. Calcium handling by renal tubules during oxygen deprivation injury to the kidney prior to reoxygenation, 1319
 Burns RJ, *see* Leenen, 499
 Burton JR, Haraphongse M, Hsu L, Kapagoda CT, Rossall RE, Schlaut B, Senaratne MPJ. Risk stratification after percutaneous transluminal coronary angioplasty, 687
 Cacciatore L, *see* Coto, 77
 Calo L, Cantaro S, Piccoli A, d'Angelo A, Giannini S, Williams HE, Borsatti A. Effect of nifedipine on urinary excretion of calcium and calcium-controlling hormones in essential hypercalciuria, 983
 Cambar J, *see* Catroux, 816
 Camm AJ. Current antiarrhythmic therapy overview, 531
 Camm AJ, *see* Kaye, 1157
 Camous JP, *see* Gibelin, 1105
 Cantaro S, *see* Calo, 983
 Caponnetto S, *see* Brunelli, 909
 Capucci A, Boriani G, Marchesini J, et al. Minimal effective concentration of propafenone and 5-hydroxypropafenone in acute and chronic therapy, 281
 Caron J, *see* Libersa, 567
 Carpentier A, *see* Fabiani, 797

- Casciani CU, *see* Bottero, 991
 Cassisa L, *see* Sechi, 63
 Castaldo B, *see* Coto, 77
 Catroux P, Benchehrroun N, Robert J, Cambar J. Influence of trimetazidine on deleterious effect of oxygen radical species in post-ischemic acute renal failure in the rat, 816
 Caudullo M, *see* Brunelli, 909
 Cavalloiti G, *see* di Somma, 1151
 Cernoch K, *see* Haerer, 515
 Challenor V, *see* Waller, 899
 Chalmers J, *see* Minson, 27
 Chávez A, *see* Cobo, 73
 Chazov EI, Oganov RG. Preventative cardiology, 755
 Cherchi A, Lai C, Onnis E, Orani E, Pirisi R, Pisano M, Rosaria, Soro A, Corsi M. Propionyl carnitine in stable effort angina, 481
 Chiariello M, *see* Santinelli, 681
 Cianfrocca C, *see* Barilla, 905
 Cianfrocca C, *see* Pelliccia, 1515
 Clauser P, *see* Maupoi, 791
 Cleroux J, *see* Mancina, 1223
 Clozel J-P, Véniant M, Osterrieder W. The structurally-novel Ca^{2+} channel blocker Ro 40-5967 which binds to the (^3H) desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts, 731
 Cobo C, Alcocer L, Chávez A. Effects of ketanserin on left ventricular hypertrophy in hypertensive patients, 73
 Cocozza M, *see* Coto, 77
 Coetzee WA, Enous R, Opie LH. Trimetazidine: Effects on delayed afterdepolarizations (DADs) and upstroke velocity of the action potential, 806
 Coffman JD. Pathogenesis and treatment of Raynaud's phenomenon, 45
 Collins KJ. Age-related changes in autonomic control: The use of beta-blockers in the treatment of hypertension, 1257
 Comba AZ, *see* Milei, 1519
 Combe C, *see* Bricaud, 861
 Condorelli M, *see* Santinelli, 681
 Conrad KA, *see* Fagan, 493
 Consolo F, *see* Arrigo, 941
 Conti A, *see* Monopoli, 59
 Corea L, Bentivoglio M, Berlioli S, Bianchini C, Savino K, Sardina M. Verapamil 240 SR versus verapamil 120 SR in arterial hypertension. A randomized double-blind placebo-controlled study with 24-hour ambulatory blood pressure monitoring, 1501
 Corona P, *see* Sellier, 820
 Corsi M, *see* Cherchi, 481
 Costagliola C, Fasano ML, Iuliano G, Ferrara LA. Effects of ketanserin on intraocular pressure, 97
 Coto V, Cocozza M, Oliviero U, Lucariello A, Picano T, Castaldo B, Iovino V, Cacciatore L. Regression of left ventricular hypertrophy and systolic function during long-term treatment with ketanserin, 77
 Coumel P. Comments of P. Coumel, 1183
 Coumel P. Encainide vs. flecainide in the treatment of chronic resistant paroxysmal atrial tachyarrhythmias, 579
 Coumel P, *see* Dessertenne, 1177
 Coumel P, *see* Le Clercq, 1161
 Covi G, *see* Sheiban, 957
 Cox JP, *see* O'Malley, 1249
 Cribier A, *see* Lardoux, 1337
 Crozier IG, Ikram H, Nicholls MG, Low CJS. Twenty-four hour profile of the hypotensive action of felodipine in essential hypertension, 439
 Curtis MJ, Bernier M, Szendey G. Torsades de pointes: a re-evaluation, 1169
 Daffonchio A, *see* Mancina, 1223
 Dahlof B, *see* Hansson, 1253
 D'Almeida P. Electrocardiographic assessment of trimetazidine antiischemic properties, 810
 Dall JLC. Key factors in the treatment of the elderly hypertensive, 1263
 Dalla-Volta S, Maraglino G, Della-Valentina P, Viena P, Desideri A. Comparison of trimetazidine with nifedipine in effort angina: A double-blind, crossover study, 853
 d'Angelo A, *see* Calo, 983
 Danielsson B, *see* Larsson, 253
 David D, *see* Rocha, 1525
 Deanfield JE. Total ischemic burden in patients with coronary artery disease, 833
 Deckers J, *see* Jost, 1037
 Deckers JW, *see* Lichtlen, 1047
 De Divitiis O, *see* Di Somma, 1151
 De Graeff PA, *see* Tio, 695
 De Jong JW. Myocardial energy metabolism, 756
 De Landsheere C, *see* Rigo, 847
 De Langen CDJ, *see* Tio, 695
 Della-Valentina P, *see* Dalla-Volta, 853
 Demange J, *see* Monpere, 824
 De Marneffe M, Waterschoot P, Bernard A, Dubois P, Boujelben F, Liebens I, Englert M. Electrophysiologic effects of intravenous xamoterol in patients with sinus node dysfunction, 523
 Den Boer MO, Sassen LMA, van der Giesen WJ, Saxena PR, Verdouw PD. Effects of dilevalol in the anesthetized pig with a partially occluded coronary artery, 1461
 Denjoy I, *see* Le Clercq, 1161
 De Paola M, *see* Santinelli, 681
 Desideri A, *see* Dalla-Volta, 853
 Dessertenne F. Ventricular tachycardia with two variable foci, 1171
 Dessertenne F, Coumel P, Fabiato A. Ventricular fibrillation and torsades de pointes, 1177
 Detry J-M, Feiler R, Berckmans T, Le Clercq P. A new semi-automated algorithm to quantify Holter-detected myocardial ischemia: Preliminary experience in the Trimetazidine European Multicenter Trial (TEMS), 841
 De Vernejoul D, *see* Lardoux, 1337
 Dews I, *see* Marks, 93
 Dieterich HA, *see* Thormann, 1403
 Dietz R, *see* Haass, 289
 DiSomma S, Liguori V, Pettito M, Cavallotti G, Savonitto S, de Divitiis O. Hemodynamic interactions between diuretics and calcium antagonists in the treatment of hypertensive patients, 1151
 Dorigo P, Gaion RM, Bergamin M, Giacometti A, Valentini E, Maragno I. Comparison between the cardiac effects induced by mizolimine and furosemide in guinea-pig atria, 1477
 Dorigo P, Gaion RM, Maragno I. Involvement of purine compounds in the inotropic action of milrinone, 509
 Doyle AE. Serotonin antagonists and vascular protection, 13
 Drici M, *see* Gibelin, 1105
 Drolet G, *see* Minson, 27
 Drummer OH, *see* Louis, 1281
 Dubois P, *see* de Marneffe, 523
 Ducloux G, *see* Monpere, 824
 Duhaylongsod FG, *see* Iverson, 269
 Dunnmon PM, *see* Firth, 1363
 Dupuis B, *see* Libersa, 808
 Dustan HP. Obesity and hypertension in blacks, 395
 Dworkin LW. Impact of calcium entry blockers on glomerular injury in experimental hypertension, 1325
 Dzau VS, *see* Gibbons, 237
 Dzwonczyk S, *see* Grover, 465
 Ebina T, *see* Minamisawa, 1417
 Edgar B, *see* Hasselgren, 1495
 Edvardsson N, *see* Juul-Moeller, 631
 Efthymiopoulos C, *see* Kirch, 487
 Ehring T, Heusch G. Felodipine prevents the poststenotic myocardial ischemia induced by α_2 adrenergic coronary constriction, 443
 Ekblom T, *see* Hansson, 1253
 Elsner D, *see* Riegger, 1395
 Emura S, *see* Ohta, 1021
 Endoh M, Satoh H, Norota I, Hirano K. Effects of a new 1,3 thiazole derivative ZSY-39 on force of contraction and cyclic AMP content in canine ventricular muscle, 1127
 Englert M, *see* de Marneffe, 523
 Enous R, *see* Coetzee, 806
 Epstein M. Introduction to focused section on calcium antagonists and the kidney, 1317

- Erne P, *see* Kiowski, 935
- Fabiani J-N, Jebara V, Carpentier A. Perioperative assessment of the quality of myocardial protection, 797
- Fabiato A, *see* Dessertenne, 1177
- Fagan TC, Conrad KA, Mayshar PV, Mackie MJ. Relationship between age and the cardiovascular response to meals, 493
- Fagard R, *see* Lijnen, 321
- Fagard R, *see* Staessen, 1237
- Fantini G, *see* Mattioli, 505
- Fariello R, *see* Boni, 265
- Farré J, *see* Brugada, 619
- Fasano ML, *see* Costagliola, 97
- Fasoli G, *see* Scognamiglio, 923
- Fehske KJ, *see* Haerer, 515
- Ferracin F, *see* Fetkovska, 105
- Ferrara LA, *see* Costagliola, 97
- Ferrari AU, *see* Mancina, 1223
- Fessler R, *see* Detry, 841
- Fetkovska N, Pletscher A, Ferracin F, Amstein R, Bühler FR. Impaired uptake of platelet 5 hydroxytryptamine in essential hypertension: Clinical relevance, 105
- Fiocchi G, *see* Fogari, 1145
- Firth BG, Dunnmon PM. Left ventricular dilatation and failure post-myocardial infarction: Pathophysiology and possible pharmacologic interventions, 1363
- Fleckenstein A, Frey M, Thimm F, Fleckenstein-Grun G. Excessive mural calcium overload—A predominant causal factor in the development of stenosing coronary plaques in humans, 1005
- Fleckenstein-Grun G, *see* Fleckenstein, 1005
- Fogari R, Zoppi A, Tettamanti F, Malamani G, Pasotti C. The effect of celiprolol on the blood lipid profile in hypertensive patients with high cholesterol levels, 1287
- Fogari R, Zoppi A, Tettamanti F, Poletti L, Rizzadri G, Fiocchi G. Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease, 1145
- Forlani A, *see* Monopoli, 59
- Frankel D, *see* Leenen, 499
- Frey M, *see* Fleckenstein, 1005
- Friedman BM, *see* Barlow, 1389
- Fudo T, *see* Kambara, 919
- Gagnol JP, *see* Puech, 549
- Gaion RM, *see* Dorigo, 509
- Gaion RM, *see* Dorigo, 1477
- Gambelli G, Amici E, Selvanetti A. Effects of nifedipine on left ventricular diastolic function in hypertension; Echo Doppler study, 951
- Gansser RE, Schneeweiss A, Weiss M, Bachmann KF. Hemodynamic and coronary vasodilative action of two nitroglycerin oral spray formulations, 475
- Garay G, *see* Milei, 1519
- Garay R. Typology of Na⁺ transport abnormalities in erythrocytes from essential hypertensive patients. A first step towards the diagnosis and specific treatment of different forms of primary hypertension, 373
- Gaudeal P, *see* Lardoux, 1337
- Ghigliotti G, *see* Brunelli, 909
- Ghione S, *see* Rosa, 133
- Giacometti A, *see* Dorigo, 1477
- Giannattasio C, *see* Mancina, 1223
- Giannini S, *see* Calo, 983
- Giasi M, *see* Santinelli, 681
- Gibbons GH, Dzau VS. Angiotensin converting enzyme inhibition and vascular hypertrophy in hypertension, 237
- Gibelin P, Sbirrazzuoli V, Drici M, Camous JP, Lapalus P, Morand P. Effects of short-term administration of dobutamine on left ventricular performance, exercise capacity, norepinephrine levels, and lymphocyte adrenergic receptor density in congestive heart failure, 1105
- Ginsburg R, *see* Narita, 723
- Ginsburg R, *see* Narita, 1097
- Giovannetti R, *see* Salvetti, 963
- Goldhammer E, *see* Silke, 457
- Gonasun LM, *see* Swartz, 413
- Gotoh E, *see* Minamisawa, 1417
- Gould SE, *see* McCarthy, 115
- Gould SE, *see* Marks, 93
- Gould SE, Silas JH, Hosie J. Could the increased antihypertensive efficacy of ketanserin in the elderly be due to altered pharmacokinetics?, 89
- Gradnik R, *see* Bracchetti, 261
- Grassi G, *see* Mancina, 1223
- Greco G, *see* Malatino, 123
- Grover GJ, Dzwonczyk S, Parham CS, Sleph PG. The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in isolated perfused rat hearts and anesthetized dogs, 465
- Guarnieri C, Mucari C. Beneficial effect of trimetazidine on mitochondrial function and superoxide production in the cardiac muscle, 814
- Guerret M, *see* Rocha, 1525
- Gugliotta HO, *see* Milei, 1519
- Guindo J, *see* Bayés de Luna, 651
- Haass M, Dietz R, Purgaj J, et al. Plasma concentrations of atrial natriuretic peptide during physical exercise in patients with congestive heart failure, 289
- Haddy FJ. Digitalislike circulating factor in hypertension: Potential messenger between salt balance and intracellular sodium, 343
- Haerer W, Bauer U, Sultan N, Cernoch K, Mouselimis N, Fehske KJ, Hetzel M, Stauch M, Hombach V. Acute and chronic effects of a diuretic monotherapy with piretanide in congestive heart failure—A placebo-controlled trial, 515
- Haitus B, *see* Obel, 613
- Halabi A, *see* Kirch, 487
- Hall WD, *see* Szlachet, 427
- Hampton JR. Flosequin for congestive heart failure. What promise does it hold?, 1313
- Hanania G, *see* Lardoux, 1337
- Hansson L, Dahlof B, Ekblom T, Lindholm L, Schersten B, Wester P-O. Key learnings from the STOP-hypertension study: An update on the progress of the ongoing Swedish study of anti-hypertensive treatment in the elderly, 1253
- Hanyok JJ, MacNeil DJ. Sotalol versus class I and II antiarrhythmic agents, 603
- Hara A, *see* Matsumura, 719
- Haraphongse M, *see* Burton, 687
- Harpey C, *see* Maridonneau-Parini, 818
- Harpey C, *see* Maupoil, 791
- Harpey C, *see* Sellier, 820
- Hashimoto K, Ohbayashi Y, Kinoshita M. Left ventricular effects of nicorandil in comparison with nitroglycerin in chronic conscious dogs, 1449
- Hasselgren B, Ronn O, Edgar B, Johansson P, Wall B. Pharmacokinetic, haemodynamic and diuretic/natriuretic effects of felodipine administered as an extended release tablet, 1495
- Hattori Y, *see* Saito, 987
- Haudenschild CC. Pathogenesis of atherosclerosis: state of the art, 993
- Hayashi H, Iwase M, Aoki T, Yokota M. Assessment of left ventricular function after sublingual administration of nifedipine in patients with moderate to severe hypertension, 969
- Hayashi M, *see* Kambara, 919
- Hearse DJ. Ischemia, reperfusion, and the determinants of tissue injury, 767
- Heber M, *see* Broadhurst, 435
- Hecker H, *see* Jost, 1037
- Hecker H, *see* Lichtlen, 1047
- Henry PD. Antiatherogenic effects of calcium-channel blockers: Possible mechanisms of action, 1015
- Herrmann G, *see* Amende, 887
- Hester RK, Shibata S. KT-362 related effects of intracellular calcium release

- and associated clinical potential: Arrhythmias, myocardial ischemia, and hypertension, 1345
- Hetzl M, *see* Haerer, 515
- Heusch G, *see* Ehring, 443
- Heusch G, *see* Linder, 1375
- Higuchi N, *see* Ohta, 1021
- Hiltgen M, *see* Lardoux, 1337
- Hirano K, *see* Endoh, 1127
- Hirsch A, *see* Szlachet, 427
- Hodsmen GP, *see* Phillips, 1209
- Holt D, *see* Robinson, 529
- Hombach V, *see* Haerer, 515
- Honore E, *see* Libersa, 808
- Hood WP Jr., *see* Amende, 887
- Hoosen S, Seedat YK, Bhigjee AI. A study of urinary and intracellular sodium and potassium, renin, aldosterone and hypertension in blacks and Indians in Natal, 363
- Hosie J, *see* Gould, 89
- Houplon M, *see* Lardoux, 1337
- Houplon M, *see* Simon, 1467
- Hsu L, *see* Burton, 687
- Huetting J, *see* Thormann, 1403
- Hugenholtz PG, *see* Jost, 1037
- Hugenholtz PG, *see* Lichtlen, 1047
- Hunt SC, Williams R, Ash KO. Changes in sodium-lithium countertransport correlate with changes in triglyceride levels and body mass index over 2-1/2 years of follow-up in Utah, 357
- Iannetti M, *see* Brunelli, 909
- Ibsen H, Westberg B. The efficacy and tolerability of long-term felodipine treatment in hypertension, 641
- Iimura O, Shimamoto K, Komura H. Effects of slow-release nifedipine on water-sodium, uric acid, and calcium metabolism, and on aldosterone secretion in patients with essential hypertension, 977
- Ikram H, *see* Crozier, 439
- INTACT Study Group, *see* Jost, 1037
- INTACT Study Group, *see* Lichtlen, 1047
- Iovino V, *see* Coto, 77
- Ishii M, *see* Minamisawa, 1417
- Iuliano G, *see* Costagliola, 97
- Iverson LIG, Duhaylongsod FG, Young J, et al. Porcine heparin increases post-operative bleeding in cardiopulmonary bypass patients, 269
- Iwase M, *see* Hayashi, 969
- Jaillon P. Pharmacokinetics and metabolism of encainide, 561
- Jardine R, *see* Obel, 613
- Jebara V, *see* Fabiani, 797
- Jianjun Liu, *see* Nayler, 879
- Johansson P, *see* Hasselgren, 1495
- John SM, *see* McCarthy, 115
- Johnston A, *see* Robinson, 529
- Johnston CI, *see* Phillips, 1209
- Jost S, Deckers J, Rafflenbeul W, Hecker H, Nellessen U, Wiese B, Hugenholtz PG, Lichtlen PR, INTACT Study Group. Features of the angiographic evaluation of the INTACT Study, 1037
- Jost S, Rafflenbeul W, Mogwitz B, et al. Vasodilatory effects of nisoldipine on coronary arteries—correlation with plasma levels, 273
- Jost S, *see* Lichtlen, 1047
- Jung L, *see* Kirch, 487
- Juul-Moeller S, Edvardsson N, Rehnqvist N. Sotalol versus quinidine in the maintenance of sinus rhythm after direct current conversion of atrial fibrillation, 631
- Kahles H, *see* Riegger, 1395
- Kahn JC, *see* Rocha, 1525
- Kambara H, Mohiuddin I, Tamaki N, Fudo T, Hayashi M, Nohara R, Konishi J, Kawai C. Effects of nifedipine on cardiac function in patients with coronary artery disease evaluated with ambulatory radionuclide monitoring, 919
- Kantor M, *see* Pederson, 451
- Kaplan NM. Individual differences mean that the cost of treatment of hypertension cannot readily be quantified, 1439
- Kapoor V, *see* Minson, 27
- Kappagoda CT, *see* Burton, 687
- Karpanou EA, *see* Vyssoulis, 81
- Kato H, *see* Ohta, 1021
- Katz RJ. Mechanisms of nitrate tolerance: A review, 247
- Kawai C, *see* Kambara, 919
- Kaye GC, Mehta D, Wafa S, Camm AJ. Acute electrophysiologic effects of an HT2=Serotonin antagonist, ketanserin, in humans, 1157
- Kazda S, *see* Knorr, 1027
- Keane WF, *see* Opsahl, 221
- Kinoshita M, Sakai K. Pharmacology and therapeutic effects of nicorandil, 1075
- Kinoshita M, *see* Hashimoto, 1449
- Kiowski W, Erne P, Buhler FR. Use of nifedipine in hypertension and Raynaud's phenomenon, 935
- Kirch W, Milferstadt S, Halabi A, Rocher I, Efthymiopoulos C, Jung L. Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity, 487
- Klein H, *see* Trappe, 1425
- Klenner C, *see* Roman, 745
- Knorr AM, Kazda S. Influence of nifedipine on experimental arteriosclerosis, 1027
- Kochsiek K, *see* Riegger, 1395
- Kok FJ, *see* Bartels, 705
- Komura H, *see* Iimura, 977
- Konishi J, *see* Kambara, 919
- Konishi M, Sakakura M, Tsushima N. Effects of ketanserin on microhemodynamics and hemorheology in patients with essential hypertension, 101
- Koskinen P, *see* Rapola, 737
- Kourti TK, *see* Vyssoulis, 81
- Krauss XH, *see* Bartels, 705
- Kremer P, *see* Thormann, 1403
- Kreuzer H, *see* Brune, 85
- Kromer EP, *see* Riegger, 1395
- Kruyssen HACM, *see* Bartels, 705
- Kulbertus H, *see* Rigo, 847
- Ladetto PE, *see* Lavezzaro, 119
- Lahiri A, *see* Broadhurst, 435
- Lai C, *see* Cherchi, 481
- Lamon KD. Evaluation of celiprolol, a new cardioselective beta₁-adrenergic blocker with vasodilating properties in the treatment of mild to moderate hypertension in the elderly, 1291
- Langford HG, Watson RL. Potassium and calcium intake, excretion, and homeostasis in blacks, and their relation to blood pressure, 403
- Lapalus P, *see* Gibelin, 1105
- Lardoux H, Louvard Y, de Vernejoul D, Picot C, Baudet M, Hiltgen M, Houplon M, Ponsonnaille J, Richard M, Luccioni R, Rocher R, Hanania G, Gaudel P, Cribier A, Letac B. French multicenter trial of anistreplase versus heparin in acute myocardial infarction, 1337
- Larochelle P. Hypertension in the elderly, 947
- Larsson R, Lindsjö MK, Danielsson B, et al. Felodipine in the treatment of patients with severe hypertension and impaired renal function, 253
- Lavanchy N, *see* Rossi, 812
- Lavezzaro G, Ladetto PE, Valente M, Stramignoni D, Zanna C, Assogna G, Salvetti A. Ketanserin and captopril interaction in the treatment of essential hypertensives, 119
- Lebrech D. Portal hypertension: Serotonin and pathogenesis, 33
- Lechi A, *see* Sheiban, 957
- LeClercq JF, Denjoy I, Mentré F, Coumel P. Flecainide acetate dose-concentration relationship in cardiac arrhythmias: Influence of heart failure and amiodarone, 1161
- Leclercq, *see* Detry, 841
- Leenen FHH, Burns RJ, Myers MG, Frankel D. Effects of nifedipine versus hydralazine on sympathetic activity and cardiac function in patients with hypertension persisting on diuretic plus beta-blocker therapy, 499
- Lenzi M, *see* Salvetti, 963
- Letec B, *see* Lardoux, 1337
- Libersa C, Caron J, Rouet R. In vitro and in vivo electrophysiological effects of encainide, 567

- Libersa C, Honore E, Adamantidis M, Rouet E, Dupuis B. Antiischemic effect of trimetazidine enzymatic and electric response in a model of in-vitro myocardial ischemia, 808
- Lichtlen P, *see* Trappe, 1425
- Lichtlen PR, Hugenholz PG, Rafflenbeul W, Hecker H, Jost S, Nikutta P, Deckers JW, INTACT study group. Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: Results of the INTACT Study (International Nifedipine Trial on Antiatherosclerotic Therapy), 1047
- Lichtlen PR, *see* Amende, 887
- Lichtlen PR, *see* Jost, 1037
- Liebner I, *see* Marneffe, 523
- Liguori V, *see* Di Somma, 1151
- Lijnen P, M'Buyama-Kabangu J-R, Fagard R, et al. Erythrocyte concentrations and transmembrane fluxes of sodium and potassium in essential hypertension: Role of intrinsic and environmental factors, 321
- Lijnen P, *see* Staessen, 1237
- Linder C, Heusch G. ACE inhibitors for the treatment of myocardial ischemia?, 1375
- Lindholm L, *see* Hansson, 1253
- Lindsjö MK, *see* Larsson, 253
- Llewellyn-Smith I, *see* Minson, 27
- Longhini C, Ansani L, Musacci G, Mele D, Vaccari M, Baracca E, Sgobino P. The effect of captopril on peripheral hemodynamics in patients with essential hypertension: Comparison between oral and sublingual administration, 751
- Look MP, *see* Bartels, 705
- Louis WJ, Drummer OH, Tung L-H. Pharmacology of celiprolol, 1281
- Louvard Y, *see* Lardoux, 1337
- Low CJS, *see* Crozier, 439
- Lucariello A, *see* Coto, 77
- Luccioni R, *see* Lardoux, 1337
- Lund-Johansen P, *see* Omvik, 1135
- McAllister RG Jr., *see* Swartz, 413
- McCarthy ST, *see* McCarthy ST, 115
- McCarthy ST, McCarthy GL, John SM, Gould SE. A placebo-controlled crossover study of ketanserin in elderly hypertensive patients, 115
- McKenna W, *see* Robinson, 529
- Mackie MJ, *see* Fagan, 493
- MacNeil DJ, *see* Hanyok, 603
- McNeil JJ, Silagy CA. Hypertension in the elderly: Epidemiology and pathophysiology, 1197
- Madoery C, *see* Bayés de Luna, 651
- Magagna A, *see* Salvetti, 963
- Malamani G, *see* Fogari, 1287
- Malatino LS, Stancanelli B, Greco G, Polizzi G, Assogna G, Zanna C, Tamburino G. Comparison of ketanserin and enalapril in the treatment of mild-to-moderate essential hypertension, 123
- Mancia G, Cleroux J, Daffonchio A, Ferrari AU, Giannattasio C, Grassi G. Reflex control of circulation in the elderly, 1223
- Mancini M, Pauciuolo P. Clinical relevance of hyperlipidaemia, 1385
- Maraglino G, *see* Dalla-Volta, 853
- Maragno I, *see* Dorigo, 509
- Maragno I, *see* Dorigo, 1477
- Marchand X, *see* Rocha, 1525
- Marchesini J, *see* Capucci, 281
- Maridonneau-Parini I, Harpey C. Trimetazidine protects the human red blood cell against oxygen free radical damage, 818
- Marigliano A, *see* Sechi, 63
- Marks C, Dews I, Gould SE, Stephens J, Van den Burg M. The effects of ketanserin on ventricular ectopic activity in man, 93
- Martin J, *see* Rossi, 812
- Maseri A. Mechanisms of myocardial ischemia, 827
- Masia S, *see* Sechi, 63
- Massie B, *see* Szlachet, 427
- Matsumura H, Hara A, Abiko Y. Effect of diltiazem on the oxyhemoglobin level of myocardial cells in the isolated, perfused rat heart during hypoxia, 719
- Mattioli AV, Modena MG, Fantini G, Mattioli G. Atenolol in dilated cardiomyopathy: A clinical instrumental study, 505
- Mattioli G, *see* Mattioli, 505
- Maupail V, Rochette L, Clauser P, Harpey C. Evolution of free radical formation during low-flow ischemia and reperfusion in isolated rat heart, 791
- Mayshar PV, *see* Fagan, 493
- Mazzone A, Ricevuti G. Interaction between morphine and granulocytic aggregation in myocardial ischemia, 303
- M'Buyama-Kabangu J-R, *see* Lijnen, 321
- M'Buyama-Kabangu J-R, Tambwe M. The efficacy of beta-adrenoceptor and calcium-entry blockers in hypertensive blacks, 389
- Mehta D, *see* Kaye, 1157
- Mele D, *see* Longhini, 751
- Melis A, *see* Sechi, 63
- Melon P, *see* Rigo, 847
- Meloni C, *see* Bottero, 991
- Mentré F, *see* LeClerc, 1161
- Meschini L, *see* Bottero, 991
- Meza H, *see* Roman, 745
- Milazzotto F, *see* Natale, 1509
- Milei J, Ale JJ, Garay G, Otero F, Comba AZ, Gugliotta HO, Storino RA. Hemodynamic effects of chronic 4'-epi-adriamycin administration, 1519
- Milferstädt S, *see* Kirch, 487
- Millar RN Scott, *see* Obel, 613
- Mills E, *see* Minson, 27
- Minamisawa K, Shionoiri H, Sugimoto K, Ueda S, Ashino K, Ebina T, Gotoh E, Ishii M. Depressor effects and pharmacokinetics of single and consecutive doses of delapril in hypertensive patients with normal or impaired renal function, 1417
- Minson J, Chalmers J, Drolet G, Kapoor V, Llewellyn-Smith I, Mills E, Morris M, Pilowsky P. Central serotonergic mechanisms in cardiovascular regulation, 27
- Mitrovic J, *see* Thormann, 1403
- Modena MG, *see* Mattioli, 505
- Mogwitz B, *see* Jost, 273
- Mohiuddin I, *see* Kambara, 919
- Momose Y, Sasayama S. Effect of OPC-8490 on the membrane potentials and membrane currents of single guinea-pig myocytes, 713
- Monopoli A, Conti A, Forlani A, Ongini E, Antona C, Biglioli P. 5-Hydroxytryptamine induces contraction in isolated human mammary artery: Effects of ketanserin, 59
- Monpere C, Brochier M, Demange J, Ducoux G, Warin JF. Combination of trimetazidine with nifedipine in effort angina, 824
- Montessoro G, *see* Sheiban, 957
- Mook PH, *see* Tio, 695
- Morand P, *see* Gibelin, 1105
- Morgan KG. The role of calcium in the control of vascular tone as assessed by the Ca^{2+} indicator aequorin, 1355
- Morganroth J. Determination of antiarrhythmic drug efficacy in the treatment of ventricular arrhythmias, 669
- Morikami Y, *see* Yasue, 915
- Morosetti M, *see* Bottero, 991
- Morosetti P, *see* Bottero, 991
- Morris M, *see* Minson, 27
- Moss AJ. Identification of patients at increased risk for potentially malignant arrhythmias, 665
- Mouselimis N, *see* Haerer, 515
- Muller-Schweinitzer E. Venoconstrictor responses to dihydroergocristine and dihydroergotamine: Evidence for the involvement of 5-HT-like receptors, 1455
- Mulrow J, *see* Robinson, 529
- Musacci G, *see* Longhini, 751
- Muscari C, *see* Guarneri, 814
- Myburgh DP, *see* Barlow, 1389
- Myers MG, *see* Leenen, 499
- Nakamura H, *see* Suzuki, 69
- Nappi JM, *see* Pool, 1089
- Narita H, Zera PH, Ginsburg R. Mechanism of action of clonidine on human coronary artery and myocardium, 1097

- Narita N, Ginsburg R. In vitro study of effect of clentiazem on rabbit aorta and on myocardium, 723
- Natale E, Ricci R, Milazzotto F. Effects of acute administration of gallopamil on left ventricular relaxation and filling dynamics in acute myocardial infarction assessed by doppler echocardiography, 1509
- Nayler WG, Jianjun Liu, Pangiotopoulos. Nifedipine and experimental cardioprotection, 879
- Nellessen U, *see* Jost, 1037
- Nesto RW. Rationale for treatment of silent myocardial ischemia: Focus on nifedipine, 929
- Nicholls MG, *see* Crozier, 439
- Nieminen MS, *see* Rapola, 737
- Nikutta P, *see* Lichtlen, 1047
- Nohara R, *see* Kambara, 919
- Norota I, *see* Endoh, 1127
- Norris RJ. Introduction: Efficacy of celiprolol in hypertension and angina pectoris, 1195
- Obel IWP, Jardine R, Haitus B, Scott Millar RN. Efficacy of oral sotalol in reentrant ventricular tachycardia, 613
- O'Brien E, *see* O'Malley, 1249
- Oganov RG, *see* Chazov, 755
- Ohbayashi Y, *see* Hashimoto, 1449
- Ohmori K, *see* Ohta, 1021
- Ohta Y, Higuchi N, Emura S, Takashima T, Oogushi K, Kato H, Ohmori K, Sunaga T. Quantitative analysis of anti-atherosclerotic effect of nifedipine in cholesterol-fed rabbits, 1021
- Okazawa M, *see* Saito, 987
- Oliviero U, *see* Coto, 77
- O'Malley K, Cox JP, O'Brien E. Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: Focus on systolic hypertension, 1249
- Omvik P, Lund-Johansen P. The initial hemodynamic response to newer antihypertensive agents at rest and during exercise: Review of visacor, doxazosin, nisoldipine, tiapamil, perindoprilat, pinacidil, dilevalol, and carvedilol, 1135
- Ongini E, *see* Monopoli, 59
- Onnis E, *see* Cherchi, 481
- Ogushi K, *see* Ohta, 1021
- OPC-8212 Multicenter Research Group. A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure, 419
- Opie LH. Discussion: Cerebral blood flow, cardiovascular reflexes, and respiratory function, 1233
- Opie LH. Discussion: Overview of epidemiology, systolic hypertension, and neurohumoral mechanisms, 1215
- Opie LH. Discussion: Overview of major trials and key factors in treatment, 1269
- Opie LH. Discussion: Required beta-blocker profile: Data on celiprolol, 1297
- Opie LH. Forum on torsades de pointes: Introduction, 1167
- Opie LH. Myocardial ischemia—metabolic pathways and implications of increased glycolysis, 777
- Opie LH. Required beta-blocker profile in the elderly, 1273
- Opie LH. What is new in myocardial ischemia, 765
- Opie LH, *see* Bayés de Luna, 649
- Opie LH, *see* Coetzee, 806
- Opsahl JA, Abraham PA, Keane WF. Renal effects of angiotensin converting enzyme inhibitors: Non-diabetic chronic renal disease, 221
- Orani E, *see* Cherchi, 481
- Osterrieder W, *see* Clozel, 731
- Otero F, *see* Milei, 1519
- Ourbak P, *see* Sellier, 820
- Pala A, *see* Sechi, 63
- Paleologos AA, *see* Vyssoulis, 81
- Panagiotopoulos S, *see* Nayler, 879
- Parham CS, *see* Grover, 465
- Pasotti C, *see* Fogari, 1287
- Paucillo P, *see* Mancini, 1385
- Pederson TR, Kantor M. Nisoldipine tablets once daily versus nifedipine capsules three times daily in patients with stable effort angina pectoris pretreated with atenolol, 451
- Pelliccia F, Cianfrocca C, Romeo F, Reale A. Hypertrophic cardiomyopathy: Long-term effects of propranolol versus verapamil in preventing sudden death in "low-risk" patients, 1515
- Pelliccia F, *see* Barilla, 905
- Pellinen TJ, *see* Rapola, 737
- Petitto M, *see* Di Somma, 1151
- Phillips PA, Hodsmann GP, Johnston CI. Neuroendocrine mechanisms and cardiovascular homeostasis in the elderly, 1209
- Picano T, *see* Coto, 77
- Piccoli A, *see* Calo, 983
- Picot C, *see* Lardoux, 1337
- Pilowsky P, *see* Minson, 27
- Pirisi R, *see* Cherchi, 481
- Pisano M Rosaria, *see* Cherchi, 481
- Pitsavos CE, *see* Vyssoulis, 81
- Pletscher A, *see* Fetkovska, 105
- Poletti L, *see* Fogari, 1145
- Polimeni PI, *see* Smyth, 291
- Polizzi G, *see* Malatino, 123
- Ponsonnaille J, *see* Lardoux, 1337
- Pool PE. Efficacy of encainide in supraventricular arrhythmias, 573
- Pool PE, Nappi JM, Weber MA. Antihypertensive monotherapy with tablet (prompt-release) diltiazem: Multicenter controlled trials, 1089
- Porter V, *see* Szlachet, 427
- Poston L. Sodium transport inhibitors in pregnancy-induced hypertension, 351
- Puech P, Gagnol JP. Class IC drugs: Propafenone & flecainide, 549
- Purgaj J, *see* Haass, 289
- Quintanilla AP, Wagener OE. Diuretics and cation transport in hypertensive blacks, 383
- Rafflenbeul W, *see* Jost, 273
- Rafflenbeul W, *see* Jost, 1037
- Rafflenbeul W, *see* Lichtlen, 1047
- Raftery EB, *see* Broadhurst, 435
- Rapola JM, Pellinen TJ, Koskinen P, Toivonen L, Nieminen MS. Hemodynamic effects of pindolol and atenolol at rest and during isometric exercise: A non-invasive study with healthy volunteers, 737
- Reale A, *see* Barilla, 905
- Reale A, *see* Pelliccia, 1515
- Reams GP, Bauer JH. Acute and chronic effects of angiotensin converting enzyme inhibitors on the hypertensive kidney, 207
- Reams GP, Bauer JH. Effects of calcium antagonists on the hypertensive kidney, 1331
- Rehnqvist N. Prevention of sudden death by beta-blockade, 675
- Rehnqvist N, *see* Juul-Moeller, 631
- Remme WJ, *see* Bartels, 705
- Reneman RS, Van der Starre PJA. Serotonin and acute cardiovascular disorders, 19
- Ricci R, *see* Natale, 1509
- Ricevuti G, *see* Mazzone, 303
- Richard M, *see* Lardoux, 1337
- Riegger GAJ, Kahles H, Wagner A, Kromer EP, Elsner D, Kochsiek K. Exercise capacity, hemodynamic, and neurohumoral changes following acute and chronic administration of flosequinan in chronic congestive heart failure, 1395
- Rigo P, de Landsheere C, Melon P, Kulbertus H. Imaging of myocardial metabolism by positron emission tomography, 847
- Rizzardi G, *see* Fogari, 1145
- Robert J, *see* Catroux, 816
- Robertson JIS. Carcinoid syndrome and serotonin: Therapeutic effects of ketanserin, 53
- Robertson JIS. Closing remarks. Serotonin and vascular disease: A survey, 137
- Robinson K, Johnston A, Walker S, Mulrow J, Holt D, McKenna W. Stability of plasma amiodarone levels during chronic oral therapy, 529

- Rocha P, Guerret M, David D, Marchand X, Kahn JC. Kinetics and hemodynamic effects of intravenous nicardipine modified by previous propranolol oral treatment, 1525
- Rocher I, *see* Kirch, 487
- Rocher R, *see* Lardoux, 1337
- Rochette L, *see* Maupoil, 791
- Rockstroh JK, *see* Schmieder, 1487
- Roman M, *see* Bayés de Luna, 651
- Roman O, Meza H, Klenner C. Effect of celiprolol on large and small arteries of the forearm circulation in hypertensive patients, 745
- Romeo F, *see* Barilla, 905
- Romeo F, *see* Pelliccia, 1515
- Ronn O, *see* Hasselgren, 1495
- Rosa C, Ghione S. Effect of ketanserin on pain perception in arterial hypertension, 133
- Rossall RE, *see* Burton, 687
- Rossi A, Lavanchy N, Martin J. Antiischemic effect of trimetazidine 31P-NMR spectroscopy study in the isolated rat heart, 812
- Rouet E, *see* Libersa, 808
- Rouet R, *see* Libersa, 567
- Ruilope LM, Alcazar JM. Renal effects of calcium entry blockers, 979
- Rutan GH. Systolic hypertension in the elderly, 1203
- Saito Y, Shirai K, Uchino J, Okazawa M, Hattori Y, Yoshida T, Yoshida S. Effect of nifedipine administration on pulse wave velocity (PWV) of chronic hemodialysis patients—two years trial, 987
- Sakai K, *see* Kinoshita, 1075
- Sakakura M, *see* Konishi, 101
- Salvetti A, Magagna A, Abdel-Haq B, Lenzi M, Giovannetti R. Nifedipine interactions in hypertensive patients, 963
- Salvetti A, *see* Lavezzaro, 119
- Sami M. Comparative hemodynamics of antiarrhythmic drugs, 545
- Santinelli C, *see* Santinelli, 681
- Santinelli V, Turco P, DePaolo M, Smimno D, Giasi M, Santinelli C, Chiariello M, Condorelli M. Propafenone in Wolff-Parkinson-White syndrome at risk, 681
- Sardina M, *see* Corea, 1501
- Sasaki J, Arakawa K. Effects of short- and long-term administration of nifedipine on serum lipoprotein metabolism in patients with mild hypertension, 1033
- Sasayama S, *see* Momose, 713
- Sassen LMA, *see* Den Boer, 1461
- Satoh H, *see* Endoh, 1127
- Satoh K, *see* Yoneyama, 1119
- Satoh K, *see* Yoneyama, 1469
- Saunders E. Cellular mechanisms in hypertension and therapeutic implications in blacks, 317
- Savino K, *see* Corea, 1501
- Savonitto S, *see* Di Somma, 1151
- Saxena PR, *see* Den Boer, 1461
- Sbirrazzuoli V, *see* Gibelin, 1105
- Schersten B, *see* Hansson, 1253
- Schlaut B, *see* Burton, 687
- Schlepper M, *see* Thormann, 1403
- Schmidt T, *see* Brune, 85
- Schmieder RE, Rockstroh JK. When is discontinuation of antihypertensive therapy indicated?, 1487
- Schneeweiss A, *see* Gansser, 475
- Schrier RW, *see* Burke, 1319
- Scognamiglio R, Fasoli G. Effects of nifedipine on left ventricular diastolic dysfunction after myocardial infarction, 923
- Scott Millar RN. Efficacy of sotalol in controlling re-entrant supraventricular tachycardias, 625
- Sechi LA, Tedde R, Cassisa L, Pala A, Marigliano A, Masia S, Melis A. Evidence for a direct and non-receptor-mediated action of 5HT₂ antagonists on transmembrane cation transport systems, 63
- Seedat YK, *see* Hoosen, 363
- Sellier P. Chronic effects of trimetazidine on ergometric parameters in effort angina, 822
- Sellier P, Harpey C, Corona P, Audoubert P, Ourbak P. Acute effects of trimetazidine on ergometric parameters in effort angina, 820
- Selvanetti A, *see* Gambelli, 951
- Senaratne MPJ, *see* Burton, 687
- Sgobino P, *see* Longhini, 751
- Sharma SK, *see* Silke, 457
- Sharpe N. Cardiac effects of ACE inhibitors, 243
- Sheiban I, Covi G, Zenorini C, Arcaro G, Arosio E, Tonni S, Montessoro G, Lechi A. Early regression of left ventricular diastolic abnormalities in hypertensive patients treated with nifedipine, 957
- Shibata S, *see* Hester, 1345
- Shimamoto K, *see* Iimura, 977
- Shionoiri H, *see* Minamisawa, 1417
- Shirai K, *see* Saito, 987
- Shulman NB. Cellular mechanisms and their implications in hypertensive blacks, 315
- Silagy CA, *see* McNeil, 1197
- Silas JH, *see* Gould, 89
- Silke B, Goldhammer E, Sharma SK, Verma SP, Taylor SH. An exercise hemodynamic comparison of verapamil, diltiazem, and amlodipine in coronary artery disease, 457
- Simon JP, Zannad F, Trechot P, Thisse JY, Houplon M, Aliot E. Acute hepatitis after a loading dose of intravenous amiodarone, 1467
- Simon R, *see* Amende, 887
- Singh BN. Is class III activity important?, 597
- Singh H, *see* Burke, 1319
- Singh RB. Calcium and blood pressure, 301
- Sleph PG, *see* Grover, 465
- Smeets JLRM, *see* Brugada, 619
- Smimno D, *see* Santinelli, 681
- Smith DHG, *see* Barlow, 1389
- Smyth DD, Polimeni PI. Drag reducing polymers: A novel class of diuretic and natriuretic compounds, 297
- Soicher ER, *see* Barlow, 1389
- Soro A, *see* Cherchi, 481
- Spallarossa P, *see* Brunelli, 909
- Specchia G. Increased coronary tone in exertional angina: The beneficial effects of calcium antagonists, 893
- Staessen J, Fagard R, Lijnen P, Van Hoof R, Amery A. Review of the major hypertension trials in the elderly, 1237
- Stancanelli B, *see* Malatino, 123
- Stauch M, *see* Haerer, 515
- Steenkamp WFJ, *see* Barlow, 1389
- Stephens J, *see* Marks, 93
- Storino RA, *see* Milei, 1519
- Stramignoni D, *see* Lavezzaro, 119
- Strandgaard S. Cerebral blood flow in the elderly: Impact of hypertension and antihypertensive treatment, 1217
- Strano A. Introduction: Nifedipine and cardioprotection, 877
- Sugimoto K, *see* Minamisawa, 1417
- Sultan N, *see* Haerer, 515
- Sunaga T, *see* Ohta, 1021
- Suzukawa M, Nakamura H. Effects of ketanserin tartrate on 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured human skin fibroblasts, 69
- Swales JD. Membrane transport of ions in hypertension, 367
- Swartz SL, Gonasun LM, McAllister RG Jr., Thadani U. A multicenter comparison of isradipine and prazosin for treatment of essential hypertension, 413
- Szendey G, *see* Curtis, 1169
- Szlachet J, Hall WD, Tubau JF, Porter V, Vollmer C, Wollam G, Hirsch A, Massie B. Left ventricular hypertrophy reversal with labetalol and propranolol: A prospective, randomized double-blind study, 427
- Taccone Gallucci M, *see* Bottero, 991
- Taira N, *see* Yoneyama, 1119
- Taira N, *see* Yoneyama, 1469
- Takashima T, *see* Ohta, 1021
- Tamaki N, *see* Kambara, 919
- Tamburino G, *see* Malatino, 123

- Tambwe M, *see* M'Buyamba-Kabangu, 389
- Tattersfield AE. Respiratory function in the elderly and the effects of beta blockade, 1229
- Taylor SH, *see* Silke, 457
- Tebbe U, *see* Brune, 85
- Tedde R, *see* Sechi, 63
- Tettamanti F, *see* Fogari, 1145
- Tettamanti F, *see* Fogari, 1287
- Textor SC. ACE inhibitors in renovascular hypertension, 229
- Thadani U, *see* Swartz, 413
- Thimm F, *see* Fleckenstein, 1005
- Thind GS. Angiotensin converting enzyme inhibitors: Comparative structure, pharmacodynamics, 199
- Thisse JY, *see* Simon, 1467
- Thomas JA. Encainide: An updated safety profile, 585
- Thormann J, Hueting J, Kremer P, Wisemann J, Mitrovic J, Dieterich HA, Schlepper M. Enoximone: True inotropic effects? Do they cause ischemia? Analysis of endsystolic pressure-volume relations using the conductance (volume) catheter technique, 1403
- Tio RA, de Langen CDJ, de Graeff PA, Van Gilst WH, Bel KJ, Wolters KGTP, Mook PH, van Wijngaarden J, Wesseling H. The effects of oral pretreatment with zofenopril, and angiotensin-converting enzyme inhibitor, on early reperfusion and subsequent electrophysiological stability in the pig, 695
- Toivonen L, *see* Rapola, 737
- Tonni S, *see* Sheiban, 957
- Touboul P. Electrophysiological evaluation of antiarrhythmic drugs, 535
- Toutouzas PK, *see* Vyssoulis, 81
- Trappe H-J, Klein H, Lichtlen P. Sotalol in patients with life-threatening ventricular tachyarrhythmias, 1425
- Trechot P, *see* Simon, 1467
- Tsushima N, *see* Konishi, 101
- Tubau JF, *see* Szlachcic, 427
- Tung LH, *see* Louis, 1281
- Turco P, *see* Santinelli, 681
- Uchino J, *see* Saito, 987
- Ueda S, *see* Minamisawa, 1417
- Vaccari M, *see* Longhini, 751
- Valente A, *see* Barilla, 905
- Valente M, *see* Lavezzaro, 119
- Valentini E, *see* Dorigo, 1477
- Van Brummelen P, *see* Van Zweiten, 1443
- Van den Burg M, *see* Marks, 93
- Van der Giessen WJ, *see* Den Boer, 1461
- Van der Starre PJA, *see* Reneman, 19
- Van Gilst WH, *see* Tio, 695
- Van Hoof R, *see* Staessen, 1237
- Vanhoutte PM. Serotonergic antagonists and vascular disease, 7
- Van Oene JC. Oral dosing with ketanserin to control high blood pressure in the elderly, 111
- Van Wijngaarden J, *see* Tio, 695
- Van Zweiten PA, Blauw GJ, van Brummelen P. The role of serotonin in cardiovascular diseases and their treatment, 1443
- Véniant M, *see* Clozel, 731
- Verdouw PD, *see* Den Boer, 1461
- Verma SP, *see* Silke, 457
- Viena P, *see* Dalla-Volta, 853
- Vollmer C, *see* Szlachcic, 427
- Vyssoulis GP, Karpanou EA, Pitsavos CE, Paleologos AA, Kourtis TK, Toutouzas PK. Left ventricular hypertrophy regression and function changes with ketanserin in elderly hypertensives, 81
- Wafa S, *see* Kaye, 1157
- Wagener OE, *see* Quintanilla, 383
- Wagner A, *see* Riegger, 1395
- Walker S, *see* Robinson, 529
- Wall B, *see* Hasselgren, 1495
- Waller D, Challenor V. The combination of slow-release nifedipine and atenolol for stable angina, 899
- Warin JF, *see* Monpere, 824
- Waterschoot P, *see* de Marneffe, 523
- Watson RL, *see* Langford, 403
- Weber MA, *see* Pool, 1089
- Weinberger MH. Racial differences in antihypertensive therapy: Evidence and implications, 379
- Weiner CP. The role of serotonin in the preeclampsia-eclampsia syndrome, 37
- Weiss M, *see* Gansser, 475
- Wenzlaff P, *see* Amende, 887
- Wesseling H, *see* Tio, 695
- Westberg B, *see* Ibsen, 641
- Wester P-O, *see* Hansson, 1253
- Wiese B, *see* Jost, 1037
- Wiesfeld ACP, *see* Bartels, 705
- Williams HE, *see* Calo, 983
- Williams R, *see* Hunt, 357
- Wisemann J, *see* Thormann, 1403
- Wollam G, *see* Szlachcic, 427
- Wolters KGTP, *see* Tio, 695
- Woolley RL. New concepts affecting the use of antiarrhythmic agents, 541
- Yamada H, *see* Yoneyama, 1469
- Yasue H, Morikami Y. Efficacy of slow-release nifedipine on ischemic attacks in patients with variant angina, 915
- Yokota M, *see* Hayashi, 969
- Yoneyama F, Satoh K, Taira N. Nicorandil increases coronary blood flow predominantly by K-channel opening mechanism, 1119
- Yoneyama F, Yamada H, Satoh K, Taira N. Cardiac versus coronary dilator effects of SD-3211, a new nondihydropyridine calcium antagonist in isolated, blood-perfused dog hearts, 1469
- Yoshida S, *see* Saito, 987
- Yoshida T, *see* Saito, 987
- Young J, *see* Iverson LIG, 269
- Zanna C, *see* Lavezzaro, 119
- Zanna C, *see* Malatino, 123
- Zannad F, *see* Simon, 1467
- Zenorini C, *see* Sheiban, 957
- Zera PH, *see* Narita, 1097
- Zoppi A, *see* Fogari, 1145
- Zoppi A, *see* Fogari, 1287

Subject Index

- Ablation (catheter), used with additional antiarrhythmic therapy, 533
- Abstract translations from symposium on serotonin and vascular disease, 141-187
- Acebutolol
antihypertensive treatment for blacks, 389, 390, 391
- blood lipid profile affected, 1277
for LVH regression, 432
respiratory function in the elderly affected, 1231
- ACE inhibitors, *see* Angiotensin-converting enzyme inhibitors
- Acetylcholine, baroreceptor modulation of heart rate in aged subjects, 1234
- Acetyl salicylic acid, drug interaction, 965
- Acidosis
inhibitory effect and severity of ischemia, 780
ischemia-induced reduction by trimetazidine, 858
trimetazidine effects during ischemia and reperfusion, 812

- Action-potential duration
 OPC-8490 effect, 713-716
 prolonged class III drugs, 598-602
 sotalol for prolongation, 625
- Action potentials, upstroke velocity and
 trimetazidine, 806-807
- Acute Infarction Ramipril Efficacy Study
 (AIRE), ACE inhibitors and myocardial
 ischemia, 1381
- Adenosine
 arrhythmias, 532
 involved in the inotropic action of milri-
 none, 509-512
- Adenosine diphosphate (ADP)
 serotonin amplifying platelet reaction,
 19-20
 stimulation of endothelium, 9, 11
- Adenosine triphosphate (ATP)
 anaerobic production of, 777, 778, 779,
 783-785
 cause of flushes, 55
 content related to impairment in con-
 traction and relaxation, 1366
 dysfunctional endothelium, 11
 glycolytic, and ischemic contracture,
 785-786
 involved in the inotropic action of milri-
 none, 509-512
 serotonin content of platelets paralleled
 by, 138
 sodium, -potassium-ATPase pump,
 321-322, 324, 326-330
 spared by potassium-channel-activa-
 tion-induced decreases in intracellu-
 lar calcium, 473
- Adrenergic blockers
 activity related to weight reduction in
 obese patients, 400
 to reverse left ventricular hypertrophy,
 427-432
- Adrenergic nerves, serotonin's tyramine-
 like effect, 9
- Adrenergic receptors, dobutamine infu-
 sion benefits influenced by, 1109-1110
- Adrenoceptors, clonidine effect, 1113,
 1116
- Adriamycin (ADM), dose-dependent car-
 diomyopathy as risk, 1519
- Aequorin, calcium indicator used in vascu-
 lar smooth muscle, 1355-1361
- Afterload reduction, augmentation of LV
 function after nifedipine administra-
 tion, 969, 971-972, 974
- Aging
 autonomic nervous control constraints
 in beta blocker use for hypertension,
 1257
 baroreceptor ability to cause blood pres-
 sure changes affected, 1223-1227
 bisoprolol vs. captopril treatment for
 hypertension, 261-264
 effect on essential hypertension renal
 disease, 207
 as factor in platelet sensitivity and re-
 sponse to 5HT, 106, 107, 108
- hypertension treatment, 1263-1267
 neuroendocrine control of cardiovascu-
 lar homeostasis, related to,
 1209-1212
 relationship with cardiovascular re-
 sponse to meals, 493-496
- AGT (decapeptide)
 experimental myocardial ischemia,
 1377-1378, 1381
 formation interactions and conversion
 to AGT II, 1375-1379, 1381-1382
- Airways
 beta-blockers effects in hypertensives
 with chronic obstructive lung disease,
 1145-1148
 respiratory function in the elderly af-
 fected by beta blockade, 1229-1232
- Ajmaline, effect on conduction character-
 istics of AV pathways, 621
- Alacepril, vs. delapril, 1417
- Aldosterone
 as factor in salt-induced changes in arte-
 rial pressure, 400
 lower level found in elderly, 1211
 nifedipine effect in hypertension, 977
 renal Na, K-ATPase activity affected, 385
 urinary and intracellular studies of
 blacks and Indians, 364
- Allopurinol, to decrease oxygen ion pro-
 duction, 800, 801, 802
- Alpha-adrenergic receptors
 HMG CoA reductase activity, 69, 72
 hypertrophy regression related to
 blockage, 80
- Alpha adrenergic system, stimulation pro-
 ducing chronotropic and inotropic ef-
 fects on the heart, 1368-1369
- Alpha-adrenoceptors
 dilevalol considered as one, 1461-1465
 increase of platelets with Raynaud's
 phenomenon, 45-46
 ketanserin and internal mammary ar-
 tery, 60
 Raynaud's phenomenon, 46, 47
- Alpha blockers
 combined with beta blockers in labetalol
 for lowering hypertension in blacks,
 380
 to reverse left ventricular hypertrophy,
 427
- Alpha-methyldopa, combined with nifedi-
 pine for hypertension, 938
- Alprenolol, enhanced by diuretic use in el-
 derly, 1274-1275
- Ambulatory blood pressure, control by ni-
 cardipine, 435-437
- Ambulatory monitoring, verapamil 240
 SR vs. verapamil 120 SR in arterial
 hypertension, 1501-1506
- Ambulatory radionuclide detector
 (VEST), nifedipine effect on cardiac
 function with coronary artery dis-
 ease, 919-922
- AMHT trial, hypertension in the elderly,
 948
- Amiloride
 hemodynamic interactions in hyperten-
 sives, 1151-1154
 respiratory function in the elderly af-
 fected, 1231
 STOP-Hypertension Study treatment,
 1254
- Amiloride congener 6-iodoamiloride, in-
 terfering with passive sodium perme-
 ability in membranes, 386
- 2-Amino, 5-phosphono valerate (2APV),
 29, 30
- Amiodarone
 acute hepatitis after loading dose,
 1467-1468
 antiarrhythmic drug, 532-533
 arrhythmias complicating hypertrophic
 cardiomyopathy, 529
 AV nodal tachycardia, 535-538
 combination therapy for atrial fibrilla-
 tion and paroxysmal supraventricular
 tachycardia, 551
 combination therapy with sotalol, 617
 combination therapy with flecainide,
 1161-1162, 1164
 dilated cardiomyopathy, 529
 effect on conduction characteristics of
 AV pathways, 621, 623
 inotropic and hemodynamic effects,
 546-547
 ischemic heart disease, 529
 paroxysmal atrial fibrillation, 582
 plasma level stability during chronic
 oral therapy, 529-530
 preventing atrial fibrillation in WPW
 syndrome, 684
 proarrhythmia incidence during EPS
 testing, 539
 programmed ventricular stimulation, 556
 restrictive cardiomyopathy, 529
 shown to reduce mortality in ventricu-
 lar tachycardia, 653-654
 side effects late in developing, 552
 systemic hypertension, 529
 vagal atrial fibrillation, 581
 Wolff-Parkinson-White syndrome, 529
- Amlodipine
 effect on hypertensive kidney,
 1331-1334
 exercise hemodynamics in coronary ar-
 tery disease, 457-462
 therapy for reduced left ventricular re-
 serve, 462
- Amplification, serotonin effect, 19
- Amrinone
 cardiotonic agent for congestive heart
 failure, 1127, 1133
 inotropic action, 509, 512
 to improve cardiac function, 1411
- Anaerobic metabolism, glycolysis in isch-
 emia, 777-788
- Anaerobiosis, glycolysis regulation and
 777, 778-780
- Anaesthesiology, myocardial energy me-
 tabolism, 756

- Anaesthetics, effects on myocardial adenosine nucleotides, 756
- Angina pectoris, *see also* Effort angina; Variant angina
 after meal phenomenon partially mediated through hemodynamic effects, 496
 celiprolol treatment, 1195-1196, 1276, 1291, 1294
 diltiazem tablet form treatment, 1089, 1094-1095
 elderly hypertensives, 1197
 exercise hemodynamics compared for 3 calcium-channel blockers, 457-462
 frequency reduced by beta blockers, 675-676
 intracoronary nifedipine before coronary angioplasty, 887
 nicorandil for treatment, 1075, 1078, 1080-1085, 1453
 nifedipine combined with atenolol, 899-903
 nifedipine vs. nisoldipine, 451-455
 nisoldipine vs. nifedipine, 451-455
 nitrate therapy, 249
 nitroglycerin oral spray formulations compared, 475-480
 pathophysiology, 899-900
 percutaneous transluminal coronary angioplasty and, 690
 preventive aspects of cardiology, 755
 propionyl carnitine activity evaluated, 481-485
 prostaglandin anti-ischemic effect, 1377
 symptom for diagnosis of coronary artery disease, 833-838
 trimetazidine effect, 820-825
 trimetazidine vs. nifedipine for treatment, 853-859
 verapamil treatment, 1509
- Angiotensin
 digital vasoconstriction and ketanserin, 46
 formation and interactions with bradykinin, prostaglandin, and sympathetic nervous system, 1375-1382
 sodium homeostasis and ANP, 1210-1211
 stimulating VSMC growth, 239
- Angiotensin converting enzyme inhibitors
 acute and chronic effects on essential hypertensive kidney, 207-214
 antiproliferative effect, 1003
 cardiac effects, 243-244
 class and side effects, 199, 205
 combined with flosequinan, 1314
 combined with nifedipine for hypertension, 938
 comparative structure, 199
 coronary blood flow and, 1378-1379
 delapril, 1417-1422
 diagnostic role for renovascular hypertension, 231
 felodipine antihypertensive therapy, 258
 for elderly hypertensives, 1193, 1196, 1267
- glomerular sclerosis lessened in animals by therapy, 1325, 1328
 hemodynamic mechanism of newer antihypertensive agents, 1135, 1139-1141
 hypertensives not normalizing blood pressure, 376
 infarct size, 1381
 in renovascular hypertension, 229-234
 ketanserin combination for hypertensives, 119-122
 mechanism of action, 200-201, 751
 myocardial ischemia treatment not recommended as yet, 1375-1382
 nifedipine interaction, 964, 966
 nondiabetic chronic renal disease affected, 221-225
 pharmacodynamics, 199, 203
 pharmacokinetics, 199, 201-203
 racial differences in response, 338, 380, 381
 renal hemodynamic effects, 203-204
 reversible myocardial events, 1378-1380
 systolic hypertension treatment in the elderly, 1207
 therapy of choice for elderly, 1303, 1304
 to prevent and/or attenuate hypertension end-organ damage, 197
 vagal tone influence without sympathetic activity influence, 267
 vascular hypertrophy in hypertension, 237-241
 zofenopril oral pretreatment effect on early reperfusion and electrophysiologic stability, 695-702
- Angiotensinogen
 intrarenal effects of angiotensin II, 209
 messenger RNA in tissues, 201
 produced within the vasculature, 239
- Angiotensin II
 attenuating effect of vasodilating drugs, 249
 blockade of effects by saralasin affecting parasympathetic activity, 267
 formation interrupted by agents, 229-233
 growth stimulant for cardiac muscle and vascular smooth muscle cells, 243
 high level in PIH serum as cause of hypertension, 355
 intrarenal effects and essential hypertensive kidney, 207, 209-210, 213-214
 open-heart surgery, 19, 23
 pressor sensitivity enhanced by serotonin, 38, 39, 40
- Anipamil, antiatherogenic effects and mechanisms of action, 1016-1018
- Anistreplase, vs. heparin in acute myocardial infarction trial, 1337-1343
- Antacids, decreasing absorption of captopril, 202
- Antiarrhythmic drugs
 classification and spectrum, 532-533
 comparative hemodynamics, 545-547
 efficacy in ventricular arrhythmia treatment, 669-673
 electrophysiologic evaluation, 535-539
 flecainide cause of functional hepatic and renal failure, 1164
 ketanserin not recommended in combination, 14, 16, 17
 safety, 653
 stereochemical influences, 541
- Antiarrhythmic effects, beta blockade and ischemic heart disease, 675, 676
- Antiarrhythmic therapy, propafenone
 minimum effective concentration values, 281-287
- Antisymphathetics, racial differences in response among hypertensives, 380
- Antithrombin III, preeclampsia, 40
- Aortic valve disease, plasma concentrations of atrial natriuretic peptide, 290, 293
- Apolipoproteins, nifedipine effect in mild hypertension, 1033-1035
- Aprindine, proarrhythmia incidence during EPS testing, 539
- Aprinidine, antiarrhythmic drug, 594
- Arrhythmias
 amiodarone treatment when complicating hypertrophic cardiomyopathy, 529
 antiarrhythmic therapy overview, 531-534
 carotid sinus massage, 532
 sotalol treatment, 1425-1431
 strategies for management, 532
- Arrhythmogenesis, ruled out by acute drug test before using class I antiarrhythmic agents, 653, 654
- Arrhythmogenic substrate
 definition, 560
 trigger factors facilitating ventricular tachycardia (VT) or ventricular fibrillation (VF), 555
- Arteriosclerosis, essential hypertensive renal disease and, 209
- Arteriosclerosis
 calcium antagonist influence, 1027-1030
 cold pressor responses in the elderly, 1260
 essential hypertensive renal disease and, 209
- Arteriosclerosis obliterans, 47
- Arteriosclerotic hypertension, isolated systolic hypertension in the elderly, 1205
- Arterioventricular nodal reentry tachycardia (AVNRT), sotalol for long-term control, 625-627, 628
- Aspirin
 prescribed for percutaneous transluminal coronary angioplasty patients, 688
 suppressing diet-induced atherosclerosis in monkeys, 1015
 therapy inhibiting serotonin delivery, 138
 to control incidence of preeclampsia, 37, 40

- Asthma**
 beta blocker effect on respiratory function, 1145-1148, 1234-1235
 celiprolol interference in treatment, 1285, 1291
 propranolol side effect, 1516
 respiratory function in elderly and beta blockade, 1229-1232
- Asymptomatic ventricular dysfunction**, improved by converting enzyme inhibition, 244
- Atenolol**
 antihypertensive treatment for blacks, 389, 390, 391
 antihypertensive treatment for elderly in trial, 1239
 blood lipid profile affected, 1277
 combination therapy for hypertension, 947, 948
 combined with nifedipine for stable angina, 899-903
 compared to bisoprolol, 261
 dose adjustment when glomerular filtration rates fall, 1273, 1274
 drug interactions, 964, 965
 effect on blood lipid profile in hypertensives with high cholesterol, 1287-1289
 effect on respiratory function in hypertension with chronic obstructive lung disease, 1145-1148
 for black hypertensives, 383
 for LVH regression, 432
 hemodynamic response, 737-742, 1139
 in dilated cardiomyopathy, 505-507
 in-vitro adrenoceptor activities, 1283, 1284
 ischemic heart disease treatment, 676
 ketanserin vs. bendrofluazide administration, 127-128
 no kinetic interaction with nifedipine, 1529
 plasma ANP increase in elderly essential hypertensives, 1211
 pretreatment before nisoldipine or nifedipine for angina pectoris, 451, 452, 453, 455
 reduction of ischemia, 931, 932
 STOP-Hypertension Study treatment, 1254
 to decrease systolic BP in elderly with ISH, 1206
 24-hour action and timing of cardiovascular events, 437
 used with a diuretic in the elderly, 1274
 vs. celiprolol, 1195, 1276-1277, 1284, 1291-1294
- Atheroma**
 cerebral blood flow with atherosclerosis in elderly, 1218
 formation and hemodynamic factors, 1015, 1018
 formation as evidence of nifedipine long-term benefit, 883, 884
 progression of, and nifedipine, 1047-1065
 retardation of, and nifedipine, 1047-1065
- Atherosclerosis**
 cerebral blood flow in the elderly, 1217, 1218, 1219
 early stage coronary analyzed by coronary angiography in INTACT study, 1037-1044
 ketanserin effect, 61, 123, 125
 nifedipine antiatherosclerotic effect in cholesterol-fed rabbits, 1021-1025
 nifedipine preventing coronary artery disease, 1047-1065
 pathogenesis: state of the art, 993-1003
 progression suppressed by calcium-channel blockers, 1015-1019
 pulse wave velocity affected by nifedipine in chronic hemodialysis patients, 987-990
 regression with lowered plasma lipid levels and elimination of atherogenic diets, 1389, 1391, 1392
 serotonin and hypertension, 5, 9, 11, 13, 1446
- Atrial fibrillation/flutter**
 class IC drug therapy, 549-550, 552
 conversion followed by sinus rhythm maintenance by sotalol or quinidine, 631
 encainide efficacy, 573, 575, 576
 encainide vs. flecainide for vagal, 579-581
 flecainide treatment, 1161
 sotalol to decrease ventricular rate, 619
 Wolff-Parkinson-White syndrome treatment with propafenone, 681, 682-684
- Atrial natriuretic peptide (ANP)**
 abnormalities in plasma related to total body sodium in elderly, 1210-1211, 1215
 flosequinan effect, 1395, 1398, 1400, 1401
 levels increasing with age, 1305
 plasma concentrations during physical exercise of congestive heart failure patients, 289-295
- Atropine**
 autonomic blockade restoring nitrate effects, 250
 sinus node disease treatment with intolerable side effects, 525
- Australian National BP Study**, systolic vs. diastolic BP for chronic heart disease development, 1204, 1241, 1243, 1302, 1303, 1490
- Australian Therapeutic Trial in Mild Hypertension**, antihypertensive treatment equally good in elderly as total population, 1253
- Automatic implantable cardioverter defibrillator (AICD)**
 sotalol therapy patients (40%) receiving, 1430
 ventricular tachycardia, 615
- Autonomic control**, age-related changes and beta blockers for hypertension, 1257-1261
- Autoregulation**, cerebral blood flow, 1217, 1218-1219
- AV nodal reentry (AVNR) tachycardia**, encainide efficacy, 573, 574, 576
- Azaperone**, zofenopril in experimental infarction, 696
- Baltimore Longitudinal Study on Aging**, no age-associated decline in cardiac output, 1257-1258
- Baroreceptor reflexes**, decreased in the elderly, 1273
- Baroreceptors**, control of blood pressure changes affected by aging, 1223-1227
- Baroreflex**, sensitivity with age-related differences, 1258-1259
- Bartter's syndrome**, calcium excretion lowered by PG synthesis inhibitors, 983
- Bay K 8644**
 calcium channel agonist influenced by mizolimine, 1477-1480, 1482
 calcium increase in platelets of essential hypertensives, 386
 marked cross tachyphylaxis with milrinone, 512
- Benazeprilat**, coronary blood flow and lactate production affected, 1379-1380
- Bendrofluazide**
 antihypertensive drug treatment for elderly in trial, 1239
 compared to ketanserin to reduce adverse symptoms of beta blockade, 127-130
 treatment comparing quality of life with ketanserin treatment, 117
- Bendroflumethiazide**, antihypertensive treatment for blacks, 390
- Bepridil**
 AV nodal tachycardia, 535-536
 cardiovascular profile similar to SD-3211, 1474
 vs. SD-3211, 1469
- Beta-adrenergic blockade**, elderly hypertensive and choice of drug, 1267
- Beta adrenergic system**, myocardial contractility, 1366-1368
- Beta-adrenoceptor antagonists**
 antianginal actions with nifedipine, 900
 dilevalol adequacy, 1461-1465
 pathophysiologic mechanisms in angina, 899
 xamoterol (intravenously) for sinus node dysfunction, 523-526
- Beta blockers**
 adverse symptoms reduced by serotonin antagonism, 127-130
 age-related decrease in sensitivity in the elderly, 1261
 antihypertensive effects, 261, 264
 AV nodal tachycardia, 535
 black hypertensives' response lower, 380

- as cause of asthma in elderly, 1234-1235
celiprolol effect on forearm arteries of hypertensive patients, 745-748
celiprolol pharmacology, 1281-1285
cold pressor responses in elderly hypertensives, 1271
combined with calcium antagonist for antihypertensive treatment, 641, 644-645, 647
dilated cardiomyopathy treatment, 505-507
effect on plasma lipids in patients with hypercholesterolemia, 1287-1289
effect on respiratory function in hypertensives, 1145-1148
efficacy as antihypertensive treatment for blacks, 386, 389-390
felodipine for hypertension, 253
for elderly hypertensives, 1193
hypertrophic cardiomyopathy symptoms improved by, 1517
kinetics influenced by rifampicin, 490
negative effect on cardiac output, 545
nifedipine interaction, 964, 966
normalizing fibrinolytic system, 676
plasma triglyceride concentration and HDL cholesterol concentration, 69
preventing sudden cardiac death, 675
proarrhythmia incidence during EPS testing, 539
profile in the elderly, 1273-1279
racial differences in response, 338
reducing chronotropic response during LBNP tests, 1259
respiratory function effects in the elderly, 1229-1232
side effects in elderly hypertensives, 1271
sotalol, 1425-1431
STOP-Hypertension Study results of antihypertensive treatments, 1253-1255
systolic BP treatment in the elderly, 1207
therapy of choice for elderly, 1303, 1305
to reverse left ventricular hypertrophy, 427
types of blockade, 676-677
vs. sotalol, 598-602
- Beta receptor blockade, hemodynamic mechanism of newer antihypertensive agents, 1135, 1138-1139, 1140
Beta receptors, lymphocyte for dobutamine evaluation, 1106-1107, 1109-1110
Beta-thromboglobulin, 46
preeclampsia concentration, 39
Bethanidine, cold pressor responses abolished by, 1259
Bezold-Jarisch reflex, triggered by serotonin, 1444
BHAT Study
 propranolol given to post-infarction population, 676
 PVCs as risk factors, 651
BHT 920, selective α_2 -adrenoceptor agonist, 443, 447, 448
- BHT 933
 α_2 -agonist inducing ischemic dysfunction, 1379
 to induce α_2 -adrenergic coronary constriction, 443-448
Bilateral nephrosclerosis, ACE inhibitors, 204
Bilateral renal artery stenosis, ACE inhibitors, 204
Biliary tumors, carcinoid syndrome, 53, 54
Bisoprolol
 double-blind comparison with captopril for elderly hypertensives, 261-264
 heart rate lowered by, 1464-1465
 vs. diltiazem, 1464-1465
- Blacks
 calcium deficit and low K intake causing hypertension, 403-405
 cellular regulation of sodium, potassium, and calcium, 337
 diuretic monotherapy for hypertension, 379
 diuretic response better than ACE inhibitor response for hypertension, 1439
 diuretics and cation transport with hypertension, 383-386
 diuretics for antihypertensive therapy, 390
 heredity and essential hypertension, 335-336
 hypertension frequency excess confirmed, 317-319
 hypertension prevalence rates based on geography and urbanization, 363
 hypertensive end-stage renal disease, 209
 obesity and hypertension, 395-401
 preeclampsia, 351
 pregnancy-induced hypertension, 351
 proposed mechanisms for essential hypertension, 338-339
 sodium-lithium countertransport and lipid correlations, 361
 sodium, potassium transport systems in essential hypertension, 321-330
 systemic regulation of sodium, potassium and calcium, 336-337
 volume expansion found in hypertensives, 376
 Zulu sodium and potassium urinary and intracellular studies, 363-365
- Blood cells (red), trimetazidine to protect against oxygen free radical damage, 818-819
Blood component therapy, cardiopulmonary bypass patients, 269-272
Blood lipid profiles, elderly affected by antihypertensive agents, 1277-1278
Blood pressure
 calcium treatment, 301
 changes caused by baroreceptors affected by aging, 1223-1227
 felodipine antihypertensive therapy, 255-257
- independent of hypertrophy reversal, 79
nifedipine vs. hydralazine for lowering, 501-502
reduction by ketanserin, 97, 98
techniques, 1301
- Body mass index
 correlated with changes in sodium-lithium countertransport, 357-361
 sodium excretion correlated, 364
Bohr effect, impaired blood oxygen release in exertional angina, 894
Bradycardia, produced by bisoprolol treatment, 264
Bradykinin
 cause of flushes, 55
 interaction with angiotensin, 1375, 1376, 1380, 1381-1382
 released from ischemic myocardium, 702
 salutary effect in congestive heart failure, 199, 201
 stimulation of endothelium, 9
Bristol-Myers Supraventricular and Ventricular Arrhythmias data base, encainide safety profile, 585-591, 594
Bronchial tumors
 carcinoid syndrome, 53
 ketanserin during anesthesia and operation, 56
BTS 53554, flosequinan metabolite, 705, 711
B-2 study, sudden cardiac death, 651-652
Bufedienolides, blocking K^+ vasodilatation, 345
Build and Blood Pressure Study (1959)
 systolic BP elevation associated with increased mortality, 1203
 systolic vs. diastolic BP for chronic heart disease development, 1204
Bulbospinal serotonin neurons, 28-30
Bumetanide
 acquired erythrocyte sodium transport abnormalities, 376
 inhibiting sodium and potassium fluxes, 323
 Na, K, Cl cotransport system inhibited, 385
Bupranolol, not affecting ZSY-39 positive inotropic effect, 1127-1130, 1132
BW A575C, beta blocker, vs. celiprolol, 1281, 1282
- ^{14}C -5HT, 106
Ca 2^+ ionophore A23187, stimulation of endothelium, 9
Caffeine-induced responses, inhibited, and calcium releases, 1348, 1349, 1352
Calcitonin, serum calcium reduced and atherosclerosis prevented by, 1021
Calcium
 blockade of entry and nifedipine cardioprotective actions, 877
 cellular regulation differences in blacks vs. whites, 337

- deprivation in hypoxic renal injury, 1320, 1321, 1323
- excretion and blood pressure interrelated, 404-405
- free clearance enhanced, 369-370
- hypertension treatment, 301
- nifedipine effect in hypercalciuria, 983-986
- nifedipine effect on metabolism in hypertension, 977
- systemic regulation differences in blacks vs. whites, 336-337
- vascular tone control as assessed by Ca^{2+} indicator aequorin, 1355-1361
- Calcium antagonists**
- antiarteriosclerotic effects, 1011-1012
- beneficial effects for exertional angina, 893
- clentiazem, 723-729, 1097-1103
- diltiazem in tablet form, 1089-1096
- effect on glomerular filtration rate in kidneys, 1331-1335
- for elderly hypertensives, 1193, 1196
- gallopamil, 1509-1513
- hemodynamic interactions with diuretics for hypertensives, 1151-1155
- hemodynamic mechanism of newer antihypertensive agents, 1135, 1139, 1141
- hypertension in the elderly, 948-950
- hypertension-related arteriosclerosis or arteriolosclerosis, 1027
- hypertrophic cardiomyopathy symptoms improved by, 1517
- intracellular effects of KT-362, 1345, 1352
- left ventricular diastolic function therapy for impairment, 951-954
- pathophysiologic mechanisms in angina, 899
- reduction of glomerular injury in experimental hypertension, 1325-1329
- renal function affected, 1317
- renal hemodynamics affected, 979-981
- Ro 40-5967 compared to verapamil for negative inotropic effects, 731-736
- therapy of choice for elderly, 1303, 1304
- variant angina treatment, 917
- verapamil 240 SR vs. verapamil 120 SR, 1501-1506
- Calcium-channel blockers**
- antiatherogenic effects and mechanisms of action, 1015-1019
- antihypertensive effects equipotent in races, 380, 381
- antihypertensive treatment in blacks, 386
- arrhythmias, 532
- elderly hypertensives, 1267
- enhancing LV diastolic filling in coronary artery disease, 1509-1513
- exercise hemodynamics of amlodipine, diltiazem and verapamil, 457-462
- ischemic injury and, 1321-1323
- isradipine as antihypertensive treatment, 413-417
- negative effect on cardiac output, 545
- nifedipine as prototype, 879
- retardation of coronary artery disease in rabbits, 1047
- systolic hypertension treatment in the elderly, 1207
- nifedipine effect in hypercalciuria, 983-986
- Calcium entry blockers (CEB), antihypertensive first-line treatment for blacks, 390-392**
- Calcium indicators, calcium role in control of vascular tone assessed by, 1355-1361**
- Calcium overload, causal factor in stenosing coronary plaque, 1005-1012**
- Calcium release, KT-362 negative inotropic effect, 1345, 1347-1352**
- Calcium uptake, muzolimine effect, 1477, 1479, 1481, 1482**
- Canine ventricular myocardium, ZSY-39, 1127-1133**
- Canrenone, steroidal nature of digitalis-like factor, 346**
- Captopril**
- absorption rate decreased by antacids, 202
- absorption rate modified by food, 201, 202, 205
- active sulphydryl group ACE inhibitor, 199, 200
- autoregulation of cerebral blood flow affected, 1218
- beta-receptor density increased, 1367
- blood pressure and heart rate responses with norepinephrine, 1377
- blood-pressure lowering effect and indomethacin, 201
- blood pressure normalization without Na^+ transport abnormalities, 376-377
- cardiac effects, 244
- cerebral blood flow in rats affected, 1233
- chronic effects on renal function, 212
- combination therapy with nifedipine for hypertension, 965
- congestive heart failure, 205
- coronary blood flow affected, 1378, 1379, 1380
- double-blind comparison with bisoprolol for elderly hypertensives, 261-264
- effect on changes induced by nitroprusside, 250
- effect on forearm arteries of hypertensive patients, 748
- effect on peripheral hemodynamics in hypertensive patients, 751-754
- effect on renal parameters, 204
- elimination kinetics, 203, 204
- glycosuria as side effect with chronic renal failure, 225
- improving reperfusion-induced cardiac dysfunction, 204
- infarct size reduced by, 1381
- interaction with indomethacin, 964
- ketanserin interaction in treating hypertensives, 119-122
- left ventricular diastolic function therapy for impairment, 951-954
- limiting infarction expansion, 1371, 1372
- LV diastolic function improved by therapy with, 959
- modest SI reduction, 1140
- pharmacokinetic and pharmacodynamic effects, 202
- plasma renin activity after treatment, 231, 233
- pretreatment to increase sensitivity for detection by isotropic renography, 232
- Raynaud's phenomenon, 49
- renal effects, 207, 211-212
- side effects, 202, 205, 225
- sublingual administration for essential hypertension, 751-754
- sulphydryl ACE inhibitor, 200, 201
- vs. delapril, 1417
- vs. flosequinan, 1314
- vs. metoprolol, 1278-1279
- Carbachol, ZSY-39 concentration-response curve shifted by, 1127-1129, 1131-1133**
- Carbacol, acting on calcium channels activated through phosphorylation, 1483**
- 5-Carboxamidotryptamine, high agonistic potency, 1459**
- Carcinoid syndrome**
- flushing reduced by ketanserin, 130
- ketanserin long-term use, 57
- serotonin and therapeutic effects of ketanserin, 53-57
- serotonin release, 51, 138, 139
- Cardiac arrest, incidence and definition in clinical trials, 657, 661-663**
- Cardiac Arrhythmia Pilot Study (CAPS), 606**
- achievements, 659, 660
- cardiac sudden death, 651
- encainide safety evaluation, 585, 586, 591-592
- sudden death definition, 658
- Cardiac Arrhythmic Suppression Trial (CAST)**
- cardiac sudden death, 652-653
- clinical aspects of trial design, 657-664
- encainide safety evaluation, 585, 586, 591-592, 594
- hypothesis that sudden cardiac death can be prevented, 669-670
- signal-averaged ECG ancillary study, 662
- sotalol-propranolol and sotalol-quinidine previous multicenter studies, 610
- Cardiac biochemistry, 756**
- Cardiac electrophysiology, definition, 765**
- Cardiac myocytes, OPC-8490 effect, 713-717**
- Cardiac performance, exercise capacity flosequinan, 1398-1401**

- Cardiac surgery
 perioperative myocardial protection, 797-803
 serotonin effect on systemic and pulmonary hypertension, 19-24
- Cardiac transplantation, arrhythmic management, 559
- Cardiology, preventive aspects of, 755
- Cardiomyopathy, risk stratification process, 665-666; *see also* Hypertrophic cardiomyopathy
- Cardioplegia, distribution during cardiac surgery, 797-800, 802-803
- Cardiopulmonary bypass operation
 ketanserin during anesthesia and operation, 56
 platelet loss minimized, 269-272
- Cardiopulmonary receptors, neurohumoral influences of volume effect by aging, 1223, 1225-1227
- Cardiopulmonary reflex, 1234
 aging effect, 1225-1227
- Cardiotonic agent, ZSY-39 for congestive heart failure, 1127-1133
- Cardiovascular diseases
 race/sex differences in mortality, 398
 training effects in the elderly, 1265
- Cardiovascular reflexes, training effects in the elderly, 1265
- Carnitine
 inhibiting pathways of fatty acid metabolism, 766
 modifying intracellular metabolism of fatty acid intermediates, 788
 tissue level proportionate to coronary flow and damage, 481, 484, 485
- Carpal tunnel syndrome, digital artery constriction, 47
- Carvedilol
 hemodynamic response to, 1135-1138, 1140
 vs. celiprolol, 1281, 1282
- Catecholamines
 ACTH control and cortisol release, 1113
 arterial constrictor action, 137, 138
 carcinoid syndrome, 54-55
 increased in children and adolescents with transport abnormalities, 376
 level during open-heart surgery, 19-22
 loss of, responsiveness, and beta-adrenergic function, 1264, 1267
 nifedipine vs. hydralazine effects, 500-503
 preeclampsia-eclampsia, 38, 40
 Raynaud's phenomenon, 46
 release facilitated by paracrine renin-angiotensin system, 239
 zofenopril and reperfusion damage, 697, 700, 702
- Celiprolol
 angina pectoris treatment, 1195-1196
 antihypertensive drug for elderly, 1304, 1305
 bioavailability, 1292
 blood cholesterol and, 1298
 blood lipid profile affected, 1277
 different from classic beta blockers, 1276
 dose adjustment when glomerular filtration rates fall, 1273, 1274
 effect on blood lipid profile in hypertensives with high cholesterol, 1287-1289
 effect on forearm artery circulation in hypertensive patients, 745-748
 effect on respiratory function in hypertension with chronic obstructive lung disease, 1145-1148
 elderly patient use, 1298-1299
 evaluation in treatment of mild to moderate hypertension in elderly, 1291-1294
 glomerular filtration rate falling requires dose reduction, 1305
 histamine effect not great, 1234-1235
 hypertension treatment, 1195-1196
 in-vitro adrenoceptor activities, 1283
 pharmacodynamics, 1291
 pharmacokinetics, 1291, 1292, 1294
 pharmacology of, 1281-1285
 qualitative differences between celiprolol and other beta blockers, 1297
 smoking not affecting metabolism in elderly, 1274
 vasodilatory capacity, 1275
 vs. atenolol, 1195, 1276-1277, 1284, 1291-1294
 vs. BW A575C, 1282
 vs. carvedilol, 1282
 vs. diltiazem, 1282, 1284
 vs. enalapril, 1195, 1196
 vs. labetalol, 1282
 vs. metoprolol, 1195, 1277
 vs. nifedipine, 1196
 vs. pindolol, 1281, 1284
 vs. propranolol, 1281, 1291-1294
- Cell viability duration, 765
- Cerebral blood flow (CBF)
 discussion of, 1233-1235
 hypertension and antihypertensive treatment in the elderly, 1217
- Cerebrovascular disease, elderly hypertensives, 1197, 1198
- Chlormadinone acetate, inhibiting Na, K-ATPase, 345
- p-Chloro-phenylalanine, inhibiting serotonin synthesis in carcinoid syndrome, 67
- Chlorothiazide
 cation transport in black hypertensives affected, 384-385
 hypotensive action with plasma volume decline, 383
- Chlorpromazine, plasma protein bindings and encaidine, 564
- Chlorthalidone
 antihypertensive drug treatment for elderly in trial, 1240, 1241
 combination antihypertensive therapy better than monotherapy, 963
- nifedipine interaction, 964-966
 to decrease systolic BP in elderly, 1206
- Cholesterol
 accumulation and arteriosclerosis development, 1005-1007
 celiprolol effect, 1195
 decreased with prazosin treatment for hypertension, 416, 417
 hyperlipidemia clinical relevance, 1385-1388
 increased with isradipine treatment for hypertension, 416, 417
 nifedipine antiatherosclerotic effect in rabbits fed with, 1021-1025
 nifedipine effect on serum lipoprotein metabolism with hypertension, 1033-1035
 reduction with simvastatin and diet with atherosclerosis, 1389-1393
 risk factor in INTACT study of coronary artery disease, 1053-1056, 1064, 1065
 sodium-lithium countertransport and lipid correlations, 357-361
- Cholesterol Lowering Atherosclerosis Study (CLAS), colestipol with niacin for lipid-lowering treatment, 1387, 1392
- Cholestyramine
 coronary artery disease treatment, 1064
 hyperlipidemia treatment used in U.S. trial, 1385
 lipid-lowering Italian trial, 1387
 lipid-lowering treatment for national study, 1386-1387
- Chromosomal aberrations, resulting from O₂ free radical damage in ischemia-reperfusion injury, 800, 801
- Chronic bronchitis
 beta blocker effect on respiratory function, 1234
 respiratory function in the elderly and beta blockade, 1229-1232
- Chronic glomerulonephritis
 ACE inhibitor effect, 222
 felodipine for hypertension, 254, 256
- Chronic heart failure, OPC-8212 long-term efficacy and safety for treatment of, 419-424
- Chronic interstitial nephritis, felodipine for hypertension, 254
- Chronic ischemic heart disease, sulphydryl donor treatment enhancing nitrate action, 248
- Chronic lung disease
 beta-blocker effect on respiratory function in hypertensives with, 1145-1148
 sotalol not used for ischemic heart disease, 1431
- Chronic obstructive airway disease (COAD), beta-blocker effect on respiratory function in hypertensives with, 1145-1148
- Chronic pyelonephritis, ACE inhibitor effect, 222

- Chronic renal failure
 angiotensin converting enzyme inhibition effect, 204, 221-225
 arterial hypertension treated with felodipine, 253
 nifedipine effect on pulse wave velocity, 987-990
 nitrandipine adequate tolerance, 980
 progression attenuated by nisoldipine, 980
- Chronic treatment, nifedipine influence on hypertension-induced vascular disease, 1028-1030
- Cibenzoline, proarrhythmia incidence during EPS testing, 539
- Cicletanine (Tenstaten), antihypertensive drug stimulating prostacyclin synthesis, 377
- Cilazapril
 coronary blood flow affected, 1379, 1380
 enalapril analog not created with lysine residue modification, 200
 nonsulfhydryl ACE inhibitor, 200
 vs. delapril, 1417
- Cimetidine
 plasma protein bindings and encainide, 564
 vs. ranitidine, 487, 490
- Cine-videodensitometry, 1042-1043
- Circadian rhythms
 ischemic heart disease, 768
 PVC rate in sotalol vs. propranolol study, 604-606
 PVC rate in sotalol vs. quinidine study, 607-608
- Cirrhosis
 encainide bioavailability, 563, 564
 ketanserin for portal pressure decrease, 33, 34
 ritanserin for portal pressure decrease, 34
- Class IC drugs, clinical efficacy and side effects, 546, 549-552
- Class III drugs
 site of action and efficacy, 634
 to prolong action-potential duration, 598-600, 602
- Clentiazem (TA-3090)
 chemical structure, 724
 effect on rabbit aorta and myocardium, 723-729
 mechanism of action on human coronary artery and myocardium, 1097-1103
- Clinical cardiologic research, myocardial energy metabolism, 756
- Clinical trials
 anistreplase vs. heparin in acute myocardial infarction, 1337-1343
 antihypertensive drug therapy discontinuation, 1487-1492
 design elements, 657-664
- Clofibrate, with nicotinic acid for lipid-lowering Swedish treatment, 1386, 1387
- Clonidine
 antihypertensive treatment for blacks, 390
 antihypertensive treatment for elderly in trial, 1241
 antisympathetic agent lowering blood pressure, 380
 combined therapy with naloxone for hormone inhibition, 1113-1116
 digital vasoconstriction and ketanserin, 46
 for LVH regression, 431
 hormone release affected when mediated by opiate receptors, 1113-1116
 nifedipine interactions, 964, 966
 serotonin to mediate hypotensive action of, 27, 30-31
 vs. nicorandil, 1077
- Cocaine, with 5-HT antagonists, 1456
- Coenzyme Q₁₀, 766
- Colchicine, mitosis arrested by, 800
- Cold pressor responses, autonomic control in elderly, 1259-1261
- Cold pressor test, to select patients for discontinuing antihypertensive therapy, 1492
- Colestipol
 national study of lipid-lowering treatment, 1392
 with niacin treatment in Cholesterol-Lowering Atherosclerosis Study, 1387
- Collagen, serotonin amplifying platelet reaction, 19-20
- Collateral circulation, vasomotor effect by nifedipine and isosorbide dinitrate, 905-907
- Competitive inhibition, nifedipine suppressive effect on atherosclerosis, 1024-1025
- Computer-assisted contour detection system (CAAS), quantitative cine film analysis of INTACT Study angiograms, 1037-1044
- Concentration-dose relationship, heart failure and flecainide with amiodarone therapy, 1161, 1163
- Conductance (volume) catheter technique, enoximone effect on end-systolic pressure-volume relationship, 1403-1413
- Conduction abnormalities, encainide safety profile, 589-590, 592, 593
- Conduction intervals, electrophysiological effects of encainide, 567
- Congestive heart failure (CHF)
 ACE inhibition therapy side effects, 225
 angiotensin converting enzyme inhibitors, 199-205, 243, 244
 atrial natriuretic peptide concentrations in plasma during physical exercise, 289-295
 beta blocker atenolol treatment study, 505-507
 converting enzyme inhibitors, 244
- dilatation and remodelling antecedent events following myocardial infarction, 1363, 1367-1368
- disopyramide contraindicated, 545
- dobutamine treatment, 1105-1106, 1109
- encainide efficacy for supraventricular arrhythmias, 577
- encainide pharmacokinetics, 564
- encainide safety profile, 589, 593
- enoximone treatment, 1403, 1411, 1413
- favorably modified by OPC-8212 treatment, 419, 424
- flecainide contraindicated, 546
- flosequinan treatment, 1313-1315, 1395-1401
- glycerol trinitrate (NTG) oral spray for hemodynamic unloading, 475
- nitrates for treatment of, 247
- piretanide monotherapy acute and chronic effects, 515-520
- propafenone aggravating or inducing, 653
- sulfhydryl donor treatment enhancing nitrate action, 248, 249
- Connective tissue diseases, Raynaud's phenomenon, 47-49
- Contractility, enoximone to induce increases, 1406, 1408, 1411-1413
- Converting enzyme inhibitors
 cardiac effects, 244
 for left ventricular hypertrophy regression, 243
- pretreatment for salvaging myocardial tissue during early reperfusion, 695, 702
- vascular response in hypertension, 239-240
- Coope-Warrender General Practice Study, 1239
- antihypertensive drug study age characteristics, 1253
- no randomized control group, 269
- Coronary angiography, anistreplase vs. heparin in acute myocardial infarction, 1338-1340, 1342
- Coronary angioplasty, intracoronary nifedipine pretreatment protective effects for myocardial ischemia, 887-890
- Coronary arteriography, atherosclerosis in hypercholesterolemic patients, 1389, 1390-1392
- Coronary artery bypass graft surgery (CABG), 1338, 1340
- atherosclerosis regression on simvastatin, 1391
- Coronary artery disease
 atenolol effect on cardiac contractility, 741
- cause of ischemia, 777
- chest pain experienced after meals, 493, 496
- exercise hemodynamic comparison of 3 calcium-channel blockers, 457-462

- Holter monitoring for evaluating total ischemic burden, 555, 841
- ketaserin as vasodilator long-term treatment, 85-87
- nifedipine effect, 454
- nifedipine effect on cardiac function evaluated with ambulatory radionuclide monitoring, 919-922
- nifedipine retardation of (INTACT Study), 1047-1065
- nisoldipine treatment, 273, 277, 451
- pindolol effect on cardiac contractility, 741
- plasma concentrations of atrial natriuretic peptide, 290
- progression or regression measured by quantitative coronary angiography, 1037-1044
- racial differences in hypertension, 337
- reduction in ventricular afterload, 448
- total ischemic burden with, 833-838
- Coronary artery bypass surgery, ketaserin and systemic arterial hypertension, 20-21, 22-23
- Coronary atherosclerosis, correlate of angina, infarction and sudden ischemic cardiac death, 827, 828, 830
- Coronary blood flow
- ACE inhibitor effect, 1378-1379
 - increased by nicorandil by K-channel opening mechanism, 1119-1126
- Coronary dilator, vs. cardiac effects of SD-3211, 1469-1475
- Coronary Drug Project, niacin for lipid-lowering treatment, 1386
- Coronary heart disease (CHD)
- hyperlipidemia prevention trials relevant, 1385-1388
 - NTG oral spray to relieve anginal attacks, 475-480
- Coronary plaque tissue, calcium overload factor in development of, 1005-1012
- Coronary spasm, serotonin pathogenetic role, 1445
- "Coronary steal" phenomenon, nifedipine and coronary collaterals, 907
- Coronary stenoses
- vasodilation and nifedipine, 273, 276, 277
 - vasodilation and nisoldipine, 273-274, 277
 - vasomotility and nisoldipine, 275-276
- Coronary vasoconstriction, pathophysiologic mechanism when exercise-induced, 893-894
- Coronary vasomotion
- ergonovine testing and IV nifedipine, 913
 - nisoldipine effect on arteries, 273-278
- Coronary vasorelaxation, clentiazem treatment, 1097, 1099-1100, 1102, 1103
- Corticosteroids, carcinoid syndrome, 57
- Costs
- hypertension therapy, 1439-1441
 - hypertensive medications as of Feb., 1989 in Dallas, Texas, 1440
- Creatine-phosphokinase activity (CPK), trimetazidine antiischemic and reperfusion effect, 808-809
- Cromakalim
- protective effects on reperfusion function and infarct size in animal models, 465-473
 - reference drug used with nicorandil to increase coronary blood flow, 1119-1125
- Cyclandelate, Raynaud's phenomenon, 48
- Cycletanine (furopyridine), potassium transport stimulated, 385
- Cyclic AMP
- OPC-8490 effect, 714, 716
 - ZSY-39 inducing, 1127-1133
- Cyproheptadine, carcinoid syndrome, 57
- Cysteine, synergistic increase of blood flow with isosorbide dinitrate, 250
- Debrisoquine
- minimum effective concentration values for antiarrhythmic therapy, 281-283, 285
 - poor metabolism phenotype, 543
- Deesterification, to form ACE inhibitors, 201, 202
- Delapril
- antihypertensive drug for patients with normal or impaired renal function, 1417-1422
 - nonsulphydryl ACE inhibitors, 200
 - pharmacokinetics, 1417, 1419-1422
 - vs. alacepril, 1417
 - vs. captopril, 1417
 - vs. cilazapril, 1417
 - vs. enalapril, 1417
 - vs. ramipril, 1417
 - with furosemide for hypertension, 1422
- Delayed afterdepolarizations (DADs), trimetazidine effects, 806
- Dementia, cerebral blood flow in the elderly, 1217, 1218
- Deoxyglucose, ¹⁸F studies of glucose to perfusion ratio and FDG uptake, 850
- Depressor effect, delapril on ACE activity, 1420, 1422
- Desmethyl-imipramine, plasma protein bindings and encainide, 564
- Desoxycorticosterone-salt (DOC-SALT) hypertension, HHR combination therapy, 1327-1328
- Dexamethasone, reducing digoxinlike immunoreactivity, 346
- Diabetes mellitus
- ACE inhibitors for hypertension studied, 202
 - beta blockade and, 1278
 - cerebral blood flow in the elderly, 1217, 1218
 - delapril for hypertension, 1422
 - essential hypertensive renal disease and, 209
 - obesity related in black women, 398
 - race/sex differences in mortality from, 398
 - serotonin having pathogenetic role, 1446
 - streptozotocin-induced and enalapril for renal protection effects, 204
- Diastolic function
- early regression of abnormalities in hypertensives given nifedipine, 957-960
 - gallopamil changing, 1512-1513
 - nifedipine effect after myocardial infarction, 923-927
- Diastolic left ventricular filling
- hypertension and diastolic impairment, 951, 952, 954
 - LV diastolic abnormalities and regression with nifedipine, 958, 960
- Diazepam, plasma protein bindings and encainide, 564
- Diazoxide renal function effect, 979
- Diclofenac, hydrochlorothiazide interaction, 965
- Diet
- atherogenic elimination for hypercholesterolemic patients with atherosclerosis, 1389-1392
 - lipid-lowering treatment, 1385-1388
 - nonpharmacologic treatment for hypertension, 1487, 1488, 1491
- Diethylthiocarbamate (DDC), reflecting K⁺ permeability after trimetazidine treatment, 818-819
- Digibind, hypertension in PIH treatment, 353
- Digitalis
- ACE inhibitors and, 205
 - acquired erythrocyte sodium transport abnormalities, 375-376
 - addition to trimetazidine for ischemic cardiomyopathy, 862
 - AV nodal tachycardia, 535
 - congestive heart failure treatment, 515
 - derivatives inhibiting the sodium, potassium-ATPase pump, 322
 - OPC-8212 and OPC-8490 as replacements, 717
 - withdrawal before OPC-8212 for congestive heart failure, 419, 420
- Digitalislike circulating substance, activation resulting in hypertension, 343-347
- Digoxin
- cross-reacting with Na, K-ATPase inhibitor, 344-346
 - plasma protein bindings and encainide, 564
 - supraventricular tachycardias' treatment, 628
- Dihydralazine, vs. nicorandil, 1082
- Dihydroergocristine (DHEC), venoconstrictor responses to, 1455-1459
- Dihydroergotamine (DHE), venoconstrictor responses to, 1455-1459

- Dihydropyridine
 antiatherogenic effects and mechanisms of action, 1016
 inhibiting incorporation of cholesteryl esters into macrophages or myocytes, 1027-1030
 renal functions affected, 979
 1,4-Dihydropyridine, derivatives, 723
 Dihydropyridine calcium antagonists
 nisoldipine, 273-278
 5,7-Dihydroxytryptamine (5,7DHT), 28-30
 1,25-Dihydroxy-vitamin D
 blacks demonstrating higher levels than whites, 336
 nifedipine effect, 983-986
 Dilated cardiomyopathy
 amiodarone for treatment, 529
 atenolol added to conventional therapy, 505-507
 enalapril to reduce mortality from, 675
 Dilevalol
 effects on anesthetized pig with partially occluded coronary artery, 1461-1465
 hemodynamic response to, 1135-1138, 1140, 1141
 in-vitro adrenoceptor activities, 1283
 vs. bisoprolol, 1464-1465
 vs. celiprolol, 1282, 1284
 Diltiazem
 antiarteriosclerotic effects, 1011
 antiatherogenic effects and mechanisms of action, 1015, 1016
 antihypertensive treatment for blacks, 391
 antihypertensive treatment similar to isradipine, 416, 417
 AV nodal tachycardia, 535
 cardioprotective effect during ischemia and reperfusion, 808-809
 clentiazem as its derivative, 723-729
 decreasing conduction capacity of AV node, 619
 effect on hypertensive kidney, 1331, 1332, 1334
 effect on hypoxic rat heart, 719-722
 effect on LV mass, 503
 efficacy on coronary vasomotility, 896
 exercise hemodynamics in coronary artery disease, 457-462
 for percutaneous transluminal coronary angioplasty, 689, 690
 increasing death rate when prior myocardial infarction and heart failure signs present, 731
 inhibiting vascular myocyte proliferation and migration, 1027, 1028
 in terms of vasodilation, 936, 937
 isovolumic relaxation time reduction induced by, 954
 lipoprotein metabolism effect, 1033
 LV diastolic filling in CAD enhanced, 1509
 no derivatives except clentiazem, 1097
 Raynaud's phenomenon, 45, 47, 50, 938-939
 serum calcium reduced and atherosclerosis prevented by, 1021
 tablet form for hypertension, and angina pectoris, 1089-1096
 vs. clentiazem, 1097, 1100-1103
 vs. KT-362, 1346, 1349
 vs. nicardipine, 1530, 1531
 vs. nicorandil, 1084
 vs. nifedipine pharmacologic potency vs. SD-3211, 1469, 1474, 1475
 Discriminant function analysis, following percutaneous transluminal coronary angioplasty, 690-691
 Disopyramide
 decrease in cardiac output and worsening of congestive heart failure, 545
 onset kinetics, 570, 571
 proarrhythmia incidence during EPS testing, 539
 stereochemical influences, 541
 Distance meter method, to measure blood flow velocities, 101
 Diuretics
 ACE inhibitors and, 204, 205
 antihypertensive and influencing vascular tone and growth, 240
 antihypertensive treatment for blacks, 389, 390
 bendroflumazide, 127-130
 captopril combination therapy and chronic renal effects, 212
 carcinoid syndrome, 57
 cation transport in black hypertensives, 383-386
 effect greater in the elderly, 1210, 1211
 effect on left ventricular hypertrophy on elderly hypertensives, 83
 enalapril combination for renal artery stenosis, 232, 233
 EWPHE study monotherapy for hypertension, 1249
 felodipine ER-10, 20, 40 mg., 1495, 1498-1500
 felodipine for hypertension, 253
 felodipine treatment and ankle edema, 258
 for lowering blood pressure in black hypertensives, 318, 319
 hemodynamic interactions with calcium antagonists for hypertensives, 1151-1155
 hypertrophy reversal not achieved, 79
 ischemic heart disease, 101
 ketanserin not recommended in combination, 14-17
 monotherapy for hypertension in blacks, 379-381
 piretanide in congestive heart failure, 515-520
 plasma triglyceride concentration and HDL cholesterol concentration, 69
 potassium-losing, 93, 95, 139
 potassium-losing and ketanserin treatment, 117
 racial differences in response, 338
 reversibility of sodium pump abnormality, 344
 STOP-Hypertension Study results of antihypertensive treatments, 1253-1255
 therapy of choice for elderly, 1303
 thiazide antihypertensive actions, 13
 to increase systolic BP in elderly with ISH, 1203, 1205-1207
 Dobutamine
 effects on repeated infusion on chronic heart failure, 1105-1110
 vs. enoximone, 1411, 1413
 Doppler echocardiography
 gallopamil effect on LV relaxation and filling dynamics in acute myocardial infarction, 1509-1513
 LV function after nifedipine, 969-974
 nifedipine and LV diastolic dysfunction measured, 923-924, 926
 nifedipine effect on LV diastolic function in hypertension, 951-954
 Dose response, diltiazem in tablet form, 1089-1095
 Double action drugs, hemodynamic response to, 1140-1142
 Double peaks phenomenon, 1180-1182
 Doxazosin
 hemodynamic response to, 1135-1139
 LDL receptor activity increased in rabbit fibroblasts, 72
 Doxorubicin, trimetazidine effect on cardiac energetics when administered with, 814-815
 Drug combinations
 atenolol and nifedipine, 646
 felodipine and beta blockers in hypertension, 644-645, 647
 hydrochlorothiazide and beta-blockers, 646
 nifedipine and atenolol, 646
 Drug interactions
 amiodarone and encainide, 564
 anticoagulants and encainide, 564
 antidiabetics and encainide, 564
 antipsychotics and encainide, 564
 beta blockers and encainide, 564
 cimetidine and encainide, 564
 digoxin and encainide, 564
 diuretics and encainide, 564
 encainide, 564
 encainide effect on plasma protein bindings of other drugs, 564
 glipizide, 487, 490
 lidocaine, 564
 lignocaine, 487
 mexiletine, 564
 midazolam, 487, 490
 nifedipine, 487, 490, 564, 963-966
 propafenone, 544
 quinidine, 544
 ranitidine, 487-490
 rifampicin, 487-490
 terbutolol, 487-490

- theophylline, 487, 490
warfarin, 487, 490
- Drug therapy, elderly hypertensives, 1197-1200
- Drug tolerance, nitrate tolerance, 247-250
- Drug withdrawal, antihypertensive therapy, 1487-1492
- Dysfunctional endothelium, preeclampsia-eclampsia syndrome, 38
- Dysopyramide, hemodynamics, 547
- Echocardiography
atenolol hemodynamic effects assessed, 737, 738, 742
atenolol in dilated cardiomyopathy, 506
pindolol hemodynamic effects assessed, 737, 738, 742
piretanide monotherapy for congestive heart failure, 516, 517, 520
to determine amount of reversal of left ventricular hypertrophy, 429, 430
- Effective renal plasma flow, calcium antagonist effect, 1331-1335
- Effective renal plasma flow/renal blood flow (ERPF/RBF), 207-214
- Efficacy/tolerance ratio
encainide, 584
flecainide, 584
- Effort angina, *see also* Angina pectoris
calcium antagonists' beneficial effects, 893-895
ergometric parameters affected by trimetazidine, 820-823
isosorbide dinitrate vs. nifedipine for exercise tolerance, 905-907
nicorandil treatment, 1083, 1085
nifedipine to increase exercise capacity, 912-913
nifedipine vs. isosorbide dinitrate for exercise tolerance, 905-907
propionyl carnitine activity evaluated, 481-485
trimetazidine combined with nifedipine for treatment, 824-825
trimetazidine vs. nifedipine for treatment, 853-859
- Eisenmenger's physiology, clentiazem therapy, 1097
- Elderly
angiotensin-converting enzyme inhibitors, 1193, 1196
antihypertensive drug treatment trials, 1237-1247
autonomic control age-related changes and beta blockers for hypertension, 1257-1261
beta blockade effects on respiratory function, 1229-1232
beta blocker use, 1193
calcium antagonist use, 1193, 1196
celiprolol for mild to moderate hypertension, 1291-1294
EWPHE study results concerning systolic hypertension, 1249-1251
factors in treatment of hypertension, 1263-1267
hypertension and its causes, 1197-1200
neuroendocrine mechanisms and cardiovascular homeostasis, 1209-1212
pulse wave velocity and nifedipine effect in hemodialysis patients, 987, 990
quality of life, 1278-1279, 1304
STOP-Hypertension Study results of antihypertensive treatments, 1253-1255
therapy of choice, 1303-1304
thromboembolic complications from serotonin, 1446
- Elderly hypertensives
cerebral blood flow in the elderly, 1217-1220
nifedipine and calcium antagonist therapy, 947-950
nifedipine slow-release for long-term therapy, 941-944
- Electrocardiographic changes, propafenone levels in antiarrhythmic therapy, 285
- Electron paramagnetic resonance (EPR) spectroscopy, free radical generation in the heart measured, 791-793
- Electrophysiologic studies (EPS)
antiarrhythmic drugs, 535-539
arrhythmia causes, 773
encainide, 567-571
encainide for supraventricular arrhythmias analyzed, 574-576
intravenous xamoterol for sinus node dysfunction, 523-526
myocardial energy metabolism, 756
nifedipine, 890
propafenone and WPW syndrome, 681-682
sotalol, 619-621
sotalol efficacy in controlling reentrant supraventricular tachycardias, 625-627
trimetazidine, 808-809
ventricular tachycardia nature and mechanism, 613-615, 617
Wolff-Parkinson-White syndrome, 666
zofenopril pretreatment effect on pig model, 695-702
- Enalapril
absorption rate not modified by food, 201, 202, 205
antihypertensive effects and prostaglandins, 201
bioavailability, 202
chronic renal failure patients given stable renal function, 224
combination therapy with nifedipine for hypertension, 965
congestive heart failure, 205
coronary blood flow affected, 1378-1380
diuretic combination for renal artery stenosis, 232
elimination kinetics, 202-204
glycosuria as side effect with chronic renal failure, 225
heart failure survival improved, 1314
interaction with indomethacin, 964
myocardial infarction attenuated by, 1381
nonsulphydryl ACE inhibitor, 199-201
parasympathetic activity affected, 265-267
pharmacokinetic and pharmacodynamic effects, 202
preventing rise in systemic and glomerular pressure in kidney, 1326, 1327
reducing dilated cardiomyopathy mortality, 675
renal effects, 207, 211-213
renal protective effects, 204
24-hour action and timing of cardiovascular events, 437
vs. celiprolol, 1195
vs. delapril, 1417
vs. ketanserin for essential hypertension, 123-125
vs. ketanserin in elderly hypertensives, 138
- Enalapril/Enaprilat, renal effects, 211
- Enaprilat, 199
bioavailability, 202
elimination kinetics, 202-203
lisinopril as lysine derivative, 200
pharmacokinetic and pharmacodynamic effects, 202
- Enantiomers, 541
- Encainide
Cardiac Arrhythmia Suppression Trial (CAST) results showing risk, 659-664
dose adjustment when kidney function is decreased, 561
effect on conduction characteristics of AV pathways, 621
efficacy in supraventricular arrhythmias, 573-577
efficacy/tolerance ratio, 584
electrophysiologic effects, 567-571
hemodynamic effects, 546, 547
increasing death rate in CAST study, 662-664
management of cardiac arrhythmias, 559-560, 633-634
metabolism of, 561-565
onset kinetics, 570, 571
ophthalmologic abnormalities, 591
oral bioavailability, 561-563
overdosage, 591
pharmacokinetics of, 561-565
plasma protein bindings and drug interactions, 564
poor metabolism phenotype, 543-544
prevention of potentially malignant arrhythmias, 654
proarrhythmia incidence during EPS testing, 539
safety profile updated, 585-594
vs. flecainide for chronic resistant par-

- oxysmal atrial tachyarrhythmias, 579-584
- End-diastolic pressure (EDP), cromakalim effect on reperfusion cardiac function, 467, 470, 471
- End diastolic volume (EDV), reduced during exercise, 919, 921-922
- Endogenous digoxinlike immunoreactivity (EDLI), 353-354
- Endothelin, ischemia effect on receptor density in isolated hearts, 880, 883, 884
- Endothelium
- atherosclerosis pathogenesis, 998-999
 - calcium-channel blockers to prevent permeation of a macromolecular marker, 1016-1017
 - coronary artery contractions shifted, 8
 - mediating vascular remodeling, 239
 - release of endothelium-derived relaxing factor, 9-11
 - structural/functional integrity determining vascular effects of serotonin, 105
- Endothelium-dependent relaxing factor
- atherosclerosis and serotonin, 11
 - serotonin and action of, 11
- Endothelium-derived relaxing factor (EDRF)
- endothelium in atherosclerosis, 998-999
 - serotonin and action of, 7-9
 - serotonin augmentation, 138
 - serotonin causing response in preeclampsia, 38-40
- End-stage renal disease
- essential hypertensive renal disease and, 208, 209
 - racial differences in hypertension, 337
- End systolic pressure-volume relationship, enoximone's unloading effects differentiated, 1403
- End systolic volume, reduced during exercise, 919, 921-922
- Energy metabolism, myocardial energy metabolism, 756
- Enoximone
- cardiotonic agent for congestive heart failure, 1127, 1133
 - congestive heart failure treatment, 1403, 1411, 1413
 - end-systolic pressure-volume relations using conductance catheter technique, 1403-1413
 - vs. dobutamine, 1411, 1413
- Enterolactone, inhibiting Na, K-ATPase activity, 345
- Environment, influence on increasing blood pressure with increasing age, 1198
- Ephedrine, vs. nicorandil, 1077
- 4'Epiaadriamycin (4'ADM), hemodynamic effects, 1519-1522
- Epidemiology
- hypertension in the elderly, 1197-1200
 - systolic hypertension in the elderly, 1215-1216
- Epidermal growth factor, as vasoconstrictor, 239
- Epinephrine
- anginal attacks associated with ST-segment elevation induced by, 894
 - pressor response in preeclampsia, 38
 - serotonin amplifying platelet reaction, 19-20, 24
- Ergonovine, vasospastic potency, 1445
- Ergonovine test, after exercise testing and coronary angiography for effort angina, 909-913
- Erythrocyte concentration
- dietary sodium variation as environmental factor influence, 329-330
 - essential hypertension in blacks, 321-330
 - familial background as host factor influence, 326-327
 - menstrual cycle as host factor influence, 327-328
 - oral contraceptives as environmental factor influence, 330
 - race as host factor influence, 325-326
 - sex as host factor influence, 328-329
- Erythrocytes
- deformability after ketanserin administration, 102
 - measurement of sodium-lithium countertransport, 357
 - Na, K-ATPase activity affected by aldosterone elevation, 385
 - sodium concentration affected by ketanserin, 63-66
 - sodium content in hypertensives, 368, 369
 - sodium transport pathways, 374-375
- Essential hypertension, *see also* Hypertension
- ACE inhibitor effect on kidney, 207-214
 - compared to renovascular hypertension after captopril treatment, 231
 - delapril therapy, 1417-1422
 - 5HT uptake and platelet activation, 105-109
 - heredity playing key role in pathogenesis, 335
 - ketanserin-captopril interaction, 119-122
 - ketanserin effect on microhemodynamics and hemorheology, 101
 - nifedipine effect on water-sodium, uric acid, calcium metabolism and aldosterone secretion in hypertension, 977
 - nifedipine treatment, 935-939
 - serotonin role in pathogenesis, 1445
 - verapamil 240 SR vs. verapamil 120 SR therapy, 1501-1506
- Essential hypertensive renal disease, pathophysiology, 207-209
- Ethacrynic acid
- Na-K-ATPase activity inhibited, 385
 - potassium transport stimulated, 385
- Etomoxir, inhibition of fatty acid oxidation, 788
- European Working Party on Hypertension in the Elderly Trial (EWPHE) antihypertensive drug treatment for the elderly, 115, 947-948, 1193, 1238, 1246, 1302, 1303
- antihypertensive treatment benefits the same for both sexes, 1269
- application of results to making treatment choices, 1267
- drop-outs from study, 1270
- key factors in treatment, 1269
- study population age and benefit characteristics, 1253
- subgroup analyses of results, 1241-1244
- systolic vs. diastolic BP for CHD development, 1204
- trial results with focus on systolic hypertension, 1249-1251
- European Trial on Systolic Hypertension in Patients Aged 60 or More (SYST-EUR), 1251
- Evans County, Georgia Study (1980), systolic vs. diastolic BP, 1203-1204
- Evening primrose oil, Raynaud's phenomenon, 49
- Exercise hemodynamics, newer antihypertensive agents, 1136-1139
- Exercise-induced angina, calcium antagonists' effect, 893-896
- Exercise testing
- atrial natriuretic peptide plasma concentration effect, 289-295
 - autonomic control and cardiovascular performance in the elderly, 1257-1258
 - dobutamine increasing tolerance for heart failure patients, 1105, 1106, 1108-1109
 - elderly hypertensives, 1264, 1265
 - flosequinan, 1314, 1395, 1396, 1398-1400
 - hemodynamics of amlodipine, diltiazem, and verapamil, 457-462
 - induced ischemia in clinical setting and ACE inhibition, 1379-1380
 - nicorandil, 1082-1083
 - nisoldipine vs. nifedipine in angina pectoris, 452-455
 - propionyl carnitine in effort angina, 481-485
 - sodium-lithium countertransport affected, 360-361, 368
 - total ischemic burden, 837
 - trimetazidine effect in effort angina, 820-823
 - trimetazidine vs. nifedipine for effort angina, 853-859
- Extended release formulation, felodipine, 1495-1500
- Factor VIII consumption, preeclampsia, 39

- "Fast" sodium channel, KT-362 primary inhibitory effect, 1350, 1353
- Felodipine**
 effect on hypertensive kidney, 1331-1334
 efficacy and tolerability of long-term treatment in hypertension, 641-647
 for hypertension with chronic renal failure, 222
 hemodynamic interactions with diuretics in hypertensives, 1151-1155
 hypertension and impaired renal function treatments, 253-258
 hypotensive action 24-hour profile, 439-442
 pharmacokinetics and hemodynamic and diuretic/natriuretic effects, 1495-1500
 pretreatment abolishing positive response to hyperventilation, 895
 profile showing increase in heart rate and cardiac output, 462
 to prevent poststenotic myocardial ischemia, 443-448
 vs. hydrochlorothiazide, 641-647
- Fenfluramine**, carcinoid syndrome, 57
- Fenofibrate**, lipid-lowering Italian trial, 1387
- Fibroblasts**, cultured human skin affected by HMG CoA reductase, 69-72
- Fibronectin**, preeclampsia syndrome, 39
- Fish-oil capsules**, Raynaud's phenomenon, 49
- Flecainide**
 acetate dose-concentration relationship in cardiac arrhythmias, 1161-1164
 Cardiac Arrhythmia Suppression Trial (CAST) comparison to encainide, 591
 Cardiac Arrhythmia Suppression Trial (CAST) results showing risk, 659-664
 conduction abnormalities, 592, 594
 drug interactions, 1164
 effect on conduction characteristics of AV pathways, 621
 efficacy and side effect profiles, 449-552
 efficacy in atrial fibrillation, 549, 550
 efficacy/tolerance ratio, 584
 electrophysiologic effects, 620
 hemodynamic effects, 546, 547
 increasing death rate in CAST study, 662-664
 junctional tachycardias treatment, 550-551
 LV function proarrhythmic effect, 559
 not useful in controlling atrial fibrillation in WPW syndrome, 684
 onset kinetics, 571
 poor metabolism phenotype, 543
 prevention of potentially malignant arrhythmias, 654
 proarrhythmia incidence during EPS testing, 539
 proarrhythmic side effects, 552
 ventricular arrhythmia treatment, 551-552
- ventricular tachycardias' treatment, 550
 vs. encainide for chronic resistant paroxysmal atrial tachyarrhythmias, 579-584
 vs. quinidine for ventricular tachycardia, 551
- Flordipine**, antiatherosclerotic effect, 1021
- Flosequin**
 combined with captopril for severe heart failure, 1313
 congestive heart failure treatment, 1395-1401
 hemodynamic effects in short term for relief of heart failure, 1313-1314
 hemodynamic effects with congestive heart failure, 705-711
 vs. captopril, 1314
- Flunarizine**
 antiatherogenic effects and mechanisms of action, 1015-1018
 serum calcium reduced and atherosclerosis prevented by, 1021
- Flurbiprofen**, drug interactions, 965
- Flushes**
 carcinoid syndrome, 53-56
 caused by bendrofluazide, 127, 129-130
 felodipine, 647
- Focal segmental glomerulosclerosis**, chronic renal failure and, 222, 223
- Folkow's postulate**, blood pressure related to wall/lumen ratio, 1199-1200
- Forearm blood flow**, celiprolol effect on circulation, 745-748
- Fosinopril**, phosphorus-containing ACE inhibitor, 200
- Fourier regression**, verapamil difference between two treatments for systolic and diastolic BP, 1503, 1505
- Framingham Heart Study (1974)**, 1215, 1285, 1302, 1303
 blood pressure rates variable with patient age, 947
 cardiovascular disease risk in elderly, 1197-1198
 incidence of myocardial infarction unrecognized, 833-834
 prognosis for myocardial infarctions, 930
 systolic BP and coronary heart disease, stroke, congestive heart failure and intermittent claudication, 1203
 systolic hypertension as independent risk factor, 1263
 systolic vs. diastolic BP for CHD development, 1204, 1205
- Frank-Starling principle**, 1264
- Free fatty acids**, delivery decreased by glucose provision, 787
- Free radicals**
 blunted by nifedipine in silent ischemia, 930
 formation during ischemia in isolated rat heart, 791, 794
- in postischemic renal injury, 816, 817
 not components of clastogenic factors, 800-803
 trimetazidine protection of red blood cells against damage by, 818-819
 trimetazidine protective effect induced by, 861
- French European Eminase Mortality Study (EMS)**, anistreplase vs. heparin in acute myocardial infarction, 1337-1343
- Frusemide**
 interaction with indomethacin, 964
- Functional residual capacity (FRC)**, effect of pulmonary hypertension following cardiac surgery, 21
- Furosemide**
 cardiac effects induced in guinea-pig atria, 1477-1483
 for ventricular dilatation, 244
 inhibiting sodium and potassium fluxes, 323, 327, 328
 intralymphocytic sodium affected, 364-365
 Na,K-ATPase activity inhibited, 385
 Na, K, Cl cotransport system inhibited, 385
 torsades de pointes following injection of, 615-617
 with delapril for hypertension, 1422
- Gallopamil**
 LV relaxation and filling dynamics in myocardial infarction improved, 1509-1513
 pharmacokinetics, 1510
 verapamil derivative, 723
 vs. KT-362, 1347-1348
- Gallopamil/verapamil**, efficacy on coronary vasomotility, 896
- Gemfibrozil**, hyperlipidemia treatment used in Helsinki Heart Study, 1385
- Gender**, as factor in 5HT uptake in hypertensive patients, 105-107
- Generics**, thiazides, 1440
- Genetic control**, lipoproteins and receptors, 1001
- Glibenclamide**
 pharmacologic antagonist of K-channel openers, 1119-1126
 potassium loss in ischemia decreased by, 784
- GLIM package** (Generalized Linear Interaction Modelling statistics package), 128
- Glipizide**, interactions with ranitidine, 487, 490
- Glomerular endotheliosis**, 38
- Glomerular filtration rate**
 angiotensin II role, 230, 233, 234
 calcium antagonist effect, 1331-1335
 chronic renal failure and ACE inhibitors, 222, 223
 essential hypertensive renal disease, 207-214

- felodipine antihypertensive therapy, 254-257
- Glomerular hemodynamics, not different in treated and untreated rats, 1328
- Glomerular sclerosis, more frequent in hypertrophied nephrectomized group, 1326, 1328-1329
- Glucose, ischemia and flux of, 783-788
- Glutathione, trimetazidine effect on oxygen radical species in post-ischemic rat acute renal failure, 816-817
- Glyburide (glibenclamide), inhibiting protective effects of cromakalim in model, 470-473
- Glyceryl trinitrate
clinical efficacy, 247-250
silent myocardial ischemia treatment, 931
- Glyceryl trinitrate (NTG) oral spray
bioavailability, 480
hydrophilic formulation vs. lipophilic solution 475-480
- Glycogen
complex role in ischemia, 777-788
source of glycolysis, 778
- Glycolysis, maintenance playing role protecting membrane function in ischemia, 777-788
- Glycosuria, ACE inhibition side effect for chronic renal failure, 225
- Granulocyte aggregation, interaction with morphine in myocardial ischemia, 303
- GR 43175, high agonistic potency, 1459
- Griseofulvin, Raynaud's phenomenon, 48
- Guanabenz
antisympathetic agent lowering blood pressure, 380
isolated systolic hypertension treatment, 1206-1207
- Guanadrel, ineffective as monotherapy for hypertension, 380
- Guanethidine
antihypertensive drug for elderly in trial, 1240
cold pressor responses abolished by, 1259
ineffective as monotherapy for hypertension, 380
Raynaud's phenomenon, 45, 48, 50
- Guanfacine, antisympathetic agent lowering blood pressure, 380
- Guinea-pig atria
inotropic action of milrinone on, 509-512
muzolimine and furosemide induced cardiac effects compared, 1477-1483
- Gut tumors, carcinoid syndrome, 53
- HAPPHY trial, 1246
- drugs of choice, 1269
- Heart
cardiovascular changes in black and white essential hypertensives, 337-338
- imaging of myocardial metabolism, 847-850
- rate affected by nifedipine, 924
- Heart failure
angiotensin converting enzyme inhibitors, 243-244
diltiazem vs. Ro 40-5967's negative inotropic effect studied, 731, 735
dobutamine repeated infusion effects, 1105-1110
elderly hypertensives, 1197
flecainide with amiodarone effect on dose-concentration relationship, 1161-1164
flosequinan hemodynamic effects, 705
ketanserin as vasodilator long-term treatment, 85-87
muscle energy metabolism, 756
- Helsinki Heart Study, lipid-lowering treatment successful in reducing myocardial infarction, 1385
- Hemodialysis
nifedipine effects on LV function in hypertensives undergoing, 991-992
nifedipine effect on pulse wave velocity, 987-990
- Hemodynamics
aging as cause of changes, 1276-1277
antiarrhythmic drugs, 545-547
atenolol at rest and during isometric exercise, 737-742
calcium-channel blockers, 457-462, 1015
celiprolol better preserving normal function in elderly, 1277
changes in forearm blood flow due to nifedipine, 936-938
deterioration as major side effect of diuretic therapy, 515, 519-520
deterioration in patients with depressed cardiac function, 937
dilevalol, 1463-1465
dobutamine infusion for chronic heart failure, 1107-1109
enoximone, 1403-1413
felodipine, 1495-1500
flosequinan, 705-711, 1396, 1398-1400
interactions between diuretics and calcium antagonists in hypertensives, 1151-1155
nicardipine, 1525-1531
nifedipine, 889-890
nitroglycerin oral spray formulations, 475-480
pindolol at rest and during isometric exercise, 737-742
Ro 40-5967 compared to verapamil, 733-736
sotalol, 1431
sotalol vs. quinidine for arrhythmias, 608
- Hemorheology, ketanserin effect with essential hypertension, 101-104
- Heparin
at start of percutaneous transluminal coronary angioplasty, 688
- bovine vs. porcine for post-operative bleeding, 269-272
- chronic renal failure effect, 222
- inhibiting VSMC growth and antihypertensive, 240
- platelet aggregation, 19, 20
- postoperative bleeding affected in cardiopulmonary bypass patients, 269-272
- vs. anistreplase in acute myocardial infarction French multicenter trial, 1337-1343
- zofenopril in experimental infarction, 696
- Hepatic dysfunction, effect on encaïnide pharmacokinetics, 562-564
- Hepatitis, after loading dose of amiodarone, 1467-1468
- HEP trial, hypertension in the elderly, 947, 948
- Hexamethonium, autonomic blockade restoring nitrate effects, 250
- Histamine, carcinoid syndrome, 53-55
- HMG CoA reductase activity
cultured human skin fibroblast, 69-72, 137
simvastatin for atherosclerosis in hypercholesterolemic patients, 1389-1393
- Holter monitoring
atrial fibrillation, 582
atrial tachycardia, 583-584
CAST substudy patients, 661-662
differential use of 24 and 48 hour ambulatory monitoring, 560
encaïnide efficacy for supraventricular arrhythmias, 575
ischemic cardiomyopathy, 861
risk stratification process for malignant arrhythmias, 665, 667
silent myocardial ischemia, 929-931
simultaneous electrocardiographic recording for nifedipine efficacy in coronary spasm, 916
to detect myocardial ischemia, 841-845
to rule out late arrhythmogenesis, 654
ventricular arrhythmia evaluation, 670-673
ventricular tachycardia, 614, 616
vs. programmed ventricular stimulation, 555-558
- Hormone release, clonidine effect when mediated through opiate receptors, 1113-1116
- Hospital vs. general practice, ketanserin pharmacokinetics for elderly hypertensives, 89-92
- Hyaline arteriosclerosis, 207
- Hydralazine
antihypertensive drug for elderly in trial, 1237, 1240, 1241
cardiac effects, 244
combined with beta blocker to control blood pressure and reduce LVH, 431-432

- congestive heart failure treatment, 1395
for hypertension with chronic renal failure, 222
interaction with indomethacin, 964
not used for initial hypertension monotherapy, 1439
preventive cardiology, 755
sinus node disease treatment, 525
stopped before felodipine treatment, 255
third- or fourth-level therapy for hypertension, 380
vs. converting enzyme inhibitors, 240
vs. nifedipine for sympathetic and cardiac function, 499-503
- Hydrochlorothiazide (HCT)**
antihypertensive treatment for blacks, 391
blood pressure normalization without Na⁺ transport abnormalities, 376-377
cation transport in black hypertensives affected, 384-385
combined with hydralazine and reserpine (HHR) to induce decline in resistance, 1326, 1327
combined with oxprenolol when treating black hypertensives, 1275
diclofenac interaction, 965
diuretics for hypertension in elderly, 1238
drug interactions, 965
effect on LV mass, 503
efficacy and tolerability of long-term treatment in hypertension, 641-647
for hypertension with chronic renal failure, 222
hemodynamic interactions with calcium antagonists in hypertensives, 1151-1154
ibuprofen interaction, 965
not a monotherapy to achieve LVH reversal, 432
preferred over propranolol for antihypertensive treatment in blacks, 390
respiratory function in the elderly affected, 1231
STOP-Hypertension Study treatment, 1254
to achieve goal diastolic blood pressures, 428, 429, 431
vs. diltiazem, 1089
vs. felodipine, 641-647
with enalapril to show renal protective effects, 204
- Hydrogen, sodium antiport, 339**
4-Hydroxy-debrisoquine, minimum effective values for antiarrhythmic therapy, 281-283, 285
6-Hydroxydopamine, pretreatment before methyl dopa injection, 30
5-Hydroxyindoleacetic acid (5HIAA)
carcinoid syndrome, 54, 57
excretion higher in hypertensive men than women, 105, 106, 108
- 4-Hydroxy-3-methoxy-mandelic acid (HMA), urinary excretion rate related to weight reduction, 400
5-Hydroxy-propafenone, pharmacokinetics and antiarrhythmic effects, 281-287
5-Hydroxytryptamine (5HT), *see* Serotonin
5-Hydroxytryptophan
carcinoid syndrome, 53-55
serotonin synthesized from, 138
Hypercalciuria, nifedipine effect, 983-986
Hypercholesterolemia
celiprolol or atenolol effect on plasma lipids, 1287-1289
endothelium function, 11
Hyperkalemia, ACE inhibitor therapy side effect with chronic renal failure, 225
Hyperkinetic syndrome, serotonin and, 33
Hyperlipidemia, clinical relevance, 1385-1388
Hyperplastic elastic arteriosclerosis, 207
Hypertension, *see also* Essential hypertension
ACE inhibitors and cardiac effects, 243-244
ACE inhibitors for reversal, 199-205
age and increased efficacy of ketanserin, 89
age and LV hypertrophy regression and function changes with ketanserin, 81-84
age related to type of drug used in therapy, 947-950
aging and autonomic control in the elderly, 1257-1261
aging and treatment risk factors, 1263-1267
aging effect on, 1209-1212
antihypertensive drugs available in the U.S., 1440
atherosclerotic complication, 13
beta-blocker effect on respiratory function with chronic obstructive lung disease, 1145-1148
beta blockers and calcium-entry blockers for treatment of blacks, 389-392
bisoprolol vs. captopril in the elderly, 261-264
calcium antagonists to reduce glomerular injury, 1325
calcium deficit and low potassium intake as its cause in blacks, 403-405
captopril, 751-754
celiprolol or atenolol effect on blood lipid profile with hypercholesterolemia, 1287-1289
celiprolol treatment, 1195-1196
cerebral blood flow in the elderly, 1217-1220
cerebral infarcts and hemorrhages, 238
chronic renal failure in nondiabetics and, 222
concomitant diseases and choice of anti-hypertensive drug therapy, 1440
costs of treatment, 1439-1441
diltiazem in tablet form, 1089-1096
discontinuation of antihypertensive therapy, 1487-1492
drug interactions (NSAIDs), 965
drug interactions with nifedipine, 964-966
drugs and lipid profiles affected, 1277-1278
drug therapy response racial differences, 338
early regression of LV diastolic abnormalities if patients given nifedipine, 957-960
elderly, 1197-1200
elderly and ketanserin efficacy and tolerability, 115-117
elderly and ketanserin vs. bendroflumazide for beta blockade symptoms, 127-130
elderly and oral dosing of ketanserin, 111-114
elderly pharmacologic treatment for systolic BP, 1203-1207
enalapril effect on parasympathetic activity, 265-267
environmental factors, 363
erythrocyte sodium transport and abnormalities, 373-377
EWPHE Study results with focus on systolic hypertension, 1249-1251
excess frequency in blacks confirmed, 317
felodipine treatment, 253-258, 641-647
felodipine 24-hour profile of hypotensive action, 439-442
hemodynamic interactions between diuretics and calcium antagonists, 1151-1155
hemodynamic responses to newer antihypertensive agents, 1135-1142
hypertrophy reversal with labetalol or propranolol, 431
isradipine vs. prazosin multicenter treatment comparison, 413-417
ketanserin and carcinoid syndrome, 53
ketanserin effect on LV hypertrophy, 73-75
KT-362, calcium release and cardiovascular disease, 1345-1353
LDL cholesterol reduced by ketanserin, 72
LV function after sublingual administration of nifedipine, 969-974
LV hypertrophy regression with long-term ketanserin, 77-80
mechanisms of, 317-319
membrane transport of ions, 367-370
nicardipine and ambulatory blood pressure control, 435-437
nifedipine effects on LV function in hemodialysis patients with, 991-992
nifedipine effect on serum lipoprotein metabolism with, 1033-1035

- nifedipine influence, 1028-1030
 nifedipine slow-release for long-term therapy, 941-944
 nifedipine vs. hydralazine effects on sympathetic activity and cardiac function, 499-508
 obesity in blacks and, 395-401
 pathophysiology, 1263-1267
 portal, and serotonin, 5, 33-34
 postoperative systemic following cardiac surgery, 19-24
 preeclampsia, 37-38
 preventive aspects of cardiology, 755
 race/sex differences in mortality from, 398
 racial differences in therapy, 379-381
 reduced by ketanserin, 133-135
 relationship between age and cardiovascular response to meals, 493-496
 revascular and ACE inhibition, 229-234
 risk factor in INTACT Study of coronary artery disease, 1053-1056, 1065
 serotonin and, 5, 9, 11
 socioeconomic factors, 397-398
 sodium-lithium countertransport and lipid correlations, 357-361
 sodium, potassium, transport systems in black hypertensives, 321-330
 STOP-Hypertension Study results in Sweden, 1253-1255
 tertatolol use and interactions with rifampicin and ranitidine, 487-490
 therapy achievements, 1302-1303
 therapy of choice in the elderly, 1303-1304
 trials in the elderly, 1237-1247
 volume expansion as factor for blacks, 383-386
- Hypertension Detection and Follow-up Program Study (HDFP study), 948, 1240, 1243
 antihypertensive treatment equally good in elderly as total population, 1253
 discontinuation of antihypertensive drug therapy, 1490
 systolic vs. diastolic BP for CHD development, 1204
 withdrawal due to adverse reactions, 1298
- Hypertension Stroke Cooperative Study, 1243
- Hypertension Trial in Elderly Patients in Primary Care (HEP), 1250
- Hypertensive nephropathy, felodipine for hypertension, 254, 256
- Hypertensive nephrosclerosis, 207, 209, 213
 racial differences in hypertension, 338
- Hypertensive retinopathy, racial differences in hypertension, 337-338
- Hypertrophic cardiomyopathy, *see also* Cardiomyopathy
 beta blockers to improve symptoms, 1517
 calcium antagonists to improve symptoms, 1517
 propranolol vs. verapamil long-term effects preventing sudden death, 1515-1518
- Hypertrophy
 left ventricular dysfunction, 1363
 noninfarcted myocardium, 1365-1370
 vascular, and hypertension, 237-240
- Hyperventilation, ischemic response abolished by nifedipine, 894-895
- Hypoalgesia, ketanserin effect, 133-135
- Hypocalcemia, action-potential duration lengthened as antiarrhythmic mechanism, 598-599
- Hypoglycemia, beta blockade and, 1278
- Hypokalemia
 ketanserin and potassium-losing diuretic treatment, 95
 QT prolongation when diuretic-induced, 139
- Hypotension, celiprolol for treatment of elderly, 1291-1294
- Hypothalamus, digitalislike circulating factor, 344
- Hypothener hammer syndrome, 47
- Hypothyroidism, action-potential duration significantly increased, 598, 602
- Hypoxia, diltiazem effect on oxymyoglobin level in rat heart during, 719-722
- Hypoxia of kidneys, calcium time-dependent increase, 1319-1321
- Ibuprofen
 hydrochlorothiazide interaction, 965
 infarct expansion affected, 1370
- ICS 205930, 29
- Idiopathic dilated cardiomyopathy, plasma concentrations of atrial natriuretic peptide, 290
- Iloprost, Raynaud's phenomenon, 49
- Imaging techniques, 766
- Imipramine, conduction abnormalities, 592, 594
- Implantable cardioverter defibrillator, to reverse mechanism of sudden cardiac death, 533
- Incessant atrial tachycardia, encainide vs. flecainide, 582
- Indacrinone, potassium transport stimulated, 385
- Indapamide, vasodilation action, 748
- Indians of Natal, sodium and potassium urinary and intracellular studies, 363-365
- Indolamines, ketanserin depleting stores of, 138
- Indomethacin
 abolishing effects of captopril and ramipril in myocardial ischemia, 1380
 blood-pressure lowering effect of captopril and, 201
 drug interactions, 964
 pretreatment effect on pressor response, 38, 39
- renal prostaglandin synthesis inhibited, 963-964
 venoconstriction response to DHEC and DHE experiment, 1456
 vs. nicorandil, 1076
- Individual therapy, costs for hypertension, 1439-1441
- Infarct expansion
 greatest in first, transmural myocardial infarctions, 1363-1365
 prevention of, 1370-1372
- Infarct size, reduction in dog models by cromakalim and pinacidil, 465-469, 471-473
- Injury, determinants of tissue, 767-774
- Inotropic agents, added with muzolimine to compare cardiac effects on guinea pigs, 1478-1483
- Intotropy
 enoximone effect, 1411-1413
 milrinone's action on guinea-pig atria, 509-512
 OPC-8212, 713, 716
- INTACT Study (International Nifedipine Trial on Antiatherosclerotic Therapy)
 angiographic evaluation features, 1037-1044
 nifedipine retardation of coronary artery disease, 1047-1065
- Internal mammary artery (IMA), serotonin-induced contractions and ketanserin, 59-61
- International Society of Hypertension, antihypertensive treatment recommendations, 1269-1270
- INTERSALT Study
 environmental/dietary influences on blood pressure with increasing age, 1198
 weak relationship between elderly salt intake and BP, 1211
- Interstitial nephritis, captopril therapy and, 225
- Interventional cardiology, angioplasty and, 995-996, 1001-1003
- Intimal hyperplasia, response to angioplasty injury, 993, 996
- Intraarterial blood pressure, ambulatory measuring technique for decrease by felodipine, 439-442
- Intracoronary nifedipine, pretreatment protective effect on myocardial ischemia and dysfunction, 887-890
- Intracranial atherosclerosis, racial differences in hypertension, 337
- Intraocular pressure (IOP), reduced by ketanserin treatment, 97-98
- Intrapulmonary shunting
 ketanserin effect, 19, 21-22, 24
 nitroprusside effect, 21
- Intravital videomicroscope system (IV-VMS), to record microcirculation kinetics on human bulbar conjunctiva, 101
- Intrinsic sympathomimetic activity (ISA)

- beta blockers and respiratory function in the elderly, 1230
 celiprolol, 1281-1284, 1298
 pindolol, 1283
 propranolol, 1284
Ion transport
 abnormalities, 374-377
 in hypertension, 367-370
 sodium-lithium countertransport and lipid correlations, 360, 361
 sodium transport and hypertension classifications, 373-377
 IPPPSH Study, 1246
 Ischemic area, ECG recording and Holter tapes for calculating, 842-845
 Ischemic cardiomyopathy, trimetazidine cardioprotective effect, 861-865
 Ischemic heart disease
 amiodarone, 529
 brief repetitive episodes causing "stunning" effect, 880, 881
 calcium channel blocker effects, 457-462
 definition, 777
 diuretics effect, 101
 effect on endothelin receptor density in isolated hearts, 880, 882-883
 ergonovine-induced prevented by intravenous nifedipine, 909-913
 flosequinan hemodynamic effects, 705
 free radicals during reperfusion and, 791-794
 glucose to perfusion ratio studied, 850
 intracoronary nifedipine pretreatment protective effects, 887-890
 J-shaped curve present with, 1246
 leading possibility to sudden death, 555
 mechanisms, 827-830
 metabolic pathways and implications of increased glycolysis, 777-788
 mortality and racial characteristic, 398
 nocardipine treatment, 1525-1531
 nicorandil efficacy, 1453
 nifedipine treatment for silent myocardial, 929-933
 race/sex differences in mortality from, 398
 pathophysiology, 835-837
 serotonin having pathogenetic role, 1446
 severity of, 780
 sudden cardiac death prevention, 675-676
 tissue injury determinants, 767-774
 total burden in coronary artery disease, 833-838
 trimetazidine effects on DADs and upstroke velocity of action potential, 806-807
 trimetazidine enzymatic and electrical response in myocardial ischemia model, 808-809
 trimetazidine NMR spectroscopy study in rat heart, 812-813
 trimetazidine's electrocardiographic assessment of properties, 810-811
 ISIS Study, atenolol for ischemic heart disease, 676
 Isolated coronary artery occlusion, nifedipine vs. isosorbide dinitrate effects on exercise tolerance, 907
 Isolated heart (rat), diltiazem effect on oxymyoglobin level during hypoxia, 719-722
 Isolated systolic hypertension (ISH)
 drug treatment response, 1250
 most cases "essential" and its prevalence, 1203, 1205-1207
 Isometric exercise, hemodynamic effects of pindolol and atenolol during, 737-742
 Isoprenaline, heart rate response reduced with age, 1234
 Isoproterenol, inotropic effect measured with ZSY-39, 1128, 1129, 1131, 1133
 Isosorbide dinitrate (ISDN)
 administered before coronary angiography to increase coronary diameter, 1037, 1050
 cardiac effects, 244
 LV diastolic function therapy for impairment, 951-954
 synergistic increase of blood flow when captopril added, 250
 vs. nicorandil, 1077, 1079, 1080, 1082, 1084-1085, 1453
 vs. nifedipine on exercise tolerance, 905-907
 Isovolumic relaxation time, LV diastolic function, 952, 954
 Isoxsuprine, Raynaud's phenomenon, 48
 Isradipine
 antiatherogenic effects and mechanisms of action, 1015, 1016, 1018
 compared with prazosin for essential hypertension treatment, 413-417
 effect on hypertensive kidney, 1331-1334
 Italian Multicenter Atherosclerosis Progression-Regression Trial, lipid-lowering treatment, 1387
 Japanese trial (by Kuramoto), 1237, 1243
 Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (1988)
 ISH treatment in elderly with nonpharmacologic therapy, 1206
 risk factors indicating benefit from antihypertensive drug therapy, 1487
 J-shaped curve, 1233
 elderly mortality with antihypertensive drug treatment, 1246
 Junctional ectopic tachycardia, encainide efficacy, 573
 Junctional tachycardia, flecainide and propafenone treatments, 550-551
 Kallikrein
 carcinoid syndrome, 54
 urinary excretion different in blacks vs. whites, 336, 383
 Kallikrein-kinin-prostaglandin systems, ACE inhibitor effects, 204
 Kallikrein kinin system
 ACE inhibition therapy, 210
 differing profile between whites and blacks, 390
 hypertension incidence correlated in blacks, 317
 KB-944, vs. SD-3211, 1469
 K-channel openers, coronary blood flow increased by, 1119-1126
 Ketanserin
 acute electrophysiologic effects in humans, 1157-1160
 age-related antihypertensive efficacy on left ventricular hypertrophy, 81-84
 antiarrhythmia drugs not recommended in combination, 14, 16, 17
 antihypertensive actions, 13-14
 captopril interaction in treating hypertensives, 119-122
 carcinoid syndrome, 53, 55-57
 decreasing HMG CoA activity, 137
 diuretics not recommended in combination, 14-17
 effect on LV hypertrophy in hypertensive patients, 73-75
 effect on transmembrane cation transport, 63-66
 efficacy in elderly hypertensives, 115-117
 elderly hypertensives and oral dosing, 111-114
 erythrocyte deformability, 102
 5HT₂ blocker, 30
 5HT₂ receptor blocker effect on DHEC and DHE, 1459
 for treating postoperative systemic and pulmonary hypertension, 20-24
 hemorheology affected in essential hypertension, 101-104
 hypertension treatment, 1443
 hypotensive effect mechanism, 7, 10, 11
 increased efficacy not due to altered pharmacokinetics, 89-92
 inhibiting S₂ receptor in preeclampsia, 40
 inhibitor of thrombotic complications of atheroma, 14
 LV hypertrophy regression during long-term treatment, 77-80
 mammary artery contractions reversed, 59-61
 microhemodynamics affected in essential hypertension, 101-104
 nifedipine interaction, 965-966
 only 5HT₂-receptor antagonist causing antihypertensive effect, 1445
 pain perception affected in arterial hypertension, 133-135
 pharmacokinetics in elderly hypertensives, 89-92
 portal pressure reduction, 33

- preventing early restenosis after percutaneous coronary angioplasty, 15
- Raynaud's phenomenon, 45, 46, 48-50, 1445
- reducing intraocular pressure due to open-angle glaucoma, 97-98
- serotonin neurons and mean arterial pressure, 29
- tolerability in elderly hypertensives, 115-117
- to lower portal venous pressure, 138
- to reduce adverse symptoms of beta blockade, 127-130
- as vasodilator long-term treatment for heart failure, 85-87
- ventricular ectopic activity suppressed in normokalemic patients, 95
- vs. enalapril for essential hypertension, 123-125
- Ketanserinol elimination half-life in elderly hypertensives, 89-92
- Ketanserin tartrate, effect on HMG CoA reductase activity in cultured human skin fibroblasts, 69-72
- Kidneys
- ACE inhibitors and renal impairment, 202-204
 - ACE inhibitors in renovascular hypertension, 229-234
 - alpha-adrenergic receptor activity, 383-384
 - beta blocker effect on elderly, 1274
 - calcium antagonists' effects, 1317, 1331-1335
 - calcium entry blockers producing effects, 979-981
 - calcium handling by renal tubules during oxygen deprivation injury prior to reoxygenation, 1319-1323
 - celiprolol effect on renal function, 1297
 - changes in black and white essential hypertensives, 337-338
 - delapril for hypertension with normal or impaired renal function, 1417-1422
 - drag-reducing polymers, 297-300
 - essential hypertension and ACE inhibitors, 207-214
 - felodipine effects, 1495, 1500
 - geriatric hypertension affected by function of, 1200
 - glomerular injury affected by calcium antagonists, 1325
 - impaired renal function and felodipine, 253-258
 - last target organ for cotransport abnormalities, 376
 - nicardipine renal clearance, 1528-1529
 - nitrendipine beneficial effect for hypertension, 1029
 - renal disease effect on encainide pharmacokinetics, 562-564
 - renal tubular disorders and calcium excretion lowering methods, 983
 - trimetazidine effect on oxygen radical species in rat renal failure, 816-817
- Kinins, carcinoid syndrome, 53-55
- KT-362
- effects on intracellular calcium release, arrhythmias, myocardial ischemia, and hypertension, 1345-1353
 - vs. diltiazem, 1346
 - vs. nicorandil, 1348
 - vs. nifedipine, 1346-1348
 - vs. nitroglycerin, 1346, 1348
 - vs. nitroprusside, 1348
 - vs. quinidine, 1350-1351
 - vs. verapamil, 1346, 1350
- Labetalol
- alpha blockers and beta blockers in combination for hypertension, 380
 - antihypertensive treatment for blacks, 390
 - blood lipid profile affected, 1277
 - clinical disadvantages of, 1281
 - elderly patient use, 1299
 - for reversal of LV hypertrophy, 427-432
 - in-vitro adrenoceptor activities, 1283
 - silent myocardial ischemia treatment, 931
 - vs. celiprolol, 1282
- Lactate, end product of anaerobic glycolysis, 780-782
- Lactate dehydrogenase (LDH) release, cromakalim effect, 467, 470-472
- Langendorff perfusion, diltiazem effect studied on oxyhemoglobin level of hypoxic rat heart, 719-720
- Left ventricular (LV) diastolic function, hydralazine vs. nifedipine effects, 499-503
- Left ventricular (LV) dilatation
- captopril and myocardial ischemia, 1381
 - congestive heart failure following, 1363-1372
 - prevention of, 1370-1372
- Left ventricular (LV) function
- amiodarone and sotalol well tolerated, 546, 547
 - anistreplase vs. heparin in acute myocardial infarction trial, 1343
 - assessment after nifedipine sublingual administration for hypertension, 969-974
 - dobutamine infusion level of benefits related to, 1109
 - enoximone effect, 1410-1413
 - filling improved by gallopamil, 1512
 - flecainide proarrhythmic side effects, 552
 - 4'epiadriamycin reversing, 1522
 - hemodynamics of nicorandil vs. nitroglycerin effect in conscious dogs, 1449-1453
 - ketanserin antihypertensive therapy for elderly patients, 81-84
 - LV filling pattern, cardiac index, and nifedipine, 923-927
 - nifedipine effect evaluation with an ambulatory radionuclide detector (VEST), 918
 - nifedipine effects in hemodialysis hypertensive patients, 991-992
 - not impaired by long-term ketanserin treatment, 79, 80
 - programmed ventricular stimulation for providing information on, 556
- Left ventricular hypertrophy (LVH)
- epidemiology of hypertension in elderly, 1198
 - ketanserin effect in hypertensive patients, 73-75
 - racial differences in hypertension, 337
 - regression achieved by converting enzyme inhibitors, 243
 - regression and function changes with ketanserin in elderly hypertensives, 81-84
 - regression during long-term ketanserin, 77-80
 - reversal by ketanserin, 138
 - reversal with labetalol and propranolol, 427-432
- Left ventricular (LV) relaxation, gallopamil effect in myocardial infarction, 1509-1513
- Left ventricular systolic function, hydralazine vs. nifedipine effects, 499-503
- Leukemia, hemodynamic effects of chronic 4'epiadriamycin treatment with, 1520-1522
- Leukotrienes, modulating vascular growth, 239
- Lidocaine
- decrease in cardiac output and worsening of congestive heart failure, 545-546
 - interaction with ranitidine, 490
 - onset kinetics, 571
 - plasma protein bindings and encainide, 564
 - proarrhythmic incidence during EPS testing, 539
 - sodium-channel block, 542
- Light transmission method, to measure platelet aggregation, 106
- Lignocaine, interaction with ranitidine, 487
- Lipid-lowering therapy
- chronic renal failure effect, 222
 - clinical relevance, 1385-1388
- Lipid peroxides
- components of elastogenic material, 800
 - thiobarbituric acid reactants as index of, 791-794
 - trimetazidine influence, 814-819
- Lipid profile, antihypertensive drugs and their effect on, 1277-1278
- Lipids
- accumulation as hallmark of atherosclerotic lesions, 1017
 - atherosclerosis stabilization on simvastatin with hypercholesterolemia, 1389-1393

- celiprolol or atenolol effect with hypercholesterolemia, 1287-1289
 correlation with Na, K-ATPase activity, 369, 370
 correlation with sodium-lithium countertransport, 368
 nifedipine effect in mild hypertension, 1033-1035
 role in atherosclerotic plaques, 993-995, 997, 1000
 sodium-lithium countertransport and hypertension, 360
- Lipoproteins**
 hyperlipidemia clinical relevance, 1385-1388
 nifedipine effect in mild hypertension, 1033-1035
 sodium-lithium countertransport and environmental stimuli, 360
- Lisinopril**
 absorption rate not modified by food, 201, 205
 beta-receptor density increased, 1367
 bioavailability, 202
 congestive heart failure, 205
 elimination kinetics, 203
 interaction with indomethacin, 964
 modest SI reduction, 1140
 nonsulphydryl ACE inhibitor and lysine derivative of enalaprilat, 199, 200
 pharmacokinetic and pharmacodynamic effects, 202
 renal effects, 207, 211, 213
- Lithium**, analogue of potassium and sodium, 323
- Liver**
 acute hepatitis after loading dose of amiodarone, 1467-1468
 encainide safety evaluation, 591
 hepatic disease effect on encainide pharmacokinetics, 562-564
 reversible abnormalities of function tests with nicardipine, 437
- Long QT syndrome (LQTS)**
 beta blockers reducing sudden death rate in, 675
 risk stratification process, 665-667
- Lorcainide**
 effect on conduction characteristics of AV pathways, 621
 onset kinetics, 571
- Low-renin hypertension**, blood vessel sensitizing activity with respect to norepinephrine, 344, 346
- LY 53587**, selective 5HT₂-receptor antagonist, 1445-1446
- Lymphocyte**, beta-receptor density tested in dobutamine evaluation, 1106-1107, 1109, 1110
- Lymphomas**, hemodynamic effects of chronic 4'epiadriamycin treatment with, 1520-1522
- Mahaim type syndrome**, encainide efficacy and AV reentry, 573, 574
- Malignant arrhythmias**, risk stratification process, 665-667
- Malondialdehyde (MDA)**
 production not changing with trimetazidine treatment, 814
 reaction with thiobarbituric acid (TBA) studied, 818, 819
 trimetazidine and oxygen radical species in post-ischemic rat renal failure, 816-817
- Mammary artery (human)**, serotonin-induced contractions and ketanserin, 59-61
- Mannitol**, renal actions, 297-300
- MAPHY Trial**
 beta-blocker mortality lower than that of diuretic group, 1245
 metoprolol protection against coronary disease, 1439
- MCI-176**
 cardiovascular profile similar to SD-3211, 1474
 vs. SD-3211, 1469
- MDL 72222**, 29
- Meals**, cardiovascular response to and relationship between age, 493-496
- Medical Research Council (MRC) Treatment Trial for Mild Hypertensives**
 cold pressor responses, 1259, 1302, 1303
 confidence limits not given, 1269
 mild hypertension after drug therapy withdrawal, 1490
 mild hypertension in younger patients, 1243, 1250
 placebo group, 1270
 withdrawal of propranolol from elderly, 1492
- Medrohalol**, improving forearm arterial compliance, 748
- Membrane currents**, OPC-8490 effect on, 713-717
- Membrane fluidity**, hypertensive, 367-370
- Membrane potentials**, OPC-8490 effect on, 713-717
- Mercurials**, Na, K-ATPase activity inhibited, 385
- Metabolic profile**
 enalapril, 123-125
 ketanserin, 123-125
- Metabolism (myocardial)**, imaging by positron emission tomography, 847-850
- Metapyrone**, increasing digoxinlike immunoreactivity, 346
- Metergoline**, abolishing pressor response, 28
- Methacholine**, causing coronary vasospasm in patients with variant angina, 1079
- Methionine (IV)**, effect on responsiveness to glycyl trinitrate, 248, 249
- Methiothepin**
 antagonizing venoconstrictor responses to serotonin, dihydroergocristine and dihydroergotamine, 1455-1459
 coronary artery contraction shifted, 8
- Methoxamine**
 induced responses inhibited by KT-362, 1348
 maintaining aortic pressure at normal level with effort angina, 907
- Methoxy-O-desmethyl-encainide (MODE)**, electrophysiologic properties, 567
- 3-Methoxy-O-desmethyl-encainide (3-MODE)**, pharmacokinetics of encainide, 561-565
- Methyldopa**
 antihypertensive actions, 13
 antihypertensive drug treatment for elderly, 1237
 antihypertensive drug treatment for elderly in trial, 1238-1241
 antisympathetic agent lowering blood pressure, 380
 combination therapy for hypertension, 947, 948
 diminishing LV mass, 73
 EWPHE Study drug treatment, 1269
 for LVH regression, 431, 432
 nifedipine interaction, 964, 966
 Raynaud's phenomenon, 48
 serotonin to mediate hypotensive action of, 27, 30-31
- Methylene blue**, pretreatment effect on pressor response, 39
- Methysergide**
 carcinoid syndrome, 57
 Raynaud's phenomenon, 46
 serotonin neurons and mean arterial pressure, 29, 30
 to control symptoms of carcinoid syndrome, 139
- Metipranolol**, ineffective antihypertensive drug for blacks, 389
- Metomidate**, zofenopril in experimental infarction, 696
- Metoprolol**
 adverse reactions in elderly, 1273
 antihypertensive actions, 13
 blood lipid profile affected, 1277
 combination therapy effect on anginal frequency, 900
 compared to bisoprolol, 261
 dilated cardiomyopathy treatment, 675
 for LVH regression, 432
 ineffective antihypertensive drug for blacks, 390
 interaction with ranitidine, 490
 ischemic heart disease treatment, 676-678
 maximal comparable workload and LV volume reduced, 484-485
 no kinetic interaction with nifedipine, 1529
 pharmacokinetic interactions, 559
 slow release producing a 24-hour hypotensive response, 437
 smoking not affecting metabolism in elderly, 1274

- STOP-Hypertension Study treatment, 1254
 vs. captopril, 1278-1279
 vs. celiprolol, 1195, 1277
- Mexiletine
 antiarrhythmic drug, 594
 decrease in cardiac output and worsening of congestive heart failure, 545-546
 onset kinetics and encainide electrophysiological effects, 570, 571
 proarrhythmia incidence during EPS testing, 539
 sodium-channel block, 543
 stereochemical influences, 541, 542
 tolerated by patients with LV dysfunction, 547
- MIAMI Trial, metoprolol for sudden death prevention, 678
- Microdialysis, 28
- Microhemodynamics, ketanserin effect with essential hypertension, 101-104
- Midazolam, interaction with ranitidine, 487, 490
- MILIS Study, sudden cardiac death, 651-652
- Milrinone
 cardiotonic agent for congestive heart failure, 1127, 1133
 purine compounds involved in inotropic action of, 509-512
- Minoxidil
 not used for initial hypertension monotherapy, 1439
 stopped before felodipine treatment, 255
 third- or fourth-level therapy for hypertension, 380
- Mitochondrial function, trimetazidine effect, 814-815
- Mitral valve disease, plasma concentrations of atrial natriuretic peptide, 290, 293
- Mitral valve prolapse (MVP), risk stratification process, 665, 666
- Modulated receptor theory, 541-543
- Moduretic Mite, STOP-Hypertension Study treatment, 1254
- Monoclonal theory, atherosclerosis, 1002
- Monocrotaline (MCT)
 heart failure model for trimetazidine and cardiomyopathy administered by, 865
 pulmonary vascular injury resulting after administration, 814-815
- Moricizine
 antiarrhythmic drug used in Cardiac Arrhythmia Suppression Trial (CAST), 591, 594
 Cardiac Arrhythmia Suppression Trial (CAST), 659-664
 conduction abnormalities, 592
- Morphine, interaction with granulocyte aggregation in myocardial ischemia, 303
- Mortality
 captopril for infarct expansion, 1371
 cold pressor responses in the elderly, 1260
 EWPHE study results showing decrease in, 1249-1250
 intention-to-treat analysis of EWPHE trial, 1238-1239
 lipid-lowering treatment effect on rates of coronary heart disease, 1385-1388
 major trials and key factors in treatment, 1269
 nitroglycerin effect on infarct expansion, 1370
 not decreased much by active treatment in antihypertensive trial, 1240-1241, 1243-1245
 systolic blood pressure related, 1301-1302
- MPIP Study, cardiac sudden death, 651-652
- Multiple Risk Factor Intervention Trial (MRFIT), 930, 1487
 Screening Study (1988) on systolic vs. diastolic BP for CHD development, 1204, 1205
- Multiple-system atrophy (MSA), *see* Shy-Drager syndrome
- Muzolimine
 cardiac effects induced in guinea-pig atria, 1477-1483
 vs. verapamil, 1477, 1479-1480
- Myocardial contractility
 Ro 40-5967 vs. verapamil for negative inotropic effects, 732-733, 735
- Myocardial energy metabolism, 756, 768
- Myocardial infarction
 ACE inhibitors not yet recommended for treatment, 1375-1382
 anistreplase vs. heparin French multicenter trial, 1337-1343
 case-fatality rate decreased in EWPHE trial, 1239
 elderly hypertensives, 1197
 electrocardiogram showing ventricular fibrillation, 1180
 gallopamil effect on LV relaxation and filling dynamics, 1509-1513
 lipid-lowering treatment and its clinical relevance, 1385-1388
 not reduced by hypotensive drug treatment, 1245-1246
 prevented by early reperfusion with zofenopril, 695
- Myocardial ischemia
 ACE inhibitor treatment not yet recommended, 1375-1382
 enoximone therapy side effect, 1412, 1413
 ergonovine-induced prevented by intravenous nifedipine, 909-913
 Holter-detected, 841-845
 interaction between morphine and granulocyte aggregation, 303
 KT-362 treatment, 1346, 1352-1353
- potassium channel activator protective effects, 465-473
 prevented by felodipine, 443-448
 reperfusion and dilevalol effect during, 1462-1464
 total ischemic burden with coronary artery disease, 833-838
- Myocardial performance, after 4'epiadriamycin chronic treatment, 1519-1522
- Myocardial protection, perioperative assessment of the quality of, 797-803
- Myocarditis, phorbol ester effect on human coronary artery, 1360
- Myocyte migration, calcium dependent and inhibited by calcium antagonists, 1027-1028, 1030
- Myocyte proliferation, calcium-channel inhibition by calcium antagonists, 1028, 1030
- Myosin light chain phosphorylation, contractile force increased in vascular smooth muscle, 1355-1361
- N-Acetylcysteine, potentiation of nitrate-induced vasodilation, 248, 249
- N-Acetyl metabolite of procainamide (NAPA), lengthening action-potential duration, 599, 602
- Nadolol
 antihypertensive treatment for blacks, 390
 autonomic blockade restoring nitrate effects, 250
 blood lipid profile affected, 1277
 combination therapy for arrhythmia, 582, 583
 dose adjustment when glomerular filtration rates fall, 1273, 1274
 for black hypertensives, 383
- Naftidrofuryl, antihypertensive properties missing, 7
- Naloxone
 combined therapy with clonidine for hormone inhibition, 1113-1116
 effect on morphine in myocardial ischemia, 303
 effect on pain threshold, 135
 hormone release affected when mediated by opiate receptors, 1113-1116
- Naproxen, drug interaction, 965
- National Heart, Lung and Blood Institute Type II Coronary Intervention Study cholestyramine for lipid-lowering treatment, 1386-1387
 cholestyramine to retard CAD progression in Type II hyperlipidemia, 1392
- Natriuresis, felodipine as extended-release tablet, 1495, 1498-1500
- N-Desmethyl-encainide (NDE)
 electrophysiologic properties, 567
 pharmacokinetics of encainide, 561-564
- Negative inotropic action
 cletiazem, 1097, 1101, 1102, 1103
 cletiazem and diltiazem effect on rabbit aorta and myocardium, 723-729

- cromakalim, 1122, 1125
 KT-362, 1345, 1346, 1352, 1353
 nicorandil, 1121, 1125, 1126
 Ro 40-5967 compared to verapamil, 735
 Neurohumoral regulation, flosequinane effect, 1401
 Neutrophil function, inhibition by morphine, 303
 Niacin
 lipid-lowering Italian trial, 1387
 lipid-lowering treatment in Coronary Drug Project, 1386
 with colestipol in lipid-lowering treatment, 1387
 Niacin derivatives, Raynaud's phenomenon, 48
 Nicardipine
 antiatherogenic effects and mechanisms of action, 1016, 1018
 combined with nifedipine, 1529
 effect on hypertensive kidney, 1331-1334
 kinetics and hemodynamic effects when modified by previous propranolol taken orally, 1525-1531
 lipoproteins metabolism effect, 1033
 nifedipine derivative, 723
 pharmacokinetics, 1527, 1528
 profile showing increase in heart rate and cardiac output, 462
 Raynaud's phenomenon, 47, 938-939
 serum calcium reduced and atherosclerosis prevented by, 1021
 sustained release with 24-hour blood pressure control, 435-437
 vs. celiprolol, 1196
 vs. diltiazem, 1530, 1531
 vs. nifedipine, 1531
 vs. verapamil, 1530, 1531
 Nicorandil
 acute myocardial ischemia treatment, 1079
 angina pectoris treatment, 1075, 1078, 1078, 1080-1083, 1453
 cardioprotective properties, 473
 coronary blood flow increased by K-channel opening mechanism, 1119-1126
 dosage and administration, 1084-1085
 drug interactions, 1084
 pharmacodynamics, 1080-1081
 pharmacokinetics, 1080-1081
 pharmacology and therapeutic effects of, 1075-1085
 side effects, 1083-1084
 therapeutic trials, 1081-1083
 vs. isosorbide dinitrate, 1453
 vs. KT-362, 1348
 vs. nitroglycerin LV effects in dogs, 1449-1453
 Nicotine, interaction with beta blockers, 1273, 1274, 1276
 Nicotinic acid
 cause of flushes, 55
 lipid-lowering treatment, 1386, 1387
 Nifedipine
 after-drug effect, 917-918
 antiatherosclerotic effect in cholesterol-fed rabbits of, 1021-1025
 antiarteriosclerotic effects, 1012
 antiatherogenic effects and mechanisms of action, 1015, 1017-1018
 antihypertensive drug treatment for elderly in trial, 1239-1240
 antihypertensive treatment for blacks, 391
 antihypertensive treatment similar to isradipine, 416, 417
 bioavailability, 455
 blunting the degree of LV dysfunction from ischemia, 930
 cardiac function with coronary artery disease evaluated with ambulatory radionuclide monitoring, 919-922
 cardioprotection and, 875, 877
 causing early regression of LV diastolic abnormalities in hypertensives, 957-960
 clearance affected by propranolol, 1529
 combination therapy with captopril for hypertension, 965
 combination therapy with enalapril for hypertension, 965
 combined with atenolol, 646-647
 combined with atenolol for stable angina, 899-903
 combined with propranolol for angina, 900, 901
 combined with trimetazidine for effort angina, 824-825
 coronary artery disease retardation: results of INTACT Study, 1047-1065
 derivatives, 723
 drug interactions, 964-966
 drug interactions in hypertensive patients, 963-966
 drug interactions with NSAIDs, 963-964
 drug interaction with ranitidine, 487, 490
 effect on forearm arteries of hypertensive patients, 748
 effect on hypertensive kidney, 1331, 1333, 1334
 effect on LV diastolic dysfunction after myocardial infarction, 923-927
 effect on LV diastolic function in hypertension, 951-954
 effect on plasma triglycerides, plasma cholesterol, and sudanophilic lesions, 880-884
 effect on water-sodium, uric acid, calcium metabolism and aldosterone secretion in hypertension, 977
 experimental cardioprotection and, 879-884
 glomerular sclerosis reduced, 1327, 1328
 increasing exercise duration for chronic stable angina, 894-896
 influence on angiographic progression of coronary artery disease, 1037-1044
 influence on experimental arteriosclerosis, 1027-1030
 intravenous to prevent ergonovine-induced myocardial ischemia with effort angina, 909-913
 ketanserin interaction, 965-966
 LV diastolic filling in CAD enhanced, 1509
 LV diastolic function therapy for impairment, 951-954
 LV function after sublingual administration for hypertension, 969-974
 LV function in hemodialysis hypertensive patients, 991-992
 maximal comparable workload and LV volume changes, 484-485
 myocardial ischemia and dysfunction and, 887-890
 oxymyoglobin level increased in hypoxic rat heart, 719
 prescribed for percutaneous transluminal coronary angioplasty patients, 688-690
 preventive aspects of cardiology, 755
 pulse wave velocity of chronic hemodialysis patients, 987-990
 Raynaud's phenomenon, 45, 47, 49-50
 reduction of vascular resistance and increase of heart rate and cardiac output, 462
 serum calcium reduced and atherosclerosis prevented by, 1021-1025
 serum lipoprotein metabolism with mild hypertension, 1033-1035
 silent myocardial ischemia treatment, 931-933
 slow-release efficacy on ischemic attacks with variant angina, 915-918
 slow-release for hypertension in the elderly, 948-950
 slow-release long-term essential hypertension therapy, 941-944
 slow release producing a 24-hour hypotensive response, 437
 stopped before felodipine treatment, 255
 "stunned" myocardium affected, 880
 to prevent poststenotic alpha-adrenoceptor-mediated vasoconstriction, 443, 448
 urinary excretion in hypercalciuria, 983-986
 use in hypertension and Raynaud's phenomenon, 935-939
 vs. celiprolol, 1196
 vs. clentiazem, 1097, 1100-1103
 vs. hydralazine for sympathetic and cardiac function, 499-503
 vs. isosorbide dinitrate on exercise tolerance, 905-907
 vs. KT-362, 1346-1348
 vs. nicardipine, 1531
 vs. nicorandil, 1078, 1081, 1082, 1084

- vs. nisoldipine for angina pectoris, 451-455
- vs. trimetazidine for effort angina, 853-859
- Nifedipine-TIAP Study, nifedipine treatment of silent ischemia, 932, 933
- Nilvadipine, antiatherogenic effects and mechanisms of action, 1016, 1018
- Nimodipine
 - antiatherogenic effects and mechanisms of action, 1016-1018
 - nifedipine derivative, 723
 - preventing vascular lesions, 1029, 1030
- Nisoldipine
 - antiatherogenic effects and mechanisms of action, 1016
 - bioavailability, 455
 - chronic renal failure progression attenuated, 980
 - compared to nifedipine for angina pectoris, 451-455
 - hemodynamic response to, 1135-1139
 - nifedipine derivative, 723
 - nifedipine electrophysiologic effects compared to, 890
 - oxymyoglobin level increased in hypoxic rat heart, 719
 - profile showing increase in heart rate and cardiac output, 462
 - Raynaud's phenomenon, 47
 - vasodilatory effects on coronary arteries, 273-278
 - vs. nifedipine for vascular selectivity, 937
- Nitrates
 - antiischemic mechanisms, 905
 - isolated systolic hypertension treatment, 1206
 - tolerance, 247-250
 - tolerance level affected by nitroglycerin, 1079, 1083
- Nitrendipine
 - antihypertensive treatment for blacks, 386, 391, 392
 - chronic renal failure patients with adequate tolerance, 980, 981
 - effect on hypertensive kidney, 1331, 1333, 1334
 - effect on LV mass peak filling rate, 503
 - glomerular injury reduced in DOC-SALT rats, 1328
 - increases in plasma norepinephrine during treatment, 499
 - influence on hypertension-induced vascular disease, 1028-1029
 - nifedipine derivative, 723
 - vs. nifedipine for vascular selectivity, 937
- Nitroglycerin
 - allowed during trimetazidine vs. nifedipine study, 854, 855
 - antiischemic effects of pretreatment, 889
 - combined with clentiazem, 1098
 - effort angina, nifedipine and coronary collaterals studied, 906
 - ischemic changes relieved during ergonovine maleate test, 910
 - maximal comparable workload and LV volume changes, 484-485
 - metabolism requiring sulfhydryl group interaction, 247-250
 - oral spray hemodynamic and coronary vasodilative action, 475-480
 - parallel reductions in number of anginal episodes, 931
 - preventing infarct expansion, 1370-1371
 - preventing narrowing of stenoses during exercise, 894
 - reduction in LV filling pressure, 927
 - reference drug used with nicorandil to increase coronary blood flow, 1119-1121, 1123-1125
 - sublingual for angina pectoris, 451, 452
 - trimetazidine combined with nifedipine in effort angina, 824-825
 - variant angina treatment, 916, 917
 - vasorelaxation induced in rabbit aorta, 724
 - vs. KT-362, 1346, 1348, 1349
 - vs. nicorandil, 1076-1080, 1082-1083
 - vs. nicorandil LV effects in dogs, 1449-1453
- Nitroglycerin ointment, Raynaud's phenomenon, 45, 48
- Nitroprusside
 - cardiac effects, 244
 - vasodilating drugs effect attenuated after withdrawal, 249, 250
 - vasodilator action activated, 1379
 - vs. ketanserin for systemic hypertension after cardiac surgery, 19, 21-22
 - vs. KT-362, 1348
- Nitroprusside-like drugs, isolated systolic hypertension treatment, 1206
- N-methyl-D-aspartate (NMDA), 30
- Nondiabetic chronic renal disease, angiotensin converting enzyme inhibition effect, 221-225
- Nonhydropyridine calcium antagonist, SD-3211, 1469-1475
- Non-insulin-dependent diabetes mellitus (NIDDM), obesity as risk factor, 398
- Nonmodulators, 214
- Nonpharmacological treatment, dietary management of hypertension, 1487, 1488, 1491
- Non-steroidal antiinflammatory drugs (NSAIDs)
 - antihypertensive drug interactions, 965
 - inhibition of prostaglandin synthesis effect, 963, 966
 - interactions with nifedipine, 963-964
- Nonsulfhydryl ACE inhibitors, 200
- Nonsustained ventricular tachycardia (NSVT), marker of sudden cardiac death, 669-672
- Noradrenaline, carcinoid syndrome, 56
- No-reflow phenomenon, 774
- Norepinephrine (NE)
 - as alpha-adrenoceptor agonist in isolated rat aorta, 1282
 - attenuating effect of vasodilating drugs, 249
 - depletion from sympathetic nerve endings with nifedipine, 502
 - differential attenuating effect, 1334
 - dobutamine trial evaluation for chronic heart failure, 1106, 1108, 1110
 - increased in the elderly after meals, 496
 - increases during treatment with nitrendipine, 499
 - induced responses inhibited by KT-362, 1348-1349
 - low-renin hypertension, 344, 346, 347
 - mammary artery contractions and ketanserin, 60
 - pressor response in preeclampsia, 38
 - Raynaud's phenomenon, 48
 - release inhibited by ACE inhibitors, 210
 - serotonin amplifying platelet reaction, 19-20, 24
 - stimulating cell growth later blocked by terazosin, 431
 - vascular reactivity decreased by chlor-thiazide, 383
 - weight reduction of obese patients related to level of, 400
- Norverapamil, plasma levels, 1503, 1505, 1506
- Nuclear magnetic resonance spectroscopy (NMR), antiischemic effects of trimetazidine studied, 812-813
- Nystatin, enhancing cell membrane permeability during sodium loading, 323
- Oakley Study, nifedipine combined with propranolol, 931
- Obesity
 - hypertension in blacks and, 395-401
 - socioeconomic factors, 396-398
- Obesity-associated hypertension, 395-401
 - mechanisms, 400
 - physiologic characteristics, 399-400
 - sodium sensitivity, 400-401
- O-desmethyl-encainide (ODE)
 - electrophysiologic properties, 567-570
 - pharmacokinetics of encainide, 561-565
- OPC-8212
 - inhibiting PDE activity, 713, 716
 - long-term efficacy and safety for mild chronic heart failure, 419-424
- OPC-8490, effect on membrane potentials and membrane currents of guinea-pig myocytes, 713-717
- Open-angle glaucoma, intraocular pressure reduced by ketanserin, 97, 98
- Open-heart surgery, catecholamine level, 19
- Oral spray, nitroglycerin formulations compared, 475-480
- Organ and tissue blood flows, dilevalol effect, 1464-1465

- Osler test, 1301
- Oslo Primary Prevention Trial, lipid-lowering treatment successful in reducing myocardial infarction, 1385, 1386, 1388
- Oxfenicine, inhibiting fatty acid oxidation, 788
- Oxprenolol
blood lipid profile affected, 1277
combined with hydrochlorothiazide when treating black hypertensives, 1275
effect on respiratory function in hypertension with chronic obstructive lung disease, 1145-1148
enhanced by a diuretic in elderly treatments, 1275
ineffective antihypertensive drug for blacks, 390
interaction with indomethacin, 964
- Oxygen free radicals, trimetazidine protecting human red blood cells against damage from, 818-819
- Oxygen paradox, damage occurring during reperfusion, 767, 769
- Oxygen radical species, trimetazidine effect in post-ischemic acute renal failure in rat, 816-817
- Oxymyoglobin, diltiazem effect in hypoxic rat heart, 719-722
- PACK (prevention of Atherosclerotic Complications with Ketanserin) trial, 13-15, 93, 95, 139
- Pain, perception in arterial hypertension affected by ketanserin, 133-135
- Pancreatic tumors, carcinoid syndrome, 53
- Papaverine, Raynaud's phenomenon, 48
- Parachloromercuribenzenesulphonate, enhancing cell membrane permeability during sodium loading, 323
- Parachlorophenylalanine, preventing pressure increase, 27
- Paracrine renin-angiotensin system, hypertension affected, 237-240
- Parasympathetic activity, enalapril effect, 265-267
- Parathyroid hormone (PTH)
blacks demonstrating higher levels than whites, 336
nifedipine effect, 983-986
regulation of serum and cell calcium levels as protection against vascular lesions, 1029, 1030
- Parkinson's disease
lung function in elderly and beta blockade, 1229
tendency to postural hypotension, 1265
- Paroxetine, 106
- Paroxysmal atrial fibrillation
encainide vs. flecainide for treatment, 581-582
flecainide treatment, 1161
- Paroxysmal atrial tachyarrhythmias, encainide vs. flecainide for treatment, 579-584
- Paroxysmal supraventricular tachycardia, propafenone preventing atrial fibrillation, 684
- Partial agonist activity (PAA), celiprolol, 1291
- Pathophysiology, hypertension in the elderly, 1197-1200
- Penbutolol, antihypertensive treatment for blacks, 390
- Penicillin, supplement in culture of human skin fibroblasts, 69
- Pentagastrin, carcinoid syndrome, 55, 56
- Percutaneous transluminal coronary angioplasty (PTCA), 232, 1338, 1340
risk stratification after, 687-692
- Perindopril
coronary blood flow affected, 1380
nonsulphydryl ACE inhibitor, 200
- Perindoprilat, hemodynamic response to, 1135-1139
- Peripheral artery disease, elderly hypertensives, 1197
- Peripheral hemodynamics, captopril effect in essential hypertension, 751-754
- Peripheral vascular disease, serotonin pathophysiologic role, 1444-1445
- Peripheral vascular resistance, flosequin, 1395, 1397-1399
- Pertussis toxin, endothelium-derived relaxing factor and, 8, 9, 11
- Pharmacogenetics, antiarrhythmic agents, 541, 543-544
- Pharmacology
myocardial energy metabolism, 756
nicorandil, 1075-1080
- Phenazine methosulfate (PMS), erythrocyte treatment in which K^+ loss and free radical generation observed, 818-819
- Phenoxybenzamine
carcinoid syndrome, 54-55, 57
Raynaud's phenomenon, 48
- Phentolamine
alpha-adrenoceptor blocking drug effect on dihydroergocristine, 1459
arterial blood pressure, 23
blocker for hypotensive action of methyldopa, 30
potentiated antihypertensive action by ritanserin, 137
- Phenylephrine
alpha₁-agonistic effect, 22-23
digital vasoconstriction and ketanserin, 46
increase in force in vascular smooth muscle, 1357-1358
portal pressure rise induced, 33
- Phenylethanolamine-N-methyl transferase (PNMT), 29
- 8-Phenyltheophylline
inotropic effect in muzolimine study of guinea-pig atria, 1477-1483
- purine compound inotropic effects antagonized by, 512
- Phenytoin, antiarrhythmic drug, 594
- Phloretin, inhibiting sodium-lithium countertransport, 323
- Phosphofructokinase, factors accelerating activity during anaerobiosis, 778-781, 787
- Phosphoinositide system, 370
- Phospholipids, fatty acid composition affected by hypertension, 369, 370
- Phosphorus-containing ACE inhibitors, 200, 202
- Pig, zofenopril pretreatment model for early reperfusion and subsequent electrophysiologic stability, 695-702
- Pinacidil
hemodynamic response to, 1135-1138, 1140
protective effects on reperfusion function and infarct size in animal models, 465-473
- Pindolol
antihypertensive drug treatment for elderly in trial, 1241
blood lipid profile affected, 1277
dilating large arteries as well as arterioles, 745
for black hypertensives, 383
hemodynamic effects at rest and during isometric exercise, 737-742
ineffective antihypertensive drug for blacks, 390
interaction with indomethacin, 964
intrinsic sympathomimetic activity (ISA) affected, 525
silent myocardial ischemia treatment, 931
sinus node dysfunction treatment, 525
STOP-Hypertension Study treatment, 1254
vs. celiprolol, 1281, 1284
- Pirbuterol, lymphocyte beta-receptor levels decreased by, 1110
- Piretanide, diuretic monotherapy in congestive heart failure, 515-520
- Piridoxilate, cardioprotective effect during ischemia and reperfusion, 808-809
- Piroxicam
propranolol interaction, 965
timolol interaction, 965
- Piroximone, cardiotonic agent for congestive heart failure, 1127
- Pituitary hormone release, clonidine effect when mediated through opiate receptors, 1113-1116
- Pivalopril, sulphydryl ACE inhibitor, 200
- Pizotofen, 5HT₂-receptor blocker and contractile responses to DHEC, 1459
- Placebo, failure of therapy for congestive heart failure piretanide study, 520
- Plaques
progression/regression of, 1386-1387
severity of, 1009-1010

- Plasma concentrations, correlated to mean arterial pressure in diltiazem trials, 1092, 1094, 1095
- Plasma protein binding, encainide with various drugs, 564
- Plasma renin activity (PRA) alterations impaired by cardiopulmonary receptors in elderly, 1225
- black hypertensives, 383, 384
- blacks vs. whites, 336, 338, 339
- calcium-channel blockers for systolic BP in elderly with decreased, 1207
- for classifying essential hypertensive patients, 373, 376
- hypertensive Zulus and Indians, 364
- nifedipine vs. hydralazine effects, 500-501
- raised by potassium supplementation in blacks, 404
- zofenopril in experimental infarction, 697-699
- Plasma volume, decreased with slow-release nifedipine for hypertension, 977
- Platelet aggregation, heparin and protamine effects postoperative bleeding with cardiopulmonary bypass, 269-272
- Platelet-derived growth factor, vascular hypertrophy, 239
- Platelets
- sensitivity to 5HT affected by age, 105, 108
 - serotonin stored to alter vessel reactivity, 38-40
- Polycystic kidney disease, felodipine for hypertension, 254
- Polyox, renal actions, 297-300
- Portal hypertension, *see* Hypertension
- Positive inotropic effect
- glibenclamide, 1126
 - isoproterenol, 1127, 1132
 - ZSY-39, 1127-1129, 1131-1133
- Positron electron tomography, 766
- Positron emission tomography, direct monitoring of enhanced glycolysis, 777
- myocardial metabolism imaging, 847-850
- Post-myocardial infarction
- encainide therapy risk increased, 594
 - risk stratification process, 665, 666
- Postoperative bleeding, heparin used for cardiopulmonary bypass patients, 269-272
- Postoperative pulmonary hypertension, serotonin effect, 19-24
- Postprandial hypotension, age correlation, 493-496
- Post-Treatment Study of Hypertension in the Elderly (POTS-Hypertension), antihypertensive drug treatment trial, 1255
- Postural hypotension
- dihydroergotamine treatment, 1455
 - in the elderly, 1301
- Potassium
- cellular regulation differences in blacks vs. whites, 337
 - elderly susceptibility to hypokalemia, 1211
 - erythrocyte concentrations and transmembrane fluxes of, 321-330
 - intracellular concentration in essential hypertension, 323-324
 - loss from diuretics used with ketanserin, 14-17
 - loss in ischemia, 784
 - supplementation effect on blood pressure, 403-404
 - systemic regulation differences in blacks vs. whites, 336-337
 - urinary intracellular studies of blacks and Indians, 363-365
- Potassium channel activators, cromakalim and pinacidil protective effects, 465-473
- Potassium channel opener, hemodynamic response to, 1140
- Potassium-sparing diuretics, drag-reducing polymers, 297-300
- Potential-dependent calcium entry, KT-362 effect, 1351
- Practolol, respiratory function affected in the elderly, 1230, 1231
- Prazosin
- cardiac effects, 244
 - confirmation of alpha-1 blockade, 380
 - congestive heart failure treatment, 1395
 - decreasing HMG CoA activity, 137
 - elderly susceptible to postural hypotensive effects of, 1212
 - first-dose reaction with marked hypotension, 1139
 - HMG CoA reductase activity in cultured human skin fibroblasts, 69-72
 - interaction with indomethacin, 964
 - in-vitro adrenoceptor activities, 1283
 - nifedipine interaction, 964
 - not able to block LVH regression, 431
 - phenolamine used in its place before, 23
 - preventive cardiology, 755
 - Raynaud's phenomenon, 45, 47-48, 50
 - reinforced by ritanserin, 137
 - stopped before felodipine treatment, 255
 - vs. isradipine for essential hypertension treatment, 413-417
- Preeclampsia
- incidence in blacks, 351
 - serotonin role in, 5, 37-41, 138
- Pregnancy, increase in sodium-lithium countertransport, 357
- Pregnancy-induced hypertension (PIH), sodium transport inhibitors, 351-355
- Preload
- reduction of LV, antiischemic action of nicorandil, 1449-1453
 - reduction of only LV end-systolic dimension decreased by nifedipine (afterload), 971-972, 974
- Premature ventricular contractions (PVCs)
- risk marker of sudden cardiac death, 651, 653
 - suppression using sotalol, 603-610
- Prenalterol, treatment effects similar to xamoterol, 526
- Prenylamine, antiarteriosclerotic effects, 1011
- Preventive aspects of cardiology, 755
- Primary aldosteronism, nifedipine decrease of mean arterial pressure, plasma aldosterone and potassium clearance, 977
- Prinzmetal's angina, coronary vasoconstriction role, 893, 1445
- Proarrhythmia
- of antiarrhythmic drugs observed during electrophysiologic evaluation, 539
 - definition of early effect, 672
 - encainide safety profile, 587-589, 593
 - encainide treatment reaction in supraventricular arrhythmias, 576
 - side effects of propafenone and flecainide, 552
 - sotalol, 1431
 - sotalol in reentrant ventricular tachycardia, 614-617
- Procainamide
- antiarrhythmic drug, 594
 - decrease in cardiac output and worsening of congestive heart failure, 545
 - effect on conduction characteristics of AV pathways, 621
 - onset kinetics, 571
 - proarrhythmia incidence during EPS testing, 539
- Prodrugs, converted by liver into active ACE inhibitors, 200, 201
- Programmed electrical stimulation, sotalol therapy and, 1428, 1430, 1431
- Programmed ventricular stimulation, vs. Holter monitoring, 555-558
- Propafenone
- aggravating or inducing congestive heart failure, 653
 - effect on conduction characteristics of AV pathways, 621
 - efficacy and side-effect profiles, 449-452
 - efficacy in atrial fibrillation, 549-550
 - electrophysiologic evaluation, 537
 - hemodynamic effects, 546
 - junctional tachycardias treatment, 550-551
 - pharmacokinetics and antiarrhythmic effects, 281-287
 - poor metabolism phenotype, 543-544
 - proarrhythmic side effects, 552
 - ventricular arrhythmia treatment, 551-552
 - Wolff-Parkinson-White syndrome treatment efficacy, 681-685
- Propranolol
- adverse reactions in elderly, 1273-1274

- antihypertensive drug treatment for blacks, 389-391
- antihypertensive drug treatment for elderly in trial, 1241
- arterial tree action, 745
- blood lipid profile affected, 1277
- combination therapy effect on anginal frequency, 900, 901
- drug interactions, 965, 1164
- effect on LV mass, 503
- effect on respiratory function in hypertension with chronic obstructive lung disease, 1145-1148
- efficacy in prevention of ventricular tachycardia induction, 536
- electrophysiologic properties compared to those of sotalol, 600
- for black hypertensives, 383
- for reversal of LV hypertrophy, 427-432
- hemodynamic response, 1139
- interaction with indomethacin, 964
- in-vitro adrenoceptor activities, 1283
- ischemic heart disease treatment, 676, 678
- maximal comparable work-load reduced, 484
- no interaction with ranitidine, 490
- piroxicam interaction, 965
- plasma protein bindings and encaïnide, 564
- pretreatment (oral) before nicardipine treatment, 1525, 1526, 1528-1529, 1531
- pretreatment to block celiprolol concentration-dependent relaxation, 748
- preventive cardiology, 755
- reducing chronotropic response during LBNP tests, 1259
- renal vasodilation, 1297
- respiratory function affected in elderly, 1230
- silent myocardial ischemia treatment, 931
- smoking effect in elderly, 1273-1274, 1276
- Trimetazidine European Multicenter Study, 842
- vs. celiprolol, 1281, 1291-1294
- vs. nicorandil, 1078, 1081, 1082, 1084-1085
- vs. propranolol in preventing sudden death, 1515-1518
- vs. sotalol, 547, 603-606, 609-610
- withdrawal of antihypertensive drug therapy, 1490, 1492
- D-Propranolol, devoid of beta blocking activity, 559
- L-Propranolol, pharmacokinetic interactions, 559
- Propionyl carnitine, activity evaluated for stable angina pectoris of effort, 481-485
- Prostacyclin
- infarct expansion affected, 1370
- Raynaud's phenomenon, 49
- release during pregnancy stimulated by serotonin, 38-40
- Prostacyclin/thromboxane ratio, pre-eclampsia, 38, 39
- Prostaglandins
- carcinoid syndrome, 54
- mediating captopril hemodynamic responses, 201
- modulating vascular growth, 239
- Raynaud's phenomenon, 46, 49, 50
- released during pacing-induced myocardial ischemia and angiotensin interactions, 1376-1377, 1381-1382
- role in low-renin essential hypertensives given enalapril, 201
- Protamine
- platelet aggregation, 19
- platelet loss cause after cardiopulmonary bypass, 269, 272
- Protein kinase C
- generating signal for increased transcriptional activity, 1368-1370
- phorbol esters causing contractions in vascular smooth muscle, 1358-1361
- Protein restriction, chronic renal failure, 222
- Proteinuria, decreased by ACE inhibitors, 221-225
- Protons, accumulation as effect of severe ischemia, 777, 780-782, 786
- P (substance), 30
- Pulmonary artery diastolic pressures (PADP), plasma concentrations of atrial natriuretic peptide during physical exercise, 289, 291-293, 295
- Pulmonary artery occlusion pressure (PAOP)
- calcium-channel blocker effect, 457-459, 462
- reduced by amlodipine, 457, 459
- Pulmonary artery pressure, right atrial pressure related, 289, 291-295
- Pulmonary edema, verapamil side effect, 1516
- Pulse wave velocity (PWV), nifedipine effect in chronic hemodialysis patients, 987-990
- Quality of life
- double-blind comparison of bisoprolol and captopril for elderly hypertensives, 261-264
- ketanserin treatment improvement for elderly hypertensives, 116, 117
- OPC-8212 treatment questionnaire for mild chronic heart failure patients, 420-423
- Quantitative coronary angiography, CAAS system, 1038-1044
- Quinapril, coronary blood flow affected, 1379, 1380
- Quinapril, nonsulphydryl ACE inhibitor, 200
- Quinidine
- chronotropism inhibited by, 509
- decrease in cardiac output and worsening of congestive heart failure, 545
- effect on conduction characteristics of AV pathways, 621
- hemodynamics, 547
- long QT syndrome, 667
- mechanism of action, 597, 602
- noncardiac adverse events incidence, 590
- onset kinetics, 571
- poor metabolism phenotype, 544
- proarrhythmia incidence during EPS testing, 539
- sodium-channel block, 542-543
- vs. encaïnide for supraventricular arrhythmias, 575
- vs. flecainide for ventricular tachycardias, 551
- vs. KT-362, 1350-1351
- vs. nicorandil, 1084
- vs. sotalol, 606-610, 1431
- vs. sotalol for sinus rhythm after conversion of atrial fibrillation, 631
- QTc interval, prolongation by ketanserin, 1157, 1159
- QT interval
- ketanserin and atherosclerosis, 14, 15
- ketanserin side effects and adverse reactions with carcinoid syndrome, 57
- no significant prolongation by ketanserin during atrial pacing, 1158, 1159
- prolongation associated with ketanserin treatment, 93-95
- prolongation by ketanserin, 139
- prolongation by ketanserin initiating and worsening ventricular arrhythmias, 1159-1160
- propafenone electrophysiologic effects, 282
- torsades de pointes, 1178
- Rabbit, antiatherosclerotic effect of nifedipine in cholesterol-fed, 1021-1025
- Radionuclide ventriculography, ADM-induced cardiotoxicity assessed by, 1519, 1521
- Ramipril
- coronary blood flow affected, 1378-1380
- nonsulphydryl ACE inhibitor, 200
- synergistic increase of blood flow not detected, 250
- vs. delapril, 1417
- Ramiprilat, coronary blood flow affected, 1379-1380
- Ranitidine
- carcinoid syndrome, 57
- drug interactions, 487, 490
- effect of teratolol elimination and plasma levels, 487-490
- Raynaud's phenomenon
- nifedipine use, 935-939
- pathogenesis and treatment, 45-50

- serotonin effect, 5, 14, 45
 serotonin's role in pathogenesis, 138
 symptoms alleviated by ketanserin, 130
- Receptor-linked calcium entry, KT-362, 1351
- Reentrant supraventricular tachycardia, sotalol efficacy (oral), 613-617
- Reentrant ventricular tachycardia, sotalol efficacy (oral), 613-617
- Reentry, sotalol for supraventricular tachycardia, 625, 626
- Reflex tachycardia
 captopril and lack of, 265
 enalapril and lack of, 267
 ketanserin not inducing, 20, 24, 80
- Regenerated endothelium, 11
- Regional myocardial blood flow, diltiazem effect, 1461
- Remnant kidney, calcium antagonist effect on oxygen utilization, 1329
- Remodeling
 captopril and myocardial ischemia, 1381
 congestive heart failure following, 1363-1372
- Renal artery stenosis, renin release role, 230, 232, 233
- Renal blood flow, poststenotic loss, 234
- Renal disease, ketanserinol clearance impaired, 91
- Renal failure
 effect on encaidine pharmacokinetics, 562-564
 race/sex differences in mortality from, 398
- Renal function, *see* Kidneys
- Renal hypertrophy, glomerular injury related to, 1325-1329
- Renal plasma flow, chronic renal failure and ACE inhibitors, 222-224
- Renal tubules, calcium handling during oxygen deprivation kidney injury prior to reoxygenation, 1319-1323
- Renal vascular resistance (RVR), 207, 210-213
 reduced by calcium antagonists, 1331-1335
- Renin
 circulating pressor substance from induced experimental hypertension, 229-232
 correlation of level of hypertension incidence in blacks, 317, 319
 low profile characteristic of elderly, 1273
 open-heart surgery, 19
 sodium homeostasis and ANP, 1210-1211
 unreliable classification for antihypertensive treatment, 390
 urinary and intracellular studies of blacks and Indians, 364, 365
- Renin-angiotensin system
 calcium entry blockers' effects, 980
 paracrine, autocrine, or intracrine role, 1369-1370
- piretanide's minor effects, 520
- Rentiapril, sulfhydryl ACE inhibitor, 200
- Reoxygenation, after O₂ deprivation in hypoxic renal injury, 1320, 1323
- Reperfusion
 absence of, 769
 arrhythmias attenuated by ACE inhibitors, 1375, 1380
 cardioprotective effect during, 808-809
 clinical criteria of, 1337-1340, 1342
 free radicals during ischemia and, 791-794
 myocardial ischemia and diltiazem during, 1462-1464
 tissue injury determinants, 767-774
 zofenopril pretreatment effect on, 695-702
- Reperfusion cardiac function, protective effects of cromakalim and pinacidil, 465-473
- Reperfusion damage, 765-766
- Reperfusion injury, KT-362 treatment, 1351-1353
- Reserpine
 antihypertensive drug treatment for elderly in trial, 1237, 1240
 antihypertensive treatment in combination with verapamil, 391
 antisympathetic agent lowering blood pressure, 380
 for hypertension with chronic renal failure, 222
- Raynaud's phenomenon, 45, 48, 50
 to eliminate noradrenaline influence, 1478, 1482
- Resibufogenin, blocking K⁺ vasodilation, 345
- Respiratory function
 beta blockade effects in the elderly, 1229-1232
 celiprolol for preservation of, 1277
- Respiratory sinus arrhythmia, parasympathetic activity, 266-267
- Rest angina, nicorandil for treatment, 1083, 1085
- Rest hemodynamics, calcium-channel blockers amlodipine, diltiazem and verapamil, 460
- Restrictive cardiomyopathy, amiodarone for treatment, 529
- Retroperitoneal fibrosis, serotonin effect, 139
- Rifampicin
 effect on tertatolol elimination and plasma levels, 487-490
 influence on kinetics of beta blockers, 490
- Right atrial pressure (RAP), plasma concentrations of atrial natriuretic peptide during physical exercise, 289-295
- Right-sided cardiac lesions, serotonin effect, 139
- Risk stratification
 after percutaneous transluminal coronary angioplasty (PTCA), 687-692
 malignant arrhythmias, 665-667
- Ritanserin
 antihypertensive properties missing, 7
 arterial blood pressure affected, 22, 23, 30
 decreasing HMG CoA activity, 137
 HMG CoA reductase activity in cultured human skin fibroblasts, 69-72
 portal pressure reduction, 33-34
 prolongation of QT interval, 94
 reinforcing antihypertensive effect of prazosin, 137
 selective 5HT₂-receptor antagonist, 1445-1446
 to lower portal venous pressure, 138
- Ro 40-5967, vs. verapamil for negative inotropic effect, 731-736
- Rubidium, analogue of potassium and sodium, 323
- Ryanodine-like action, KT-362 intracellular calcium antagonist, 1345, 1349-1350, 1352, 1353
- Safety, encaidine profile, 585-594
- Sarafotoxin S6b, binding displaceable by, 882
- Saralasin
 coronary blood flow affected, 1379
 normalizing blood pressures in renovascular hypertension, 230, 231, 233
 to block angiotensin II effects and increase parasympathetic activity, 267
- SATAPEC (computer system), cardiac electric potential recordings processed, 810-811
- Scleroderma, Raynaud's phenomenon, 49
- SD-3211
 cardiac versus coronary dilator effects in dog hearts, 1469-1475
 vs. diltiazem, 1469, 1474, 1475
 vs. verapamil, 1469, 1474, 1475
- Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT), 877
- Separan, renal actions, 297-300
- Serotonin (5-hydroxytryptamine)
 acute disorders following cardiac surgery, 19-24
 amplifying platelet response in 5HT uptake, 105-109
 carcinoid syndrome, 53-55, 57
 creatinine sulphate, 106
 effect on transmembrane cation transport, 63-66
 endothelium-derived relaxing factor and, 7-8
 human mammary artery contractions produced, 59-61
 involvement in pathophysiology of hypertension, 123-125
 ketanserin acute electrophysiologic effects in humans, 1157-1160
 ketanserin-captopril combination for hypertensives, 119-122

- ketanserin to reduce adverse symptoms of beta blockade, 127-130
- liberation resulting from platelet aggregation, 13
- mediating vasoconstrictor responses, 1459
- modulating vascular growth, 239
- platelet bound, 137
- portal hypertension decrease, 33-34
- preeclampsia-eclampsia syndrome, 37-41
- Raynaud's phenomenon vasospasm indication, 46, 47
- receptors, 29, 48, 59-61
- role in cardiovascular diseases and their treatment, 5, 1443-1446
- spinal content, 28
- vascular disease and, 7-11
- SG-86 (N-2-hydroxyethyl nicotinamide), nicorandil converted to, 1080
- Shy-Drager syndrome, baroreflex sensitivity, 1258
- Sickle cell trait, erythrocyte concentration and transmembrane fluxes of sodium and potassium, 326
- Signal averaging, zofenopril in experimental infarction, 697, 700, 701
- Silent myocardial ischemia, 765
- nifedipine efficacy in patients with variant angina, 915-918
- nifedipine treatment for, 931-933
- pathophysiology, 929-930
- rational for treatment of, 930-931
- Simvastatin, atherosclerosis treatment in hypercholesterolemic patients, 1389-1393
- SIN-1 (vasodilator), 250
- Sinus node dysfunction, xamoterol (intravenous) electrophysiologic effects, 523-526
- Sleep disturbance, bendrofluzide as cause, 128, 129, 130
- S-methyl captopril, present in circulation, 202
- Smoking, *see also* Tobacco consumption
- Oslo Primary Prevention Trial (lipid-lowering) stressing cessation of, 1385-1386
- prevention recommendations for control of, 1533
- propranolol age-related fall-off in systemic clearance, 1274, 1276
- risk factor in INTACT Study of coronary artery disease, 1053-1056, 1065
- senile emphysema, 1277
- serotonin having pathogenic role, 1446
- Sodium
- angiotensin loss and enhanced reabsorption, 230
- blood pressure in blacks increased by intake, 383
- cellular regulation differences in blacks vs. whites, 337
- enalapril monotherapy for essential hypertension affected by diet, 213, 214
- erythrocyte concentrations and transmembrane fluxes of, 321-330
- excretion capacity decreased in hypertensive kidney, 238
- excretion level related to blood pressure, 1198-1199
- factor in pathogenesis of hypertension in blacks, 318, 319
- internal, decreased apparent affinity characterizing abnormalities, 375
- intracellular, hypertensives studied, 368
- intracellular concentration in essential hypertension, 323-324, 347-348
- intralymphocytic, 364-365
- proteinuria decreased with dietary restriction, 224-225
- related to increased blood pressure in elderly, 1210, 1211
- systemic regulation differences in blacks vs. whites, 336-337
- urinary excretion augmented by nifedipine, 977
- urinary and intracellular studies of blacks and Indians, 363-365
- Sodium diuresis, nitrendipine for essential hypertension, 980-981
- Sodium, potassium-ATPase, digitalis-like factor in hypertension, 343-347
- Sodium, potassium, Cl cotransport system, abnormalities compensated, 374, 375
- Sodium-potassium pump
- digitalis-like factor in hypertension, 343-345, 347-348
- digitalis-sensitive and abnormalities, 374, 375
- Sodium transport inhibitor, in pregnancy-induced hypertension, 351-355
- SOLVD Study, prevention of LV dilatation, 1371
- Somatostatin, carcinoid syndrome, 57
- Sotalol
- antiarrhythmic efficacy in ventricular tachyarrhythmias, 1425-1431
- AV nodal tachycardia, 535-536
- beta-blocking activity, 599-602
- blood lipid profile affected, 1277
- combination therapy with amiodarone, 617
- dose adjustment when glomerular filtration rates fall, 1273, 1274
- efficacy in controlling reentrant supraventricular tachycardias, 625-628
- electrophysiologic effects, 619-621
- hemodynamics, 547
- inotropic and hemodynamic effects, 546-547
- issues in arrhythmia management, 559-560
- lengthening QT interval, 15
- management of cardiac arrhythmias, 633-634
- mechanism of action, 597-599
- preventing atrial fibrillation in WPW syndrome, 684
- programmed ventricular stimulation, 556, 557
- reentrant ventricular tachycardia treatment, 613-617
- supraventricular arrhythmias mechanism of action, 619-623
- ventricular tachycardia, 537
- ventricular tachycardia/fibrillation treatment, 601
- vs. Class I and II antiarrhythmic agents, 603-610
- vs. propranolol for arrhythmias, 603-606, 609-610
- vs. quinidine, 606-610, 1431
- vs. quinidine for sinus rhythm after conversion of atrial fibrillation, 631
- d-Sotalol
- antiarrhythmic efficacy in ventricular tachyarrhythmias, 1425-1431
- beta blocking activity, 600, 602
- effect on conduction characteristics of AV pathways, 621
- electrophysiologic effects, 622, 623
- l-Sotalol
- antiarrhythmic efficacy in ventricular tachyarrhythmias, 1425-1431
- beta blocking activity, 600, 602
- Spanish Trial on Sudden Death, 651
- Spasm
- caused by acute ischemic stimuli, 829
- variant angina and nifedipine efficacy on ischemic attacks, 915
- Spiperone, 5HT₂ receptor blocker effect on DHEC and DHE, 1459
- Spontaneous defibrillation, 1180-1181
- SQ 13,534, captopril stereoisomer, 204-205
- SQ 14,534, free-radical scavenger properties, 204-205
- SQ 29852, phosphorus-containing ACE inhibitor, 200
- Stanozolol, Raynaud's phenomenon, 49
- Steal phenomenon, nisoldipine vs. nifedipine, 455
- Step-down Treatment of Mild Systemic Hypertension, 1490
- Steroids, interference and endogenous digoxinlike immunoreactivity, 353
- Stockholm Ischaemic Heart Disease Secondary Prevention Study, clofibrate with nicotinic acid for lipid-lowering treatment, 1386
- Stokes-Adams syncope, torsades de pointes leading to, 1179
- Strain gauge plethysmography, captopril and peripheral hemodynamics measured, 751-752
- Streptomycin, supplement in culture of human skin fibroblasts, 69
- Streptozocin, carcinoid syndrome chemotherapy, 57
- Streptozotocin, inducing diabetes mellitus in study of enalapril renal protection, 204

Stroke

- cerebral blood flow in the elderly, 1217, 1218
- elderly hypertensives, 1197
- EWPHE Study results showing decrease in nonfatal, 1250
- hospitalization required and risk factors of, 1263, 1267
- isolated systolic hypertension related, 1205
- mortality related to hypotensive drugs, 1246
- race/sex differences in mortality from, 398
- trials overview and key factors in treatment, 1269
- ST-segment elevation
 - exercise and vasospastic angina, 893
 - myocardial ischemia and intracoronary nifedipine pretreatment, 887-888, 890
 - nifedipine in coronary spasm, 916-917
 - reperfusion effect, 1342
- "Stunned" myocardium
 - frequent bouts of ischemia as cause, 930, 933
 - KT-362 effect, 1352
 - nicorandil treatment, 1453
 - nifedipine effect, 880, 881, 883
 - tissue injury determinants, 767, 771, 773
- Sublingual administration, captopril for essential hypertension, 751-754
- Substance P, carcinoid syndrome, 53-55
- Sudden cardiac death (SCD)
 - arrhythmogenic substrate leading to, 555, 556
 - coronary artery disease incidence, 834, 836-837
 - definition used, 658, 660, 661
 - elderly hypertensives, 1197
 - electrophysiologic evaluation significance for preventing, 537, 538
 - encainide efficacy, 573
 - encainide updated safety profile, 585-587, 593
 - flecainide therapy, 1161, 1164
 - pharmacologic intervention, 559
 - premature ventricular contractions as risk factor, 651, 653
 - prevention by beta blockade, 675-678
 - propranolol vs. verapamil long-term effects in preventing, 1515-1518
 - reperfusion arrhythmias, 772
 - sotalol and sustained ventricular tachycardia, 1429-1430
 - ventricular fibrillation as cause, 1180
 - ventricular premature complexes (VPCs) indicative of risk, 669, 672
- Sulphydryl ACE inhibitors, 200-205
- Sulphydryl groups
 - active in captopril, 199, 200
 - captopril and effects on renal function, 212
 - captopril donor enhancement of nitrate

- action, 250
- depletion interaction required for nitroglycerin metabolism, 247-249
- Sulindac, not attenuating blood-pressure lowering effect of captopril, 201
- Sulmazole, cardiotoxic agent for congestive heart failure, 1127
- Superoxide production in cardiac muscle, trimetazidine effect, 814-815
- Supraventricular arrhythmias
 - amiodarone plus flecainide to prevent recurrences, 654
 - class IC drugs for treatment, 549, 551
 - electrophysiologic evaluation, 535-536
 - encainide efficacy, 573-577
 - encainide safety profile, 585-594
 - sotalol efficacy in controlling, 625-628
- Supraventricular tachyarrhythmias, Wolff-Parkinson-White syndrome predisposing, 666
- Supraventricular tachycardias, sotalol for termination, 621
- Surgical procedures
 - ischemic heart disease, 613
 - percutaneous transluminal coronary angioplasty follow-up, 690, 691
 - supraventricular tachycardias, 634
 - zofenopril pretreatment effect on early reperfusion, 696
- Survival and Ventricular Enlargement (SAVE) Trial
 - ACE inhibitors and myocardial ischemia, 1381
 - prevention of dilatation, 1371
- Sustained monomorphic ventricular tachycardia (SMVT), sotalol treatment, 1425, 1427-1431
- Swedish League Against Hypertension, 1253-1254
- Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) Study
 - antihypertensive treatment in the elderly in Sweden, 1253-1255
 - blood pressure as weak predictor for mortality, 1269
 - mortality correlated to BP and analysis of results, 1270-1271
- Sympathetic activity, hydralazine vs. nifedipine effects, 499-503
- Symptomatic sick-sinus syndrome, xamoterol (intravenous) therapy, 523-526
- Symptomatic ventricular premature beats,
 - flecainide treatment, 1161
- Systemic hypertension, amiodarone, 529
- Systolic blood pressure, terbutaline effect, 1276
- Systolic hypertension
 - elderly hypertensives, 1215-1216
 - EWPHE Study results with focus on, 1249-1251
 - major risk indicator, 1270
 - pharmacologic vs. nonpharmacologic treatment in the elderly, 1203-1207
- Systolic Hypertension in the Elderly Pro-

gram (SHEP)

- efficacy of diuretic in decreasing systolic BP in elderly with ISH, 1203, 1205-1206, 1215
- withdrawal due to adverse reactions, 1298
- Systolic time intervals, echocardiography and, 737, 738, 742
- Systolic vs. diastolic blood pressure, 1301-1302
- Teprotide
 - coronary blood flow affected, 1378-1380
 - first ACE inhibitor, 199
 - infarct size affected, 1381
- Teprotide/captopril, for essential hypertension and causing renal effects, 211
- Terazosin, for LVH regression, 431
- Terbutaline, systolic blood pressure affected, 1276
- Tertatolol
 - bioavailability, 487
 - interaction with rifampicin and ranitidine pharmacokinetics, 487-490
- Theophylline
 - interaction with ranitidine, 487, 490
 - purine compound inotropic effects antagonized by, 512
 - sinus node disease treatment, 525
- Thiazides
 - antihypertensive drug treatment for elderly in trial, 1237, 1245-1246
 - EWPHE Study drug treatment, 1269
 - generic use, 1440
 - interaction with indomethacin, 964
 - nifedipine interaction, 965-966
 - preferred treatment for black hypertensives, 383
- Thiazole derivative, ZSY-39, 1127-1133
- Thirst, changes related to aging, 1209, 1211
- Thoracic outlet syndrome, digital artery constriction, 47
- Thromboangiitis obliterans, 47
- Thrombocytopenia, heparin-induced, 269, 272
- Thrombolysis, second, anistreplase in acute myocardial infarction trial, 1338
- Thrombosis
 - caused by acute ischemic stimuli, 829
 - encrustation in atherosclerosis, 993, 1000
- Thromboxane, modulating vascular growth, 239
- Thromboxane A₂
 - endothelial dysfunction, 11
 - inhibitors, 46
 - liberation resulting from platelet aggregation, 13, 15
- Tiapamil
 - hemodynamic response to, 1135-1139
 - verapamil derivative, 723
- Tienilic acid, potassium transport stimulated, 385

- TIMI II Trial, thrombolysis and beta blockade vs. thrombolysis alone, 678
- Timolol
drug interactions, 965
ischemic heart disease treatment, 676
pharmacokinetic interactions, 559
respiratory function in the elderly affected, 1231
- Tobacco consumption, *see also* Smoking
prevention recommendations for control of, 1533
- Tocainide
antiarrhythmic drug, 594
decrease in cardiac output and worsening of congestive heart failure, 545-546
onset kinetics, 571
proarrhythmia incidence during EPS testing, 539
stereochemical influences, 541, 542
- Tolazoline, Raynaud's phenomenon, 48
- Tolerability, felodipine treatment in hypertension, 641-647
- Torsades de pointes
cause of, 634
description of phenomenon, 1177-1179
ECG configurations of ventricular tachycardias, 1173-1176
evaluation of it as electrocardiographic phenomenon, 1169, 1183
forum introduction, 1167
long QT syndrome, 667
proarrhythmia event, 672
sotalol induced, 614-615, 616, 1431
ventricular fibrillation and, 675, 1177-1182
- Total peripheral resistance (TPR), as physiologic characteristic of obesity hypertension, 399
- Trandolapril, coronary blood flow affected, 1378, 1379
- Transient ischemic attacks (TIAs), cerebral blood flow in the elderly, 1218
- Transmembrane cation transport, ketanserin treatment effect on sodium transport, 63-66
- Transport systems
essential hypertension and, 351-352
for classifying hypertensives, 373-377
lithium-sodium countertransport, studies of hypertensives, 337, 368
pregnancy-induced hypertension and, 352-353
sodium-lithium countertransport, 323, 325, 326, 330, 337, 357-361, 374
sodium-potassium and environmental factor influence, 329-330
sodium-potassium and host factor influence, 325-329
sodium, potassium-ATPase activity, black hypertensives, 384, 385
sodium, potassium-ATPase pump (active), 321-322, 324, 326-330, 337-338
sodium-potassium cotransport, 322-328, 330, 337, 368-369
sodium, potassium transport disagreement on status in the erythrocyte in essential hypertension, 384
trimetazidine protection of red blood cells against oxygen free radical damage, 818-819
- Triamterene
combination therapy for hypertension, 948
EWPHE Study drug treatment, 1269
- Trigeminal cardiorespiratory reflexes, autonomic control, and age-related changes and beta blockade, 1260
- Trigeminal reflexes, elderly hypertensives and beta blockade, 1271
- Triglycerides
levels correlated with changes in sodium-lithium countertransport, 357-361
nifedipine effect on serum lipoprotein metabolism with hypertension, 1033-1035
- Trimetazidine (TMZ), 766
acute effects on ergometric parameters in effort angina, 820-821
antiischemic effect in myocardial ischemia model, 808-809
antiischemic effects: ³¹P-NMR spectroscopy study in isolated rat heart, 812-813
cardioprotective effect during ischemia and reperfusion, 808-809
cardioprotective effect in severe ischemic cardiomyopathy, 861-865
chronic effects on ergometric parameters in effort angina, 822-823
combined with nifedipine for effort angina, 824-825
delayed afterdepolarization (DADs) and upstroke velocity of action potential, 806-807
effect during reperfusion, 791, 793, 794
electrocardiographic assessment of antiischemic properties, 810-811
glucose flux promotion in ischemia, 787
mitochondrial function and superoxide production in cardiac muscle, 814-815
oxygen radical species effect in postischemic acute renal failure in rat, 816-817
red blood cells and oxygen free radical damage, 818-819
Trimetazidine European Multicenter Study, 842, 845
vs. nifedipine for effort angina, 853-859
- Trimetazidine European Multicenter Study, comparison of antiischemic effects of propranolol and trimetazidine, 842, 845
- Tryptophan, avoided in study determining 5HT uptake in men, 106
- Underperfusion, cerebral blood flow in the elderly, 1219-1220
- Unilateral renal artery stenosis, ACE inhibitors, 204
- Unloading, enoximone improvement of LV function by, 1403, 1413
- Urapidil, antihypertensive treatment, 1443, 1446
- Uric acid, nifedipine effect with essential hypertension, 977
- U.S. Health and Nutrition Examination Surveys, 1199
- U.S. Lipid Research Clinics Coronary Primary Prevention Trial, lipid-lowering treatment successful in reducing myocardial infarction, 1385
- U.S. Postmarketing Adverse Experiences Report, encaidine safety evaluation, 585, 586, 593-594
- Valvular heart disease, 21
- Valvular stenosis, ACE inhibitors avoided, 244
- Variant angina, *see also* Angina pectoris
nicorandil for treatment, 1083
nifedipine efficacy on ischemic attacks, 915-918
nifedipine for treatment, 909
- Variation of heart period (VHP), parasympathetic activity, 265-267
- Vascular injury, atherogenesis hypothesis, 993, 995-998, 1001
- Vascular relaxation, KT-362, 1346-1350
- Vascular resistance
celiprolol effect, 1276
flosequinan hemodynamic effects in heart failure, 708-711
nicardipine effect, 1531
- Vascular smooth muscle
angiotensin II as growth stimulant, 243
arterial wall changes in hypertension, 237, 239
atherosclerosis, 999-1001
blood cells used to monitor changes, 368
cells' endothelin binding, 880
contraction mechanisms, 1355-1361
depolarization subsequent to sodium transport inhibition, 352
glucose and glycogen operating in different cytosolic compartments, 787
impaired relaxation, 248
increased contractile activity due to sodium intake, 343
isradipine as hypertension treatment because of high selectivity for, 413
nicorandil to relax, 1075, 1076
relaxed by cromakalim and pinacidil, 465
serotonin and, 7-11
structure modified by prolonged phosphoinositide hydrolysis, 370
- Vascular spasm, atherosclerosis, 1002-1003
- Vasoconstriction, vs. cytoplasmic ionized calcium levels, 1355-1361

- Vasodilators**
 celiprolol therapy of hypertensives, 745-748
 effect of increasing extracellular sodium chloride concentration, 343
 elderly hypertensives, 1267
 flosequin, 705-711, 1395-1401
 for treatment of heart failure, 85, 87
 hypertrophy reversal not achieved, 79
 nifedipine potent arterial properties, 936-937
 nitrate induced, 247, 248, 249
 nitroglycerin oral spray formulations and their effects, 475-480
 serotonin, 1444
 treatment stopped before felodipine antihypertensive therapy, 255
 vascular hypertrophy, 239-240
- Vasomotor changes, autonomic control**
 age-related changes, and beta blockade, 1260
- Vasomotor tone, under different control mechanisms in epicardial and resistance vessels, 830**
- Vasopressin**
 aging and water homeostasis, 1211-1212
 open-heart surgery, 19, 20
- Vasoselectivity, clentiazem vs. diltiazem and nifedipine, 723-725, 1103**
- Vasospasm, 138**
 nitrocompounds for treatment, 276-277
 Raynaud's phenomenon, 45-47, 49
- Vena cava balloon occlusion for rapid load changes, enoximone effect on end-systolic pressure-volume relationship, 1405-1407, 1412**
- Venoconstriction, dihydroergocristine and dihydroergotamine responses, 1455-1459**
- Ventricular arrhythmias**
 anistreplase treatment and frequency, 1340, 1342
 antiarrhythmic drug efficacy, 669-673
 encainide safety profile, 585-594
 flecainide therapy, 549, 551-552
 markers for sudden deaths, 1517
 models to detect and evaluate, 670-671
 physiopathology, 652-654
 plasma concentration/effects relationships, 565
 prognostic classification, 669-670
 propafenone treatment, 551-552
 prevented by KT-362, 1345, 1350-1353
 spontaneous variability, 671-672
- Ventricular ectopy**
 Holter monitoring requirements, 555, 558
 suppressed by ketanserin in normotensive patients, 95
- Ventricular fibrillation**
 ACE inhibitors and arrhythmias during myocardial ischemias, 1380
 characteristics and classification scheme, 1179-1182
 hypothermia and, 1180-1182
 nicorandil treatment effect, 1121, 1124, 1125
 related to sudden cardiac death, 675, 678
 reperfusion-induced, 772
 sotalol treatment, 1425, 1427-1431
 torsades de pointes and, 1177-1182
- Ventricular premature beats (VPBs)**
 Cardiac Arrhythmia Suppression Trial (CAST), 591, 592
 propafenone minimum effective values in antiarrhythmic therapy, 281-283, 286
 sotalol therapy, 1428
- Ventricular premature complexes (VPCs)**
 sudden cardiac death possibility, 669-672
- Ventricular tachycardias (VT)**
 antiarrhythmic effect from lower drug doses in combination, 543
 ECG configurations and interpretations, 1171-1176
 electrophysiologic evaluation, 536-537, 539
 flecainide treatment, 550-552, 1161, 1163
 programmed ventricular stimulation, 556-557
 sotalol efficacy, 613-617, 1425-1431
 two variable foci and classification scheme of, 1171-1176
- Ventricular tachycardia/fibrillation**
 Holter monitoring results, 556
 sotalol treatment, 601
- Ventricular Tachycardia/Heart Disease and Boston studies, encainide safety evaluation, 585, 586, 592-593**
- Ventrolateral medulla, serotonin content and stimulation of, 28-31**
- Verapamil**
 aggravating number and duration of vagal atrial fibrillations, 581
 angina pectoris treatment, 1509
 antiarteriosclerotic effects, 1011, 1012
 antiatherogenic effects and mechanisms of action, 1015-1018
 antihypertensive therapy for blacks, 391, 392
 antihypertensive treatment similar to isradipine, 416, 417
 AV nodal tachycardia, 535
 bioavailability, 1506
 cardioprotective effect during ischemia and reperfusion, 808-809
 chronic stable angina treatment, 931
 compared to Ro 40-5967 for negative inotropic effects, 731-736
 decreasing conduction capacity of AV node, 619
 derivatives, 723
 drug interactions, 965
 effect on hypertensive kidney, 1331-1332
 effect on renal function by inhibiting Ca^{2+} uptake, 1319, 1322, 1323
 efficacy in prevention of ventricular tachycardia induction, 536
 enhancing metabolism of LDL cholesterol in cultured arterial smooth muscle cells, 1065
 exercise hemodynamics in coronary artery disease, 457-462
 inhibiting vascular myocyte proliferation and migration, 1027, 1028
 ischemic heart disease treatment, 676
 isovolumic relaxation time reduced, 954
 lessening glomerular sclerosis in remnant kidneys, 1327, 1329
 lipoprotein metabolism effect, 1033
 LV diastolic filling in CAD enhanced, 1509
 mechanism of action, 1505
 plasma protein bindings and encainide, 564
 preventive aspects in cardiology, 755
 proarrhythmia incidence during EPS testing, 539
 Raynaud's phenomenon, 47
 serum calcium reduced and atherosclerosis prevented by, 1021, 1024
 stereochemical influences, 541
 supraventricular tachycardias' treatment, 628
 verapamil 240 SR vs. verapamil 120 SR, 1501-1506
 vs. KT-362, 1346, 1350
 vs. mizolimine, 1477, 1479-1481, 1483
 vs. nicardipine, 1530, 1531
 vs. nicorandil, 1084
 vs. nifedipine pharmacologic potency in terms of vasodilation, 936, 937
 vs. propranolol in preventing sudden death, 1515-1518
 vs. SD-3211, 1469, 1474, 1475
 Verapamil hydrochloride, antihypertensive treatment for blacks, 391
 Vesnarinone, cardiotonic agent for congestive heart failure, 1127, 1133
 Veterans Administration Cooperative Study, antihypertensive drug treatment in elderly trial, 1243, 1244
 Veterans Administration Trial on Mild Hypertension, hypertension in elderly men, 948
 Veterans Cooperative Study Group (1975), discontinuation of antihypertensive therapy, 1488, 1489
 Vinyl chloride disease, 47
 Visacor, hemodynamic response to, 1135-1138
 Vitamin D, 336, 405, 983-986
- Warfarin**
 interaction with ranitidine, 487, 490
 plasma protein bindings and encainide, 564
- Western Collaborative Group Study (1976), systolic vs. diastolic BP, 1203, 1204, 1216**

Whites

- cellular regulation of sodium, potassium, and calcium, 337
 - heredity and essential hypertension, 335-336
 - obesity and hypertension, 395-401
 - relative racially-based efficacy of antihypertensive agents, 379-381
 - systemic regulation of sodium, potassium and calcium, 336-337
- Wolff-Parkinson-White (WPW) syndrome
- amiodarone treatment, 529, 623
 - atrial fibrillation induced, 549
 - electrophysiologic evaluation of antiarrhythmic drugs, 535, 536
 - encainide efficacy and AV reentry, 573-575
 - flecainide or encainide safety in use, 654

flecainide therapy, 1161

- prevalence in live births in United Kingdom, 527
- propafenone efficacy in treatment, 681-685
- risk stratification process, 665, 666
- sotalol as antiarrhythmic therapy, 609, 619, 620, 625-628

Women, calcium therapy for essential hypertension, 301

- World Health Organization, antihypertensive treatment recommendations and studies, 1269-1270, 1302, 1303

- Xamoterol (intravenous) (corwin), sinus node dysfunction treatment and its electrophysiologic effects, 523-526

- Yohimbine, antagonizing venoconstriction responses to serotonin, dihydroergocristine and dihydroergotamine, 1455-1459

Zofenopril

- bioavailability, 695-696
 - effect on early reperfusion and electrophysiologic stability in the pig, 695-702
 - pharmacokinetics, 696
 - sulfhydryl ACE inhibitor, 200
- Zofenoprilat, coronary blood flow affected, 1379
- ZSY-39, effect on force of contraction and cyclic AMP content in canine ventricular muscle, 1127-1133

